Polyomavirus neutralizing antibodies

ABSTRACT

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

FIELD OF THE INVENTION

The present disclosure is directed to anti-VP1 antibodies, antibodyfragments, and their uses for the reducing the likelihood or treatmentof polyoma virus infection.

BACKGROUND OF THE INVENTION

Of the human polyomaviruses, BK virus (BKV) and JC virus (JCV) were thefirst two identified. These two polyomavirus were isolated fromimmunosuppressed patients and published in the same issue of Lancet in1971 (Gardner et al., Lancet 1971 1:1253-1527, and Padgett et al.,Lancet 1971 1:1257-1260). Polyomaviruses are icosahedral, non-enveloped,double-stranded DNA viruses. They measure 40-45 nm in diameter and arecomprised of 88% protein and 12% DNA.

The BKV genome is a circular double-stranded DNA of approximately 5 Kbin length and contains three major divisions: the early coding region,the late coding region, and a non-coding control region. The earlycoding region encodes for the three regulatory proteins (large tumorantigen [TAg], small tumor antigen [tAg], and truncated tumor antigen[truncTAg]), which are the first viral proteins expressed in a newlyinfected cell and are responsible for facilitating viral DNA replicationand establishing a favorable cellular environment. The late codingregion encodes the three structural proteins (VP1, VP2, and VP3) thatmake up the viral capsid, as well as the agnoprotein, the role of whichduring viral replication is less well-defined. The non-coding controlregion contains the origin of replication as well as the early and latepromoters that drive expression of the viral gene products.

BKV has been detected in many different cell types including epithelialcells of the kidney, bladder, and ureter (typical sites of persistence),tonsillar tissue, and lymphocytes (proposed sites of primary infectionand dissemination) (Chatterjee et al., J. Med. Virol. 2000; 60:353-362,Goudsmit et al., J. Med. Virol. 1982; 10:91-99, Heritage et al., J. Med.Virol. 1981; 8:143-150, Shinohara et al., J. Med. Virol. 1993;41(4):301-305). The primary cell surface receptors for BKV are thegangliosides GT1b, GD1b, and GD3, all of which have a terminalα2,8-linked sialic acid and are fairly ubiquitous, allowing infection ofvarious cell types (Neu et al., PLos Patholog. 2013; 9(10):e1003714 ande1003688, see also, O'Hara et al., Virus Res. 2014; 189:208-285). Thenon-enveloped icosahedral virion of BKV is composed of three differentviral proteins: 360 copies of the major viral capsid protein VP1arranged in 72 pentamers and 72 copies combined of the minor viralcapsid proteins VP2 and VP3, with one VP2 or VP3 molecule associatedwith each VP1 pentamer Only VP1 is exposed on the virion surface atentry and each pentamer has five low affinity binding sites for theganglioside receptor. Binding of VP1 pentamers to ganglioside receptorson the cell surface initiates internalization through acaveolae-mediated endocytic pathway, followed by trafficking of thevirus to the endoplasmic reticulum and finally to the nucleus (Tsai andQian, J. Virol 2010; 84(19):9840-9852).

Infection with the human polyomavirus BK (BKV) is essentiallyubiquitous, with estimates ranging between 80 and 90% of the populationglobally infected (Knowles W. A., Adv. Exp. Med. Biol. 2006; 577:19-45).Primary infection most often occurs during childhood (i.e., before age10) and results in either a mild, non-specific, self-limited illness orno symptoms at all. Persistent infection is established in theepithelial cells of the renal tubules, ureters, and bladder, and iseffectively controlled by the immune system. Transient asymptomaticviral shedding in the urine of immunocompetent adults occurssporadically but results in no disease or sequelae. However, compromisedimmune function, particularly with immunosuppression following renal orhematopoietic stem cell transplantation, can lead to uncontrolled BKVreplication and ultimately to BKV-associated nephropathy (BKVAN) orhemorrhagic cystitis (HC), a painful disease of the bladder. There areno effective antiviral therapies against BKV and the current standard ofcare is reduction of immunosuppression, which increases the risk ofacute rejection. Even with the current, more aggressive approaches tomonitoring and prevention, up to 10% of renal transplant recipients willdevelop BKVAN and 15-30% of those patients will suffer graft loss due toBKVAN. Among those undergoing reduction in immunosuppressive regimenupon detection of BKV viremia, up to 30% will experience an acuterejection episode as a result.

Although BKV was first described in 1971 (supra), it was not until the1990s that BK associated nephropathy (BKVAN) was reported in theliterature as a cause of kidney transplant injury (Purighalla et al.,Am. J. Kidney Dis. 1995; 26:671-673 and Randhawa et al., Transplantation1999; 67:103-109). In early management of BKVAN, testing positive for BKhad severe consequences, with more than 50% of the patients having graftdysfunction and graft loss (Hirsch et al., New Engl. J. Med. 2002;347:488-496). BK viral reactivation may begin after transplantation, andis seen in about 30%-50% of the patients by 3 monthspost-transplantation (Bressollette-Bodin et al., Am J. Transplant. 2005;5(8):1926-1933 and Brennan et al., Am. J. Transplant. 2004;4(12):2132-2134). BK viral reactivation can be first seen by virus andviral DNA in the urine, then in the plasma and finally in the kidney.(Brennan et al., Am. J. Transplant. 2005; 5(3):582-594 and Hirsch etal., N Eng. J. Med. 2002; 347(7):488-496). About 80% of kidneytransplant patients have BK virus in the urine (BK viruria) and 5-10% ofthese patients progress to BKVAN (Billet et al., Transplantation 1999;67(6):918-922 and Bressollette-Bodin et al., Am J. Transplant. 2005;5(8):1926-1933). BKV effects the renal tubular epithelial cells causingnecrosis and lytic destruction with denudation of the basement membrane,which allows tubular fluid to accumulate in the interstitum, whichresults in interstitial fibrosis and tubular atrophy (Nickeleit et al.,J. Am. Soc. Neprol. 1999; 10(5):1080-1089) all of which can affect thecondition of the transplant. Patients may present with deterioration ofrenal function, tubule-interstitial nephritis and ureteric stenosis(Gamer et al., Lancet 1971; 1(7712):1253-1257 and Hirsch Am. J.Transplant 2002; 2(1)25-30).

BKV can also cause pneumonitis, retinitis and meningoencephalitis inimmunocompromised hosts (Reploeg et al., Clin. Infect. Dis. 2001;33(2):191-202). BKV disease in hematopoietic stem cell transplant (HSCT)recipients typically manifests as hemorrhagic cystitis (HC), which canvary in severity. Viruria (but not viremia) and painful hematuria areassociated with the clinical presentation of HC. The current standard ofcare is supportive in nature, involving primarily forcedhydration/diuresis and pain management measures. The most severe casesrequire blood transfusions, clot evacuation, and can lead to death insome instances. HC of any cause (e.g. drug, radiation, viral) isrelatively common among HSCT recipients but BKV-associated HC occurs inapproximately 10-12% of patients usually within 6 months aftertransplantation There are other viral etiologies of HC, with adenovirusbeing a more common cause of HC among pediatric HSCT recipients comparedwith adult HSCT recipients. BK virus has also been observed in otherimmunocompromised conditions such as systemic lupus erythromatosis,other solid organ transplants and in HIV/AIDS patients (Jiang et al.,Virol. 2009; 384:266-273).

At this point, the treatment of BK nephropathy associated with organtransplantation is the reduction of immunosuppression in an attempt toprevent graft dysfunction and graft loss (Wiseman et al., Am. J. KidneyDis. 2009; 54(1): 131-142 and Hirsch et al., Transplantation 2005;79(1): 1277-1286). There are no fixed clinical regimes for thereduction, as reduction of the immunosuppression may help to preventprogression from viremia to the extensive damage associated withclinical nephropathy, but this also increases the risk of acute organrejection (Brennan et al., Am. J. Transplant 2005; 5(3):582-594).Clinicians have reported the use of therapeutics such as cidofovir,leflunomide or quinolones in combination with the reduction ofimmunosuppressants, however the reports find this approach ineffective,with the added burden of managing additional side effects (Randhawa andBrennan Am. J. Transplant 2006; 6(9):2000-2005). As such, there is anunmet and useful need in the field for therapies that neutralize polyomaviruses such as BK and that can be used in an immunocompromised host.

JC virus is also a polyoma virus which is also highly prevalent in thepopulation (80%), although JC vines is generally acquired later than BKvirus (Padgett et al., J. Infect. Dis. 1973; 127(4):467-470 and Sabathet al., J. Infect. Dis. 2002; 186 Suppl. 2:5180-5186). After initialinfection, JC virus establishes latency in the lymphoid organs andkidneys and when reactivated, invades the central nervous system viainfected B-lymphocytes. Once in the CNS, the JC virus causes progressivemultifocal leukoencephalopathy (PML), which is a progressivedemylenating central nervous system disorder. PML most often presents asan opportunistic infection in HIV/AIDS patients and has also beenreported in immunosuppressed patients (Angstrom et al., Brain 1958;81(1):93-111 and Garcia-Suarez et al., Am. J. Hematol. 2005;80(4):271-281). PML patients present with confusion, mental statuschanges, gait ataxia, focal neurological defects such as hemi paresis,limb paresis and visual changes (Richardson E. P., N. Eng. J. Med. 1961;265:815-823). The prognosis of patients with PML is poor and isespecially poor in patients with HIV/AIDS (Antinori et al., J.Neurovirol. 2003; 9 suppl. 1:47-53). This further highlights the unmetand useful need in the field for therapies that neutralize polyomaviruses such as JC.

SUMMARY OF THE INVENTION

The present disclosure is directed to neutralizing antibodies to humanpolyomaviruses and/or fragments thereof, antibodies that recognize BKvirus and/or JC virus and their respective VP1 pentamers and fragmentsthereof.

An antibody, wherein said antibody or antigen binding fragment thereofspecifically binds VP1.

The antibody wherein said antibody or antigen binding fragment thereofspecifically binds BK virus serotype I-serotype IV VP1. In oneembodiment, the antibody or antigen binding fragment thereof binds toBKV serotype I VP1 with a binding affinity of 5.0 pM or less, binds toBKV serotype II VP1 with a binding affinity of 29.0 pM or less, binds toBKV serotype III VP1 with a binding affinity of 6.0 pM or less and/orbinds to BKV serotype IV VP1 with a binding affinity of 185.0 pM orless. In another embodiment, the antibody or antigen binding fragmentthereof further binds to JCV VP1 and specific JCV VP1 mutants with abinding affinity in the high nanomolar range.

The antibody wherein said antibody or antigen binding fragmentspecifically binds to a VP1 of Table 1. In one embodiment, the antibodyor antigen binding fragment thereof binds to two or more of the VP is ofTable 1. In one embodiment, the antibody or antigen binding fragmentthereof binds to BKV VP1 serotype I and BKV VP1 serotype II. In anotherembodiment, the antibody or antigen binding fragment thereof binds toBKV VP1 serotype I and BKV VP1 serotype III. In another embodiment, theantibody or antigen binding fragment thereof binds to BKV VP1 serotype Iand BKV VP1 serotype IV. In another embodiment, the antibody or antigenbinding fragment thereof binds to BKV VP1 serotype II and BKV VP1serotype III. In another embodiment, the antibody or antigen bindingfragment thereof binds to BKV VP1 serotype II and BKV VP1 serotype IV.In another embodiment, the antibody or antigen binding fragment thereofbinds to BKV VP1 serotype I and JCV VP1. In a preferred embodiment, theantibody or antigen binding fragment thereof binds to BKV VP1 serotypesI, II, III and IV. Furthermore, the antibody or antigen binding fragmentthereof binds to BKV VP1 serotypes I, II, III and IV and JCV VP1.

The antibody wherein said antibody or antigen binding fragmentspecifically binds to one or more amino acids residues of a VP1 epitope(SEQ ID NO:500 or SEQ ID NO:501). In one embodiment, the antibody orantigen binding fragment specifically binds to one or more of aminoacids Y169, R170 and K172, e.g., binds to Y169 and R170, e.g., asdetermined by scanning alanine mutagenesis, as described herein.

The antibody wherein said antibody or antigen binding fragment comprisesthe sequence GFTFXNYWMT (SEQ ID NO. 507), wherein X can be any aminoacid (Xaa). In another embodiment, X can be N (Asn), S (Ser), K (Lys) orQ (Gln).

An antibody, wherein said antibody or antigen binding fragment thereofcomprises: (i) a heavy chain variable region that comprises (a) a HCDR1(CDR-Complementarity Determining Region) of SEQ ID NO: 6, (b) a HCDR2 ofSEQ ID NO:7, (c) a HCDR3 of SEQ ID NO:8 and a light chain variableregion that comprises: (d) a LCDR1 of SEQ ID NO:16, (e) a LCDR2 of SEQID NO:17, and (f) a LCDR3 of SEQ ID NO:18;

-   -   (ii) a heavy chain variable region that comprises (a) a HCDR1 of        SEQ ID NO:26, (b) a HCDR2 of SEQ ID NO:27, (c) a HCDR3 of SEQ ID        NO:28; and a light chain variable region that comprises: (d) a        LCDR1 of SEQ ID NO:36, (e) a LCDR2 of SEQ ID NO:37, and (1) a        LCDR3 of SEQ ID NO:38;    -   (iii) a heavy chain variable region that comprises (a) a HCDR1        of SEQ ID NO:46, (b) a HCDR2 of SEQ ID NO:47, (c) a HCDR3 of SEQ        ID NO:48; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:56, (e) a LCDR2 of SEQ ID NO:57, and (f) a        LCDR3 of SEQ ID NO:58;    -   (iv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:66, (b) a HCDR2 of SEQ ID NO:67, (c) a HCDR3 of SEQ        ID NO:68; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:76, (e) a LCDR2 of SEQ ID NO:77, and (f) a        LCDR3 of SEQ ID NO:78;    -   (v) a heavy chain variable region that comprises: (a) a HCDR1 of        SEQ ID NO:86, (b) a HCDR2 of SEQ ID NO:87, (c) a HCDR3 of SEQ ID        NO:88; and a light chain variable region that comprises: (d) a        LCDR1 of SEQ ID NO:96, (e) a LCDR2 of SEQ ID NO:97, and (f) a        LCDR3 of SEQ ID NO:98;    -   (vi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:106, (b) a HCDR2 of SEQ ID NO: 107, (c) a HCDR3 of        SEQ ID NO:108; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:116, (c) a LCDR2 of SEQ ID        NO:117, and (f) a LCDR3 of SEQ ID NO:118;    -   (vii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:126, (b) a HCDR2 of SEQ ID NO: 127, (c) a HCDR3 of        SEQ ID NO:128; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:136, (e) a LCDR2 of SEQ ID        NO:137, and (f) a LCDR3 of SEQ ID NO:138;    -   (viii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:146, (b) a HCDR2 of SEQ ID NO:147, (c) a HCDR3 of        SEQ ID NO:148; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:156, (e) a LCDR2 of SEQ ID        NO:157, and (f) a LCDR3 of SEQ ID NO:158;    -   (ix) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:166, (b) a HCDR2 of SEQ ID NO: 167, (c) a HCDR3 of        SEQ ID NO:168; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:176, (e) a LCDR2 of SEQ ID        NO:177, and (f) a LCDR3 of SEQ ID NO: 178;    -   (x) a heavy chain variable region that comprises: (a) a HCDR1 of        SEQ ID NO:186, (b) a HCDR2 of SEQ ID NO:187, (c) a HCDR3 of SEQ        ID NO:188; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:196, (e) a LCDR2 of SEQ ID NO:197, and (f)        a LCDR3 of SEQ ID NO:198;    -   (xi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:206, (b) a HCDR2 of SEQ ID NO:207, (c) a HCDR3 of        SEQ ID NO:208; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:216, (e) a LCDR2 of SEQ ID        NO:217, and (f) a LCDR3 of SEQ ID NO:218;    -   (xii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:226, (b) a HCDR2 of SEQ ID NO:227, (c) a HCDR3 of        SEQ ID NO:228; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:236, (e) a LCDR2 of SEQ ID        NO:237, and (f) a LCDR3 of SEQ ID NO:238;    -   (xiii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:246, (b) a HCDR2 of SEQ ID NO:247, (c) a HCDR3 of        SEQ ID NO:248; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:256, (c) a LCDR2 of SEQ ID        NO:257, and (f) a LCDR3 of SEQ ID NO:258;    -   (xiv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:266, (b) a HCDR2 of SEQ ID NO:267, (c) a HCDR3 of        SEQ ID NO:268; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO: 276, (e) a LCDR2 of SEQ ID        NO:277, and (1) a LCDR3 of SEQ ID NO:278;    -   (xv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:286, (b) a HCDR2 of SEQ ID NO:287, (c) a HCDR3 of        SEQ ID NO:288; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:296, (e) a LCDR2 of SEQ ID        NO:297, and (f) a LCDR3 of SEQ ID NO:298;    -   (xvi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:306, (b) a HCDR2 of SEQ ID NO:307, (c) a HCDR3 of        SEQ ID NO:308; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:314, (e) a LCDR2 of SEQ ID        NO:315, and (1) a LCDR3 of SEQ ID NO:316;    -   (xvii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:322, (b) a HCDR2 of SEQ ID NO:323, (c) a HCDR3 of        SEQ ID NO:324; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:332, (e) a LCDR2 of SEQ ID        NO:333, and (f) a LCDR3 of SEQ ID NO:334;    -   (xviii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:342, (b) a HCDR2 of SEQ ID NO:343, (c) a        HCDR3 of SEQ ID NO:344; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:349, (e) a LCDR2 of SEQ ID        NO:350, and (f) a LCDR3 of SEQ ID NO:351;    -   (xix) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:356, (b) a HCDR2 of SEQ ID NO:357, (c) a HCDR3 of        SEQ ID NO:358; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:363, (e) a LCDR2 of SEQ ID        NO:364, and (f) a LCDR3 of SEQ ID NO:365;    -   (xx) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:370, (b) a HCDR2 of SEQ ID NO:371, (c) a HCDR3 of        SEQ ID NO:372; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:377, (c) a LCDR2 of SEQ ID        NO:378, and (f) a LCDR3 of SEQ ID NO:379;    -   (xxi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:384, (b) a HCDR2 of SEQ ID NO:385, (c) a HCDR3 of        SEQ ID NO:386; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:391, (e) a LCDR2 of SEQ ID        NO:392, and (f) a LCDR3 of SEQ ID NO:393;    -   (xxii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:398, (b) a HCDR2 of SEQ ID NO:399, (c) a HCDR3 of        SEQ ID NO:400; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:405, (e) a LCDR2 of SEQ ID        NO:406, and (f) a LCDR3 of SEQ ID NO:407;    -   (xxiii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:412, (b) a HCDR2 of SEQ ID NO:413, (c) a        HCDR3 of SEQ ID NO:414; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:419, (e) a LCDR2 of SEQ ID        NO:420, and (f) a LCDR3 of SEQ ID NO:421;    -   (xxiv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:426, (b) a HCDR2 of SEQ ID NO:427, (c) a HCDR3 of        SEQ ID NO:428; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:433, (e) a LCDR2 of SEQ ID        NO:434, and (f) a LCDR3 of SEQ ID NO:435;    -   (xxv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:440, (b) a HCDR2 of SEQ ID NO:441, (c) a HCDR3 of        SEQ ID NO:442; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:447, (e) a LCDR2 of SEQ ID        NO:448, and (f) a LCDR3 of SEQ ID NO:449;    -   (xxvi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:454, (b) a HCDR2 of SEQ ID NO:455, (c) a HCDR3 of        SEQ ID NO:456; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:461, (e) a LCDR2 of SEQ ID        NO:462, and (f) a LCDR3 of SEQ ID NO:463;    -   (xxvii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:468, (b) a HCDR2 of SEQ ID NO:469, (c) a        HCDR3 of SEQ ID NO:470; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:475, (c) a LCDR2 of SEQ ID        NO:476, and (f) a LCDR3 of SEQ ID NO:477;    -   (xxviii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:482, (b) a HCDR2 of SEQ ID NO:483, (c) a        HCDR3 of SEQ ID NO:484; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:489, (e) a LCDR2 of SEQ ID        NO:490, and (f) a LCDR3 of SEQ ID NO:491.

An antibody, wherein said antibody or antigen binding fragment thereofcomprises: (i) a heavy chain variable region that comprises (a) a HCDR1(CDR-Complementarity Determining Region) of SEQ ID NO: 508, (b) a HCDR2of SEQ ID NO:509, (c) a HCDR3 of SEQ ID NO:510 and a light chainvariable region that comprises: (d) a LCDR1 of SEQ ID NO:511, (e) aLCDR2 of SEQ ID NO:512, and (f) a LCDR3 of SEQ ID NO:513;

-   -   (ii) a heavy chain variable region that comprises (a) a HCDR1 of        SEQ ID NO:514, (b) a HCDR2 of SEQ ID NO:515, (c) a HCDR3 of SEQ        ID NO:516; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:517, (e) a LCDR2 of SEQ ID NO:518, and (f)        a LCDR3 of SEQ ID NO:519;    -   (iii) a heavy chain variable region that comprises (a) a HCDR1        of SEQ ID NO:520, (b) a HCDR2 of SEQ ID NO:521, (c) a HCDR3 of        SEQ ID NO:522; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:523, (e) a LCDR2 of SEQ ID        NO:524, and (1) a LCDR3 of SEQ ID NO:525;    -   (iv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:526, (b) a HCDR2 of SEQ ID NO:527, (c) a HCDR3 of        SEQ ID NO:528; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:529, (e) a LCDR2 of SEQ ID        NO:530, and (f) a LCDR3 of SEQ ID NO:531;    -   (v) a heavy chain variable region that comprises: (a) a HCDR1 of        SEQ ID NO:532, (b) a HCDR2 of SEQ ID NO:533, (c) a HCDR3 of SEQ        ID NO:534; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:535, (e) a LCDR2 of SEQ ID NO:536, and (f)        a LCDR3 of SEQ ID NO:537;    -   (vi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:538, (b) a HCDR2 of SEQ ID NO:539, (c) a HCDR3 of        SEQ ID NO:540; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:541, (c) a LCDR2 of SEQ ID        NO:542, and (f) a LCDR3 of SEQ ID NO:543.

The antibody wherein at least one amino acid within a CDR is substitutedby a corresponding residue of a corresponding CDR of another anti-VP1antibody of Table 2.

The antibody wherein one or two amino acids within a CDR have beenmodified, deleted or substituted.

The antibody that retains at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identity over either the variable heavy chain region or the variablelight chain region.

The antibody that comprises the modifications in Table 3.

The antibody wherein the antibody is a monoclonal antibody, a chimericantibody, a humanized antibody, a human engineered antibody, a humanantibody, a single chain antibody (scFv) or an antibody fragment.

The antibody wherein said antibody or antigen binding fragment thereofcomprises:

-   -   (i) a heavy chain variable region (vH) that comprises SEQ ID        NO:12, and a light chain variable region (vL) that comprises SEQ        ID NO: 22;    -   (ii) a heavy chain variable region (vH) that comprises SEQ ID        NO: 32, and a light chain variable region (vL) that comprises        SEQ ID NO: 42;    -   (iii) a heavy chain variable region (vH) that comprises SEQ ID        NO: 52, and a light chain variable region (vL) that comprises        SEQ ID NO: 62;    -   (iv) a heavy chain variable region (vH) that comprises SEQ ID        NO: 72, and a light chain variable region (vL) that comprises        SEQ ID NO: 82;    -   (v) a heavy chain variable region (vH) that comprises SEQ ID        NO:92, and a light chain variable region (vL) that comprises SEQ        ID NO:102;    -   (vi) a heavy chain variable region (vH) that comprises SEQ ID        NO:112, and a light chain variable region (vL) that comprises        SEQ ID NO:122;    -   (vii) a heavy chain variable region (vH) that comprises SEQ ID        NO: 132, and a light chain variable region (vL) that comprises        SEQ ID NO:142;    -   (viii) a heavy chain variable region (vH) that comprises SEQ ID        NO: 152, and a light chain variable region (vL) that comprises        SEQ ID NO:162;    -   (ix) a heavy chain variable region (vH) that comprises SEQ ID        NO:172, and a light chain variable region (vL) that comprises        SEQ ID NO:182;    -   (x) a heavy chain variable region (vH) that comprises SEQ ID NO:        192, and a light chain variable region (vL) that comprises SEQ        ID NO:202;    -   (xi) a heavy chain variable region (vH) that comprises SEQ ID        NO:212, and a light chain variable region (vL) that comprises        SEQ ID NO:222;    -   (xii) a heavy chain variable region (vH) that comprises SEQ ID        NO:232, and a light chain variable region (vL) that comprises        SEQ ID NO:242;    -   (xiii) a heavy chain variable region (vH) that comprises SEQ ID        NO:252, and a light chain variable region (vL) that comprises        SEQ ID NO:262;    -   (xiv) a heavy chain variable region (vH) that comprises SEQ ID        NO:272, and a light chain variable region (vL) that comprises        SEQ ID NO:282;    -   (xv) a heavy chain variable region (vH) that comprises SEQ ID        NO:292, and a light chain variable region (vL) that comprises        SEQ ID NO:302;    -   (xvi) a heavy chain variable region (vH) that comprises SEQ ID        NO:312, and a light chain variable region (vL) that comprises        SEQ ID NO:320;    -   (xvii) a heavy chain variable region (vH) that comprises SEQ ID        NO:328, and a light chain variable region (vL) that comprises        SEQ ID NO:338;    -   (xviii) a heavy chain variable region (vH) that comprises SEQ ID        NO:348, and a light chain variable region (vL) that comprises        SEQ ID NO:355;    -   (xix) a heavy chain variable region (vH) that comprises SEQ ID        NO:362, and a light chain variable region (vL) that comprises        SEQ ID NO:369;    -   (xx) a heavy chain variable region (vH) that comprises SEQ ID        NO:376, and a light chain variable region (vL) that comprises        SEQ ID NO:383;    -   (xxi) a heavy chain variable region (vH) that comprises SEQ ID        NO:390, and a light chain variable region (vL) that comprises        SEQ ID NO:397;    -   (xxii) a heavy chain variable region (vH) that comprises SEQ ID        NO:404, and a light chain variable region (vL) that comprises        SEQ ID NO:411;    -   (xxiii) a heavy chain variable region (vH) that comprises SEQ ID        NO:418, and a light chain variable region (vL) that comprises        SEQ ID NO:425;    -   (xxiv) a heavy chain variable region (vH) that comprises SEQ ID        NO:432, and a light chain variable region (vL) that comprises        SEQ ID NO:439;    -   (xxv) a heavy chain variable region (vH) that comprises SEQ ID        NO: 446, and a light chain variable region (vL) that comprises        SEQ ID NO:453;    -   (xxvi) a heavy chain variable region (vH) that comprises SEQ ID        NO:460, and a light chain variable region (vL) that comprises        SEQ ID NO:467;    -   (xxvii) a heavy chain variable region (vH) that comprises SEQ ID        NO:474, and a light chain variable region (vL) that comprises        SEQ ID NO:481; or    -   (xxviii) a heavy chain variable region (vH) that comprises SEQ        ID NO:488, and a light chain variable region (vL) that comprises        SEQ ID NO:495.

The antibody that retains at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or99% identity over either the variable light or variable heavy region.

The antibody wherein one, two, three, four or five, but less than 10amino acids within the variable light or variable heavy region have beenmodified, deleted or substituted.

The antibody wherein the antibody is a monoclonal antibody, a chimericantibody, a humanized antibody, a human engineered antibody, a humanantibody, a single chain antibody (scFv) or an antibody fragment.

The antibody of any of the preceding embodiments wherein the antibody orfragment thereof has reduced glycosylation or no glycosylation or ishypofucosylated.

A composition comprising a plurality of an antibody or antigen bindingfragment of any of the preceding embodiments, wherein at least 0.05%,0.1%, 0.5%, 1%, 2%, 3%, 5% or more of the antibodies in the compositionhave an α2,3-linked sialic acid residue, and wherein said antibody orantigen binding fragment thereof comprises: (i) a heavy chain variableregion that comprises (a) a HCDR1 (CDR-Complementarity DeterminingRegion) of SEQ ID NO: 6, (b) a HCDR2 of SEQ ID NO:7, (c) a HCDR3 of SEQID NO:8 and a light chain variable region that comprises: (d) a LCDR1 ofSEQ ID NO:16, (e) a LCDR2 of SEQ ID NO:17, and (f) a LCDR3 of SEQ IDNO:18;

-   -   (ii) a heavy chain variable region that comprises (a) a HCDR1 of        SEQ ID NO:26, (b) a HCDR2 of SEQ ID NO:27, (c) a HCDR3 of SEQ ID        NO:28; and a light chain variable region that comprises: (d) a        LCDR1 of SEQ ID NO:36, (e) a LCDR2 of SEQ ID NO:37, and (1) a        LCDR3 of SEQ ID NO:38;    -   (iii) a heavy chain variable region that comprises (a) a HCDR1        of SEQ ID NO:46, (b) a HCDR2 of SEQ ID NO:47, (c) a HCDR3 of SEQ        ID NO:48; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:56, (e) a LCDR2 of SEQ ID NO:57, and (f) a        LCDR3 of SEQ ID NO:58;    -   (iv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:66, (b) a HCDR2 of SEQ ID NO:67, (c) a HCDR3 of SEQ        ID NO:68; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:76, (e) a LCDR2 of SEQ ID NO:77, and (f) a        LCDR3 of SEQ ID NO:78;    -   (v) a heavy chain variable region that comprises: (a) a HCDR1 of        SEQ ID NO:86, (b) a HCDR2 of SEQ ID NO:87, (c) a HCDR3 of SEQ ID        NO:88; and a light chain variable region that comprises: (d) a        LCDR1 of SEQ ID NO:96, (e) a LCDR2 of SEQ ID NO:97, and (f) a        LCDR3 of SEQ ID NO:98;    -   (vi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:106, (b) a HCDR2 of SEQ ID NO: 107, (c) a HCDR3 of        SEQ ID NO:108; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:116, (c) a LCDR2 of SEQ ID        NO:117, and (f) a LCDR3 of SEQ ID NO:118;    -   (vii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:126, (b) a HCDR2 of SEQ ID NO: 127, (c) a HCDR3 of        SEQ ID NO:128; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:136, (e) a LCDR2 of SEQ ID        NO:137, and (1) a LCDR3 of SEQ ID NO:138;    -   (viii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:146, (b) a HCDR2 of SEQ ID NO:147, (c) a HCDR3 of        SEQ ID NO:148; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:156, (e) a LCDR2 of SEQ ID        NO:157, and (f) a LCDR3 of SEQ ID NO:158;    -   (ix) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:166, (b) a HCDR2 of SEQ ID NO: 167, (c) a HCDR3 of        SEQ ID NO:168; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:176, (e) a LCDR2 of SEQ ID        NO:177, and (f) a LCDR3 of SEQ ID NO: 178;    -   (x) a heavy chain variable region that comprises: (a) a HCDR1 of        SEQ ID NO:186, (b) a HCDR2 of SEQ ID NO:187, (c) a HCDR3 of SEQ        ID NO:188; and a light chain variable region that comprises: (d)        a LCDR1 of SEQ ID NO:196, (e) a LCDR2 of SEQ ID NO:197, and (f)        a LCDR3 of SEQ ID NO:198;    -   (xi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:206, (b) a HCDR2 of SEQ ID NO:207, (c) a HCDR3 of        SEQ ID NO:208; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:216, (e) a LCDR2 of SEQ ID        NO:217, and (f) a LCDR3 of SEQ ID NO:218;    -   (xii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:226, (b) a HCDR2 of SEQ ID NO:227, (c) a HCDR3 of        SEQ ID NO:228; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:236, (e) a LCDR2 of SEQ ID        NO:237, and (f) a LCDR3 of SEQ ID NO:238;    -   (xiii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:246, (b) a HCDR2 of SEQ ID NO:247, (c) a HCDR3 of        SEQ ID NO:248; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:256, (e) a LCDR2 of SEQ ID        NO:257, and (f) a LCDR3 of SEQ ID NO:258;    -   (xiv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:266, (b) a HCDR2 of SEQ ID NO:267, (c) a HCDR3 of        SEQ ID NO:268; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO: 276, (e) a LCDR2 of SEQ ID        NO:277, and (f) a LCDR3 of SEQ ID NO:278;    -   (xv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:286, (b) a HCDR2 of SEQ ID NO:287, (c) a HCDR3 of        SEQ ID NO:288; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:296, (e) a LCDR2 of SEQ ID        NO:297, and (f) a LCDR3 of SEQ ID NO:298;    -   (xvi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:306, (b) a HCDR2 of SEQ ID NO:307, (c) a HCDR3 of        SEQ ID NO:308; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:314, (e) a LCDR2 of SEQ ID        NO:315, and (f) a LCDR3 of SEQ ID NO:316;    -   (xvii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:322, (b) a HCDR2 of SEQ ID NO:323, (c) a HCDR3 of        SEQ ID NO:324; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:332, (e) a LCDR2 of SEQ ID        NO:333, and (f) a LCDR3 of SEQ ID NO:334;    -   (xviii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:342, (b) a HCDR2 of SEQ ID NO:343, (c) a        HCDR3 of SEQ ID NO:344; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:349, (e) a LCDR2 of SEQ ID        NO:350, and (f) a LCDR3 of SEQ ID NO:351;    -   (xix) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:356, (b) a HCDR2 of SEQ ID NO:357, (c) a HCDR3 of        SEQ ID NO:358; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:363, (e) a LCDR2 of SEQ ID        NO:364, and (f) a LCDR3 of SEQ ID NO:365;    -   (xx) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:370, (b) a HCDR2 of SEQ ID NO:371, (c) a HCDR3 of        SEQ ID NO:372; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:377, (e) a LCDR2 of SEQ ID        NO:378, and (f) a LCDR3 of SEQ ID NO:379;    -   (xxi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:384, (b) a HCDR2 of SEQ ID NO:385, (c) a HCDR3 of        SEQ ID NO:386; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:391, (e) a LCDR2 of SEQ ID        NO:392, and (f) a LCDR3 of SEQ ID NO:393;    -   (xxii) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:398, (b) a HCDR2 of SEQ ID NO:399, (c) a HCDR3 of        SEQ ID NO:400; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:405, (e) a LCDR2 of SEQ ID        NO:406, and (f) a LCDR3 of SEQ ID NO:407;    -   (xxiii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:412, (b) a HCDR2 of SEQ ID NO:413, (c) a        HCDR3 of SEQ ID NO:414; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:419, (e) a LCDR2 of SEQ ID        NO:420, and (f) a LCDR3 of SEQ ID NO:421;    -   (xxiv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:426, (b) a HCDR2 of SEQ ID NO:427, (c) a HCDR3 of        SEQ ID NO:428; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:433, (e) a LCDR2 of SEQ ID        NO:434, and (f) a LCDR3 of SEQ ID NO:435;    -   (xxv) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:440, (b) a HCDR2 of SEQ ID NO:441, (c) a HCDR3 of        SEQ ID NO:442; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:447, (e) a LCDR2 of SEQ ID        NO:448, and (f) a LCDR3 of SEQ ID NO:449;    -   (xxvi) a heavy chain variable region that comprises: (a) a HCDR1        of SEQ ID NO:454, (b) a HCDR2 of SEQ ID NO:455, (c) a HCDR3 of        SEQ ID NO:456; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:461, (e) a LCDR2 of SEQ ID        NO:462, and (f) a LCDR3 of SEQ ID NO:463;    -   (xxvii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:468, (b) a HCDR2 of SEQ ID NO:469, (c) a        HCDR3 of SEQ ID NO:470; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:475, (e) a LCDR2 of SEQ ID        NO:476, and (f) a LCDR3 of SEQ ID NO:477;    -   (xxviii) a heavy chain variable region that comprises: (a) a        HCDR1 of SEQ ID NO:482, (b) a HCDR2 of SEQ ID NO:483, (c) a        HCDR3 of SEQ ID NO:484; and a light chain variable region that        comprises: (d) a LCDR1 of SEQ ID NO:489, (e) a LCDR2 of SEQ ID        NO:490, and (f) a LCDR3 of SEQ ID NO:491.

A composition comprising a plurality of an antibody or antigen bindingfragment of any of the preceding embodiments, wherein none of theantibodies comprise a bisecting GlcNAc.

A pharmaceutical composition comprising the antibody or fragmentthereof, of any of the preceding embodiments wherein the composition isprepared as a lyophilisate.

A pharmaceutical composition comprising the antibody or fragment thereofof any of the preceeding embodiments and a pharmaceutically acceptablecarrier. In one embodiment, the carrier is a histidine buffer. In oneembodiment, the pharmaceutical composition comprises a sugar (e.g.,sucrose).

A method of neutralizing a BK virus or JC virus infection comprisingadministering via injection or infusion to a patient in need aneffective amount of the antibody or the pharmaceutical composition. Themethod wherein the antibody or antigen binding fragment thereofneutralizes BKV serotype I and BKV serotype II. In another embodiment,the antibody or antigen binding fragment thereof neutralizes BKVserotype I and BKV serotype III. In another embodiment, the antibody orantigen binding fragment thereof neutralizes BKV serotype I and BKVserotype IV. In another embodiment, the antibody or antigen bindingfragment thereof neutralizes BKV serotype II and BKV serotype III. Inanother embodiment, the antibody or antigen binding fragment thereofneutralizes BKV serotype II and BKV serotype IV. In another embodiment,the antibody or antigen binding fragment thereof neutralizes BKVserotype I and JCV. In a specific embodiment, the antibody or antigenbinding fragment thereof neutralizes BKV serotypes I, II, III and IV.Furthermore, the antibody or antigen binding fragment thereofneutralizes BKV serotypes I, II, III and IV and JCV. In a preferredembodiment, anti-VP1 antibodies neutralized infection by all fourserotypes of BKV (I-IV), these anti-VP1 antibodies specifically includeP8D11, the modifications of P8D11, and EBB-C1975-B5.

A method of treating or reducing the likelihood of a BK virus or JCvirus associated disorder, comprising administering via injection orinfusion to a patient in need an effective amount of the antibody or thepharmaceutical composition, and wherein the disorder is: nephropathy,BKVAN, hemorrhagic cystitis (HC), Progressive MultifocalLeukoencephalopathy (PML), granule cell neuronopathy (GCN), interstitialkidney disease, ureteral stenosis, vasculitis, colitis, retinitis,meningitis, and immune reconstitution inflammatory syndrome (IRIS).

The method wherein the antibody or composition is reconstituted prior toinjection or infusion.

The method wherein the antibody or the pharmaceutical composition isadministered in combination with another therapeutic agent.

The method wherein the therapeutic agent is an immunosuppressive agent.

The method wherein the immunosuppressive agent is a monophosphatedehydrogenase inhibitor, a purine synthesis inhibitor, a calcineurininhibitor or an mTOR inhibitor.

The method wherein the immunosuppressive agent is mycophenolate mofetil(MMF), mycophenolate sodium, azathioprine, tacrolimus, sirolimus orcyclosporine.

The method wherein the therapeutic agent is an additional anti-VP1antibody.

The antibody or fragment thereof of any of the preceding embodiments foruse as a medicament.

The antibody or fragment thereof or the pharmaceutical composition, foruse in the neutralization of a BK virus or JC virus infection.

The antibody or fragment thereof, or the pharmaceutical composition, foruse in the treatment or reducing the likelihood of: nephropathy, BKVAN,hemorrhagic cystitis (HC), Progressive Multifocal Leukoencephalopathy(PML), granule cell neuronopathy (GCN), interstitial kidney disease,ureteral stenosis, vasculitis, colitis, retinitis, meningitis, andimmune reconstitution inflammatory syndrome (IRIS).

The use of the antibody or fragment thereof, administered in combinationwith another therapeutic agent.

The use of the antibody or fragment thereof wherein the therapeuticagent is an immunosuppressive agent.

The use of the antibody or fragment thereof wherein theimmunosuppressive agent is a monophosphate dehydrogenase inhibitor, apurine synthesis inhibitor, a calcineurin inhibitor or an mTORinhibitor.

The use of the antibody or fragment thereof, wherein theimmunosuppressive agent is: mycophenolate mofetil (MMF), mycophenolatesodium, azathioprine, tacrolimus, sirolimus or cyclosporine.

A nucleic acid that encodes the antibody or antigen binding fragment ofany of the preceding embodiments.

A vector comprising the nucleic acid.

A host cell comprising the vector.

A process for producing an antibody or antigen binding fragmentcomprising cultivating the host cell and recovering the antibody fromthe culture.

A diagnostic reagent comprising the antibody or antigen binding fragmentthereof which is labeled.

The diagnostic reagent wherein the label is selected from the groupconsisting of a radiolabel, a fluorophore, a chromophore, an imagingagent, and a metal ion.

Definitions

Unless stated otherwise, the following terms and phrases as used hereinare intended to have the following meanings:

The term “antibody” as used herein refers to a polypeptide of theimmunoglobulin family that is capable of binding a corresponding antigennon-covalently, reversibly, and in a specific manner. For example, anaturally occurring IgG antibody is a tetramer comprising at least twoheavy (H) chains and two light (L) chains inter-connected by disulfidebonds. Each heavy chain is comprised of a heavy chain variable region(abbreviated herein as VH) and a heavy chain constant region. The heavychain constant region is comprised of three domains, CH1, CH2 and CH3.Each light chain is comprised of a light chain variable region(abbreviated herein as VL) and a light chain constant region. The lightchain constant region is comprised of one domain, CL. The VH and VLregions can be further subdivided into regions of hypervariability,termed complementarity determining regions (CDR), interspersed withregions that are more conserved, termed framework regions (FR). Each VHand VL is composed of three CDRs and four FRs arranged fromamino-terminus to carboxy-terminus in the following order: FR1, CDR1,FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy andlight chains contain a binding domain that interacts with an antigen.The constant regions of the antibodies may mediate the binding of theimmunoglobulin to host tissues or factors, including various cells ofthe immune system (e.g., effector cells) and the first component (Clq)of the classical complement system.

The term “antibody” includes, but is not limited to, monoclonalantibodies, human antibodies, humanized antibodies, camelid antibodies,chimeric antibodies, and anti-idiotypic (anti-Id) antibodies (including,e.g., anti-Id antibodies to antibodies of the present disclosure). Theantibodies can be of any isotype/class (e.g., IgG, IgE, IgM, IgD, IgAand IgY), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).

“Complementarity-determining domains” or “complementary-determiningregions (“CDRs”) interchangeably refer to the hypervariable regions ofVL and VH. The CDRs are the target protein-binding site of the antibodychains that harbors specificity for such target protein. There are threeCDRs (CDR1-3, numbered sequentially from the N-terminus) in each humanVL or VH, constituting about 15-20% of the variable domains. CDRs can bereferred to by their region and order. For example, “VHCDR1” or “HCDR1”both refer to the first CDR of the heavy chain variable region. The CDRsare structurally complementary to the epitope of the target protein andare thus directly responsible for the binding specificity. The remainingstretches of the VL or VH, the so-called framework regions, exhibit lessvariation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4.W.H. Freeman & Co., New York, 2000).

The positions of the CDRs and framework regions can be determined usingvarious well known definitions in the art, e.g., Kabat, Chothia, and AbM(see, e.g., Johnson et al., Nucleic Acids Res., 29:205-206 (2001);Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987); Chothia et al.,Nature, 342:877-883 (1989); Chothia et al., J. Mol. Biol., 227:799-817(1992); Al-Lazikani et al., J. Mol. Biol., 273:927-748 (1997)).Definitions of antigen combining sites are also described in thefollowing: Ruiz et al., Nucleic Acids Res., 28:219-221 (2000); andLefranc, M. P., Nucleic Acids Res., 29:207-209 (2001); MacCallum et al.,J. Mol. Biol., 262:732-745 (1996); and Martin et al., Proc. Natl. Acad.Sci. USA, 86:9268-9272 (1989); Martin et al., Methods Enzymol.,203:121-153 (1991); and Rees et al., In Sternberg M. J. E. (ed.),Protein Structure Prediction, Oxford University Press, Oxford, 141-172(1996).). In a combined Kabat and Chothia numbering scheme, in someembodiments, the CDRs correspond to the amino acid residues that arepart of a Kabat CDR, a Chothia CDR, or both. For instance, in someembodiments, the CDRs correspond to amino acid residues 26-35 (HC CDR1),50-65 (HC CDR2), and 95-102 (HC CDR3) in a VH, e.g., a mammalian VH,e.g., a human VH; and amino acid residues 24-34 (LC CDR1), 50-56 (LCCDR2), and 89-97 (LC CDR3) in a VL, e.g., a mammalian VL, e.g., a humanVL.

Both the light and heavy chains are divided into regions of structuraland functional homology. The terms “constant” and “variable” are usedfunctionally. In this regard, it will be appreciated that the variabledomains of both the light (VL) and heavy (VH) chain portions determineantigen recognition and specificity. Conversely, the constant domains ofthe light chain (CL) and the heavy chain (CH1, CH2 or CH3) conferimportant biological properties such as secretion, transplacentalmobility, Fc receptor binding, complement binding, and the like. Byconvention, the numbering of the constant region domains increases asthey become more distal from the antigen binding site or amino-terminusof the antibody. The N-terminus is a variable region and at theC-terminus is a constant region; the CH3 and CL domains actuallycomprise the carboxy-terminal domains of the heavy and light chain,respectively.

The term “antigen binding fragment,” as used herein, refers to one ormore portions of an antibody that retain the ability to specificallyinteract with (e.g., by binding, steric hindrance,stabilizing/destabilizing, spatial distribution) an epitope of anantigen. Examples of binding fragments include, but are not limited to,single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), Fab fragments,F(ab′) fragments, a monovalent fragment consisting of the VL, VH, CL andCH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two Fabfragments linked by a disulfide bridge at the hinge region; a Fdfragment consisting of the VH and CH1 domains; a Fv fragment consistingof the VL and VH domains of a single arm of an antibody; a dAb fragment(Ward et al., Nature 341:544-546, 1989), which consists of a VH domain;and an isolated complementarity determining region (CDR), or otherepitope-binding fragments of an antibody.

Furthermore, although the two domains of the Fv fragment, VL and VH, arecoded for by separate genes, they can be joined, using recombinantmethods, by a synthetic linker that enables them to be made as a singleprotein chain in which the VL and VH regions pair to form monovalentmolecules (known as single chain Fv (“scFv”); see, e.g., Bird el al.,Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci.85:5879-5883, 1988). Such single chain antibodies are also intended tobe encompassed within the term “antigen binding fragment.” These antigenbinding fragments are obtained using conventional techniques known tothose of skill in the art, and the fragments are screened for utility inthe same manner as are intact antibodies.

Antigen binding fragments can also be incorporated into single domainantibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies,triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger andHudson, Nature Biotechnology 23:1126-1136, 2005). Antigen bindingfragments can be grafted into scaffolds based on polypeptides such asfibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describesfibronectin polypeptide monobodies).

Antigen binding fragments can be incorporated into single chainmolecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1) which,together with complementary light chain polypeptides, form a pair ofantigen binding regions (Zapata et al., Protein Eng. 8:1057-1062, 1995;and U.S. Pat. No. 5,641,870).

The term “monoclonal antibody” or “monoclonal antibody composition” asused herein refers to polypeptides, including antibodies and antigenbinding fragments that have substantially identical amino acid sequenceor are derived from the same genetic source. This term also includespreparations of antibody molecules of single molecular composition. Amonoclonal antibody composition displays a single binding specificityand affinity for a particular epitope.

The term “human antibody,” as used herein, includes antibodies havingvariable regions in which both the framework and CDR regions are derivedfrom sequences of human origin. Furthermore, if the antibody contains aconstant region, the constant region also is derived from such humansequences, e.g., human germline sequences, or mutated versions of humangermline sequences or antibody containing consensus framework sequencesderived from human framework sequences analysis, for example, asdescribed in Knappik et al., J. Mol. Biol. 296:57-86, 2000).

The human antibodies of the present disclosure can include amino acidresidues not encoded by human sequences (e.g., mutations introduced byrandom or site-specific mutagenesis in vitro or by somatic mutation invivo, or a conservative substitution to promote stability ormanufacturing).

The term “recognize” as used herein refers to an antibody or antigenbinding fragment thereof that finds and interacts (e.g., binds) with itsepitope, whether that epitope is linear or conformational. The term“epitope” refers to a site on an antigen to which an antibody or antigenbinding fragment of the disclosure specifically binds. Epitopes can beformed both from contiguous amino acids or noncontiguous amino acidsjuxtaposed by tertiary folding of a protein. Epitopes formed fromcontiguous amino acids are typically retained on exposure to denaturingsolvents, whereas epitopes formed by tertiary folding are typically loston treatment with denaturing solvents. An epitope typically includes atleast 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in aunique spatial conformation. Methods of determining spatial conformationof epitopes include techniques in the art, for example, x-raycrystallography and 2-dimensional nuclear magnetic resonance (see, e.g.,Epitopc Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996)). A “paratope” is the part of the antibody whichrecognizes the epitope of the antigen.

The phrase “specifically binds” or “selectively binds,” when used in thecontext of describing the interaction between an antigen (e.g., aprotein) and an antibody, antibody fragment, or antibody-derived bindingagent, refers to a binding reaction that is determinative of thepresence of the antigen in a heterogeneous population of proteins andother biologics, e.g., in a biological sample, e.g., a blood, serum,plasma or tissue sample. Thus, under certain designated immunoassayconditions, the antibodies or binding agents with a particular bindingspecificity bind to a particular antigen at least two times thebackground and do not substantially bind in a significant amount toother antigens present in the sample. In one aspect, under designatedimmunoassay conditions, the antibody or binding agent with a particularbinding specificity binds to a particular antigen at least ten (10)times the background and does not substantially bind in a significantamount to other antigens present in the sample. Specific binding to anantibody or binding agent under such conditions may require the antibodyor agent to have been selected for its specificity for a particularprotein. As desired or appropriate, this selection may be achieved bysubtracting out antibodies that cross-react with molecules from otherspecies (e.g., mouse or rat) or other subtypes. Alternatively, in someaspects, antibodies or antibody fragments are selected that cross-reactwith certain desired molecules.

The term “affinity” as used herein refers to the strength of interactionbetween antibody and antigen at single antigenic sites. Within eachantigenic site, the variable region of the antibody “arm” interactsthrough weak non-covalent forces with antigen at numerous sites; themore interactions, the stronger the affinity.

The term “isolated antibody” refers to an antibody that is substantiallyfree of other antibodies having different antigenic specificities. Anisolated antibody that specifically binds to one antigen may, however,have cross-reactivity to other antigens. Moreover, an isolated antibodymay be substantially free of other cellular material and/or chemicals.

The term “corresponding human germline sequence” refers to the nucleicacid sequence encoding a human variable region amino acid sequence orsubsequence that shares the highest determined amino acid sequenceidentity with a reference variable region amino acid sequence orsubsequence in comparison to all other all other known variable regionamino acid sequences encoded by human germline immunoglobulin variableregion sequences. The corresponding human germline sequence can alsorefer to the human variable region amino acid sequence or subsequencewith the highest amino acid sequence identity with a reference variableregion amino acid sequence or subsequence in comparison to all otherevaluated variable region amino acid sequences. The corresponding humangermline sequence can be framework regions only, complementaritydetermining regions only, framework and complementary determiningregions, a variable segment (as defined above), or other combinations ofsequences or subsequences that comprise a variable region. Sequenceidentity can be determined using the methods described herein, forexample, aligning two sequences using BLAST, ALIGN, or another alignmentalgorithm known in the art. The corresponding human germline nucleicacid or amino acid sequence can have at least about 90%, 91% 92%, 93%,94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with thereference variable region nucleic acid or amino acid sequence.

A variety of immunoassay formats may be used to select antibodiesspecifically immunoreactive with a particular protein. For example,solid-phase ELISA immunoassays are routinely used to select antibodiesspecifically immunoreactive with a protein (see, e.g., Harlow & Lane,Using Antibodies, A Laboratory Manual (1998), for a description ofimmunoassay formats and conditions that can be used to determinespecific immunoreactivity). Typically a specific or selective bindingreaction will produce a signal at least twice over the background signaland more typically at least 10 to 100 times over the background.

The term “equilibrium dissociation constant (KD, M)” refers to thedissociation rate constant (kd, time-1) divided by the association rateconstant (ka, time-1, M-1). Equilibrium dissociation constants can bemeasured using any known method in the art. The antibodies of thepresent disclosure generally will have an equilibrium dissociationconstant of less than about 10⁻⁷ or 10⁻⁸ M, for example, less than about10⁻⁹ M or 10⁻¹⁰ M, in some aspects, less than about 10⁻¹¹ M, 10⁻¹² M or10⁻¹³ M.

The term “bioavailability” refers to the systemic availability (i.e.,blood/plasma levels) of a given amount of drug administered to apatient. Bioavailability is an absolute term that indicates measurementof both the time (rate) and total amount (extent) of drug that reachesthe general circulation from an administered dosage form.

As used herein, the phrase “consisting essentially of” refers to thegenera or species of active pharmaceutical agents included in a methodor composition, as well as any excipients inactive for the intendedpurpose of the methods or compositions. In some aspects, the phrase“consisting essentially of” expressly excludes the inclusion of one ormore additional active agents other than an anti-VP1 antibody of thepresent disclosure. In some aspects, the phrase “consisting essentiallyof” expressly excludes the inclusion of one or more additional activeagents other than an anti-VP1 antibody of the present disclosure and asecond co-administered agent.

The term “amino acid” refers to naturally occurring, synthetic, andunnatural amino acids, as well as amino acid analogs and amino acidmimetics that function in a manner similar to the naturally occurringamino acids. Naturally occurring amino acids are those encoded by thegenetic code, as well as those amino acids that are later modified,e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Aminoacid analogs refer to compounds that have the same basic chemicalstricture as a naturally occurring amino acid, i.e., an α-carbon that isbound to a hydrogen, a carboxyl group, an amino group, and an R group,e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) ormodified peptide backbones, but retain the same basic chemical structureas a naturally occurring amino acid. Amino acid mimetics refers tochemical compounds that have a structure that is different from thegeneral chemical structure of an amino acid, but that functions in amanner similar to a naturally occurring amino acid.

The term “conservatively modified variant” applies to both amino acidand nucleic acid sequences. With respect to particular nucleic acidsequences, conservatively modified variants refers to those nucleicacids which encode identical or essentially identical amino acidsequences, or where the nucleic acid does not encode an amino acidsequence, to essentially identical sequences. Because of the degeneracyof the genetic code, a large number of functionally identical nucleicacids encode any given protein. For instance, the codons GCA, GCC, GCGand GCU all encode the amino acid alanine Thus, at every position wherean alanine is specified by a codon, the codon can be altered to any ofthe corresponding codons described without altering the encodedpolypeptide. Such nucleic acid variations are “silent variations,” whichare one species of conservatively modified variations. Every nucleicacid sequence herein which encodes a polypeptide also describes everypossible silent variation of the nucleic acid. One of skill willrecognize that each codon in a nucleic acid (except AUG, which isordinarily the only codon for methionine, and TGG, which is ordinarilythe only codon for tryptophan) can be modified to yield a functionallyidentical molecule. Accordingly, each silent variation of a nucleic acidthat encodes a polypeptide is implicit in each described sequence.

For polypeptide sequences, “conservatively modified variants” includeindividual substitutions, deletions or additions to a polypeptidesequence which result in the substitution of an amino acid with achemically similar amino acid. Conservative substitution tablesproviding functionally similar amino acids are well known in the art.Such conservatively modified variants are in addition to and do notexclude polymorphic variants, interspecies homologs, and alleles. Thefollowing eight groups contain amino acids that are conservativesubstitutions for one another: 1) Alanine (A), Glycine (G); 2) Asparticacid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4)Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine(M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7)Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see,e.g., Creighton, Proteins (1984)). In some aspects, the term“conservative sequence modifications” are used to refer to amino acidmodifications that do not significantly affect or alter the bindingcharacteristics of the antibody containing the amino acid sequence.

The term “optimized” as used herein refers to a nucleotide sequence thathas been altered to encode an amino acid sequence using codons that arepreferred in the production cell or organism, generally a eukaryoticcell, for example, a yeast cell, a Pichia cell, a fungal cell, aTrichoderma cell, a Chinese Hamster Ovary cell (CHO) or a human cell.The optimized nucleotide sequence is engineered to retain completely oras much as possible the amino acid sequence originally encoded by thestarting nucleotide sequence, which is also known as the “parental”sequence.

The terms “percent identical” or “percent identity,” in the context oftwo or more nucleic acids or polypeptide sequences, refers to the extentto which two or more sequences or subsequences that are the same. Twosequences are “identical” if they have the same sequence of amino acidsor nucleotides over the region being compared. Two sequences are“substantially identical” if two sequences have a specified percentageof amino acid residues or nucleotides that are the same (i.e., 60%identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identityover a specified region, or, when not specified, over the entiresequence), when compared and aligned for maximum correspondence over acomparison window, or designated region as measured using one of thefollowing sequence comparison algorithms or by manual alignment andvisual inspection. Optionally, the identity exists over a region that isat least about 30 nucleotides (or 10 amino acids) in length, or morepreferably over a region that is 100 to 500 or 1000 or more nucleotides(or 20, 50, 200 or more amino acids) in length.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are entered into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. Default programparameters can be used, or alternative parameters can be designated. Thesequence comparison algorithm then calculates the percent sequenceidentities for the test sequences relative to the reference sequence,based on the program parameters.

A “comparison window”, as used herein, includes reference to a segmentof any one of the number of contiguous positions selected from the groupconsisting of from 20 to 600, usually about 50 to about 200, moreusually about 100 to about 150 in which a sequence may be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned. Methods of alignment of sequencesfor comparison are well known in the art. Optimal alignment of sequencesfor comparison can be conducted, e.g., by the local homology algorithmof Smith and Waterman, Adv. Appl. Math. 2:482c (1970), by the homologyalignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443(1970), by the search for similarity method of Pearson and Lipman, Proc.Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations ofthese algorithms (GAP, BESTFIT, FASTA, and TFASTA in the WisconsinGenetics Software Package, Genetics Computer Group, 575 Science Dr.,Madison, Wis.), or by manual alignment and visual inspection (see, e.g.,Brent et al., Current Protocols in Molecular Biology, 2003).

Two examples of algorithms that are suitable for determining percentsequence identity and sequence similarity are the BLAST and BLAST 2.0algorithms, which are described in Altschul et al., Nuc. Acids Res.25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410,1990, respectively. Software for performing BLAST analyses is publiclyavailable through the National Center for Biotechnology Information.This algorithm involves first identifying high scoring sequence pairs(HSPs) by identifying short words of length W in the query sequence,which either match or satisfy some positive-valued threshold score Twhen aligned with a word of the same length in a database sequence. T isreferred to as the neighborhood word score threshold (Altschul et al.,supra). These initial neighborhood word hits act as seeds for initiatingsearches to find longer HSPs containing them. The word hits are extendedin both directions along each sequence for as far as the cumulativealignment score can be increased. Cumulative scores are calculatedusing, for nucleotide sequences, the parameters M (reward score for apair of matching residues; always >0) and N (penalty score formismatching residues; always <0). For amino acid sequences, a scoringmatrix is used to calculate the cumulative score. Extension of the wordhits in each direction are halted when: the cumulative alignment scorefalls off by the quantity X from its maximum achieved value; thecumulative score goes to zero or below, due to the accumulation of oneor more negative-scoring residue alignments; or the end of eithersequence is reached. The BLAST algorithm parameters W, T, and Xdetermine the sensitivity and speed of the alignment. The BLASTN program(for nucleotide sequences) uses as defaults a word length (W) of 11, anexpectation (E) or 10, M=5, N=−4 and a comparison of both strands. Foramino acid sequences, the BLASTP program uses as defaults a word lengthof 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (seeHenikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89:10915)alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparisonof both strands.

The BLAST algorithm also performs a statistical analysis of thesimilarity between two sequences (see, e.g., Karlin and Altschul, Proc.Natl. Acad. Sci. USA 90:5873-5787, 1993). One measure of similarityprovided by the BLAST algorithm is the smallest sum probability (P(N)),which provides an indication of the probability by which a match betweentwo nucleotide or amino acid sequences would occur by chance. Forexample, a nucleic acid is considered similar to a reference sequence ifthe smallest sum probability in a comparison of the test nucleic acid tothe reference nucleic acid is less than about 0.2, more preferably lessthan about 0.01, and most preferably less than about 0.001.

The percent identity between two amino acid sequences can also bedetermined using the algorithm of E. Meyers and W. Miller, (Comput.Appl. Biosci. 4:11-17, 1988) which has been incorporated into the ALIGNprogram (version 2.0), using a PAM120 weight residue table, a gap lengthpenalty of 12 and a gap penalty of 4. In addition, the percent identitybetween two amino acid sequences can be determined using the Needlemanand Wunsch, (J. Mol. Biol. 48:444-453, 1970), algorithm which has beenincorporated into the GAP program in the GCG software package (availablefrom University of South Florida), using either a BLOSUM 62 matrix or aPAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and alength weight of 1, 2, 3, 4, 5, or 6.

Other than percentage of sequence identity noted above, anotherindication that two nucleic acid sequences or polypeptides aresubstantially identical is that the polypeptide encoded by the firstnucleic acid is immunologically cross reactive with the antibodiesraised against the polypeptide encoded by the second nucleic acid, asdescribed below. Thus, a polypeptide is typically substantiallyidentical to a second polypeptide, for example, where the two peptidesdiffer only by conservative substitutions. Another indication that twonucleic acid sequences are substantially identical is that the twomolecules or their complements hybridize to each other under stringentconditions, as described below. Yet another indication that two nucleicacid sequences are substantially identical is that the same primers canbe used to amplify the sequence.

The term “nucleic acid” is used herein interchangeably with the term“polynucleotide” and refers to deoxyribonucleotides or ribonucleotidesand polymers thereof in either single- or double-stranded form. The termencompasses nucleic acids containing known nucleotide analogs ormodified backbone residues or linkages, which are synthetic, naturallyoccurring, and non-naturally occurring, which have similar bindingproperties as the reference nucleic acid, and which are metabolized in amanner similar to the reference nucleotides. Examples of such analogsinclude, without limitation, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides,peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence alsoimplicitly encompasses conservatively modified variants thereof (e.g.,degenerate codon substitutions) and complementary sequences, as well asthe sequence explicitly indicated. Specifically, as detailed below,degenerate codon substitutions may be achieved by generating sequencesin which the third position of one or more selected (or all) codons issubstituted with mixed-base and/or deoxyinosine residues (Batzer et al.,(1991) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) J. Biol. Chem.260:2605-2608; and Rossolini et al., (1994) Mol. Cell. Probes 8:91-98).

The term “operably linked” in the context of nucleic acids refers to afunctional relationship between two or more polynucleotide (e.g., DNA)segments. Typically, it refers to the functional relationship of atranscriptional regulatory sequence to a transcribed sequence. Forexample, a promoter or enhancer sequence is operably linked to a codingsequence if it stimulates or modulates the transcription of the codingsequence in an appropriate host cell or other expression system.Generally, promoter transcriptional regulatory sequences that areoperably linked to a transcribed sequence are physically contiguous tothe transcribed sequence, i.e., they are cis-acting. However, sometranscriptional regulatory sequences, such as enhancers, need not bephysically contiguous or located in close proximity to the codingsequences whose transcription they enhance.

The terms “polypeptide” and “protein” are used interchangeably herein torefer to a polymer of amino acid residues. The terms apply to amino acidpolymers in which one or more amino acid residue is an artificialchemical mimetic of a corresponding naturally occurring amino acid, aswell as to naturally occurring amino acid polymers and non-naturallyoccurring amino acid polymer. Unless otherwise indicated, a particularpolypeptide sequence also implicitly encompasses conservatively modifiedvariants thereof.

The term “subject” includes human and non-human animals. Non-humananimals include all vertebrates, e.g., mammals and non-mammals, such asnon-human primates, sheep, dog, cow, chickens, amphibians, and reptiles.Except when noted, the terms “patient” or “subject” are used hereininterchangeably.

The terms “BKV” or “BK virus” refer to a member of the familyPolyomaviridae, genus Orthopolyomavirus. Polyomaviruses are icosahedral,non-enveloped, double-stranded DNA viruses with a genome ofapproximately 5,000 base pairs. They measure approximately 40-45 nM indiameter (Bennett et al., Microbes and Infection. 2012:14(9):672-683).

“JCV” or “JC virus” refers to a member of the family Polyomaviridae,genus Orthopolyomavirus. JCV is related to BKV, and is also anicosahedral, non-enveloped, double-stranded DNA virus with a genome ofapproximately 5,000 base pairs. They measure approximately 40-45 nM indiameter (Johne et al., Arch. Virol. 2011; 156(9):1627-1634).

The terms “BKV nephropathy” or “BKV-associated nephropathy” or “BKVAN”refer to the inflammatory interstitial nephropathy resulting from thelytic infection with BKV, characterized by viral cytopathogenic changesand viral gene expression, primarily in the renal tubular epithelium.

The term “VP1” refers to the major polyoma virus capsid subunit protein.“VP1 pentamers” are composed of five monomers of VP1.

TABLE 1 VP1 sequences Name Sequence SEQ ID NO VP1 BKVMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEV (SEQ ID serotype IKTGVDAITEVECFLNPEMGDPDENLRGFSLKLSAENDFS NO: 1)SDSPERKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVQTEVIGITSMLNLHAGSQKVHEHGGGKPIQGSNFHFFAV GGDPLEMQGVLMNYRTKYPEGTITPKNPTAQSQVM N TDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQRVDGQPMYGMESQVEEVRVFDGTERLPGDPD MIRYIDKQGQLQTKML VP1 BKVMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEV (SEQ ID serotype IIKTGVDAITEVECFLNPEMGDPDDNLRGYSLKLTAENAFD NO: 2)SDSPDKKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGGKPVQGSNFHFFAV GGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVM N TDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGTEQLPGDPD MIRYIDRQGQLQTKMV VP1 BKVMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEV (SEQ ID serotype IIIKTGVDAITEVECFLNPEMGDPDDHLRGYSQHLSAENAF NO: 3)DSDSPDKKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGGKPVQGSNFHFFA VGGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVM NTDHKAYLDKNNAYPVECWIPDPSKNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGIEQLPGDP DMIRYIDRQGQLQTKMV VP1 BKVMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEV (SEQ ID serotype IVKTGVDAITEVECFLNPEMGDPDNDLRGYSLRLTAETAFD NO: 4)SDSPDRKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGGKPIQGSNFHFFAV GGDPLEMQGVLMNYRTKYPEGTVTPKNPTAQSQVM N TDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLPRYFKIRLRKRSVKNPYPISFLLSDLINRRTQRVDGQPMYGMESQVEEVRVFDGTEQLPGDPD MIRYIDRQGQLQTKMV JCV VP1MAPTKRKGERKDPVQVPKLLIRGGVEVLEVKTGVDSITE (SEQ IDVECFLTPEMGDPDEHLRGFSKSISISDTFESDSPNKDMLP NO: 5)CYSVARIPLPNLNEDLTCGNILMWEAVTLKTEVIGVTTLMNVHSNGQATHDNGAGKPVQGTSFHFFSVGGEALELQG VVF NYRTKYPDGTIFPKNATVQSQVMNTEHKAYLDKN KAYPVECWVPDPTRNENTRYFGTLTGGENVPPVLHITNTATTVLLDEFGVGPLCKGDNLYLSAVDVCGMFTNRSGSQQWRGLSRYFKVQLRKRRVKNPYPISFLLTDLINRRTPRVDGQPMYGMDAQVEEVRVFEGTEELPGDPDMMRYVDRY GQLQTKML

“Virus-like particles” or “VLP” are an assembly of VP1 pentamers intoviral capsids. VLPs are composed of 72 VP1 pentamers. VLPs arestructurally very similar to actual virus but lack the minor capsidproteins (VP2 and VP3) as well as the viral DNA genome, and thereforeare non-infectious. VLPs are useful as viral epitopes are presented in asimilar conformation to the actual virus.

“IC50” (half-maximal inhibitory concentration) refers to theconcentration of a particular antibody which induces a signal halfway(50%) between the baseline control and the maximum possible signal. Forexample, the IC50 is the concentration of antibody at which 50% of theavailable binding sites on the VP1 antigen are occupied.

“EC50” (half-maximal effective concentration) refers to theconcentration of a particular antibody which induces a response halfway(50%) between the baseline control and the maximum possible effect aftera specific exposure or treatment time. For example, the EC50 is theconcentration of antibody at which virus infection is neutralized by50%.

“EC90” refers to the concentration of a particular antibody whichinduces a response corresponding to 90% of the maximum possible effectafter a specific exposure or treatment time. For example, the EC90 isthe concentration of antibody at which virus infection is neutralized by90%.

“Neutralization” refers to the inhibition of viral infection of a hostcell, as demonstrated by the absence of viral gene expression. Withoutbeing held to any one theory, mechanisms of neutralization by aparticular antibody could include blocking the interaction of viralcapsid proteins with cell surface receptors or disruption of any stageof the entry and trafficking process prior to delivery of the viralgenome to the nucleus of the host cell.

As used herein, the terms “treat,” “treating,” or “treatment” of anydisease or disorder refer in one aspect, to ameliorating the disease ordisorder (i.e., slowing or arresting or reducing the development of thedisease or at least one of the clinical symptoms thereof). In anotheraspect, “treat,” “treating,” or “treatment” refers to alleviating orameliorating at least one physical parameter including those which maynot be discernible by the patient. In yet another aspect, “treat,”“treating,” or “treatment” refers to modulating the disease or disorder,either physically, (e.g., stabilization of a discernible symptom),physiologically, (e.g., stabilization of a physical parameter), or both.

The phrase “reducing the likelihood” refers to delaying the onset ordevelopment or progression of the disease, infection or disorder.

The term “therapeutically acceptable amount” or “therapeuticallyeffective dose” interchangeably refers to an amount sufficient to effectthe desired result (i.e., a reduction in tumor size, inhibition of tumorgrowth, prevention of metastasis, inhibition or prevention of viral,bacterial, fungal or parasitic infection). In some aspects, atherapeutically acceptable amount does not induce or cause undesirableside effects. A therapeutically acceptable amount can be determined byfirst administering a low dose, and then incrementally increasing thatdose until the desired effect is achieved. A “prophylactically effectivedosage,” and a “therapeutically effective dosage,” of the molecules ofthe present disclosure can prevent the onset of, or result in a decreasein severity of, respectively, disease symptoms, including symptomsassociated polyoma viral infection.

The term “co-administer” refers to the simultaneous presence of twoactive agents in the blood of an individual. Active agents that areco-administered can be concurrently or sequentially delivered.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1D graphically represents affinity measurements for anti-VP1antibodies on VP1 pentamers for BKV serotypes I-IV by SET assay.

FIG. 2 is a table of SET affinity values (K_(D)) for anti-VP1 antibodieson VP1 pentamers for BKV serotypes I-IV.

FIG. 3A-3E graphically represents affinity measurements for anti-VP1antibodies on VP1 pentamers or VLPs for BKV serotypes I-IV by Biacore.

FIG. 4 is a graph of anti-VP1 antibodies binding to BKV serotype I VLPsas measured by ELISA.

FIG. 5 is a graph of anti-VP1 antibodies binding to BKV serotype IV VLPsas measured by ELISA.

FIG. 6 is a graph of anti-VP1 antibodies binding to BKV serotype IV VP1pentamers as measured by ELISA.

FIG. 7 is a table of IC50 values generated by ELISA for anti-VP1antibodies binding to VLPs or VP1 pentamers for BKV serotypes I and IV.

FIG. 8 is a graph of anti-VP1 antibodies binding to BKV serotype I VLPsas measured by ELISA.

FIG. 9 is a table of IC50 values generated by ELISA for anti-VP1antibodies binding to BKV serotype I VLPs.

FIG. 10 is a graph of anti-VP1 antibodies binding to JC virus VLPs asmeasured by ELISA.

FIG. 11 is a table of IC50 values generated by ELISA for anti-VP1antibodies binding to JCV VLPs.

FIG. 12A-B shows two blots. The upper panel (FIG. 12A) is a Western blotdemonstrating no binding of anti-VP1 antibodies to denatured BKV VP1.The lower panel (FIG. 12B) is a dot-blot of non-denatured BKV VP1pentamers, demonstrating binding of anti-VP1 antibodies to non-denaturedVP1 pentamers.

FIG. 13A-13F graphically represents binding of anti-VP1 antibodies towild type BKV serotype I VP1 pentamers by Biacore, but that pointmutations in the VP1 can disrupt binding.

FIG. 14 is a table summarizing the key residues for binding identifiedin the epitopes of anti-VP1 antibodies.

FIG. 15 is a graph of anti-VP1 antibodies neutralizing BKV serotype Iinfection.

FIG. 16 is a graph of anti-VP1 antibodies neutralizing BKV serotype IIinfection.

FIG. 17 is a graph of anti-VP1 antibodies neutralizing BKV serotype IIIinfection.

FIG. 18 is a graph of anti-VP1 antibodies neutralizing BKV serotype IVinfection.

FIG. 19 is a table summarizing the neutralizing activity (EC50 and EC90)of anti-VP1 antibodies on BKV serotypes I-IV and JC virus.

FIG. 20 is a graph of anti-VP1 antibodies neutralizing infection withBKV serotypes I, II, and IV.

FIG. 21 is a table summarizing the neutralizing activity (EC50 and EC90)of anti-VP1 antibodies on BKV serotypes I-IV.

FIG. 22 is a graph of anti-VP1 antibodies neutralizing infection withBKV serotype I.

FIG. 23 is a table summarizing the neutralizing activity (EC50 and EC90)of anti-VP1 antibodies on BKV serotype I.

FIG. 24 is a graph of anti-VP1 antibodies neutralizing infection withJCV.

FIG. 25 is a graph of anti-VP1 antibodies neutralizing infection withJCV.

FIG. 26 is table summarizing the neutralizing activity (EC50 and EC90)of anti-VP1 antibodies on JCV infection.

FIG. 27 is table of antibody P8D11 affinity on JC virus VLPs and VLPscontaining point mutations.

FIG. 28 is deuterium exchange epitope mapping of a P8D11 Fab bound toBKV VP1 pentamers.

FIG. 29A is a table that shows anti-BKV antibody contact residues in theEF loop when certain mutations are introduced by alanine scanning. FIG.29B-29C shows the SPR graphs of anti-BKV antibody binding to wild typeand mutated residues in VP1.

FIG. 30 is an X-ray crystal structure of P8D11 in complex with BKV VP1pentamer.

FIG. 31A-B is a graphical representation of how P8D11 contacts theresidues of the VP1 pentamer.

DETAILED DESCRIPTION

The present disclosure provides for antibodies, antibody fragments(e.g., antigen binding fragments), that bind and neutralize BKV. Inparticular, the present disclosure is directed to antibodies andantibody fragments (e.g., antigen binding fragments) that bind to VP1proteins, and neutralize viral infection upon such binding. Furthermore,the present disclosure provides antibodies that have desirablepharmacokinetic characteristics and other desirable attributes, and thuscan be used for reducing the likelihood of or treating BKvirus-associated nephropathy (e.g. BKVAN). The present disclosurefurther provides pharmaceutical compositions comprising the antibodiesand methods of making and using such pharmaceutical compositions for theprevention and treatment of polyoma virus infection and associateddisorders.

Anti-VP1 Antibodies

The present disclosure provides for antibodies or antibody fragments(e.g., antigen binding fragments) that specifically bind to VP1.Antibodies or antibody fragments (e.g., antigen binding fragments) ofthe present disclosure include, but are not limited to, the humanmonoclonal antibodies or fragments thereof, isolated as described, inthe Examples below.

The present disclosure in certain aspects provides antibodies orantibody fragments (e.g., antigen binding fragments) that specificallybind to VP1, said antibodies or antibody fragments (e.g., antigenbinding fragments) comprise a VH domain having an amino acid sequence ofSEQ ID NO:12, 32, 52, 72, 92, 112, 132, 152, 172, 192, 212, 232, 252,272, 292, 312, 328, 348, 362, 376, 390, 404, 418, 432, 446, 460, 474,and 488 (Table 2). The present disclosure also provides antibodies orantibody fragments (e.g., antigen binding fragments) that specificallybind to VP1, said antibodies or antibody fragments (e.g., antigenbinding fragments) comprise a VH CDR having an amino acid sequence ofany one of the VH CDRs listed in Table 2. In particular aspects, thepresent disclosure provides antibodies or antibody fragments (e.g.,antigen binding fragments) that specifically bind to VP1, saidantibodies comprising (or alternatively, consist of) one, two, three, ormore VH CDRs having an amino acid sequence of any of the VH CDRs listedin Table 2.

The present disclosure provides antibodies or antibody fragments (e.g.,antigen binding fragments) that specifically bind to VP1, saidantibodies or antibody fragments (e.g., antigen binding fragments)comprise a VL domain having an amino acid sequence of SEQ ID NO: 22, 42,62, 82, 102, 122, 142, 162, 182, 202, 222, 242, 262, 282, 302, 320, 338,355, 369, 383, 397, 411, 425, 439, 453, 467, 481, and 495 (Table 2). Thepresent disclosure also provides antibodies or antibody fragments (e.g.,antigen binding fragments) that specifically bind to VP1, saidantibodies or antibody fragments (e.g., antigen binding fragments)comprise a VL CDR having an amino acid sequence of any one of the VLCDRs listed in Table 2. In particular, the disclosure providesantibodies or antibody fragments (e.g., antigen binding fragments) thatspecifically bind to VP1, said antibodies or antibody fragments (e.g.,antigen binding fragments) comprise (or alternatively, consist of) one,two, three or more VL CDRs having an amino acid sequence of any of theVL CDRs listed in Table 2.

Other antibodies or antibody fragments (e.g., antigen binding fragments)of the present disclosure include amino acids that have been mutated,yet have at least 60, 70, 80, 90 or 95 percent identity in the CDRregions with the CDR regions depicted in the sequences described inTable 2. In some aspects, it includes mutant amino acid sequenceswherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated inthe CDR regions when compared with the CDR regions depicted in thesequence described in Table 2.

The present disclosure also provides nucleic acid sequences that encodeVH, VL, the full length heavy chain, and the full length light chain ofthe antibodies that specifically bind to VP1. Such nucleic acidsequences can be optimized for expression in mammalian cells.

TABLE 2 anti- VP1 Antibodies P8D11 SEQ ID NO: 6 HCDR1 NYWMT (Kabat)SEQ ID NO: 7 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 8 HCDR3VRSGRYFALDD (Kabat) SEQ ID NO: 9 HCDR1 GFTFNNY (Chothia) SEQ ID NO: 10HCDR2 KKDGSE (Chothia) SEQ ID NO: 11 HCDR3 VRSGRYFALDD (Chothia)SEQ ID NO: 12 VH QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 13 DNA CAGGTGCAGCTGGTGGAATCAGGCGGCACACTGVH GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCG CTGCTAGTGGCTTCACCTTTAACAACTACTGGATGACCTGGGTTAGGCAGGCCCCTGGTAAAGGCCTC GAGTGGGTGGCAAATATCAAGAAGGACGGTAGCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGG TTCACTATCTCTAGGGATAACGCTAAGAATAGCCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGA TACCGCCGTCTACTTCTGTGCTACCGTCAGATCAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAG GCACACTGGTCACCGTGTCTAGC SEQ ID NO: 14Heavy QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGRF TISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 15 DNACAGGTGCAGCTGGTGGAATCAGGCGGCACACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCTGCTAGTGGCTTCACCTTTAACAACTACTGGA TGACCTGGGTTAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTAG CGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAGC CTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGATC AGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGCGCTAGCACTA AGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGGT TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCGG CGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGTG CCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAGA ACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGG ACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTGGT ACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCT ACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAA AGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCACG GGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGAC CTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAG AACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTGA CCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCA CAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 16 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 17 LCDR2DDSNRPS (Kabat) SEQ ID NO: 18 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 19LCDR1 DNIGSRP (Chothia) SEQ ID NO: 20 LCDR2 DDS (Chothia) SEQ ID NO: 21LCDR3 WSSSTDH (Chothia) SEQ ID NO: 22 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 23 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 24 LightQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPIE CS SEQ ID NO: 25 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P8D11A SEQ ID NO: 26 HCDR1 NYWMT(Kabat) SEQ ID NO: 27 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 28HCDR3 VRSGRYFALDD (Kabat) SEQ ID NO: 29 HCDR1 GFTFSNY (Chothia)SEQ ID NO: 30 HCDR2 KKDGSE (Chothia) SEQ ID NO: 31 HCDR3 VRSGRYFALDD(Chothia) SEQ ID NO: 32 VH QVQLVESGGTLVQPGGSLRLSCAASGFTFSNYWMTWVRQAPGKGLEWVANTKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 33 DNA VHCAGGTGCAGCTGGTGGAATCAGGCGGCACACTG GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCGCTGCTAGTGGCTTCACCTTCTCTAACTACTGGA TGACCTGGGTCAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGC SEQ ID NO: 34 HeavyQVQLVESGGTLVQPGGSLRLSCAASGFTFSNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 35 DNACAGGTGCAGCTGGTGGAATCAGGCGGCACACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCTGCTAGTGGCTTCACCTTCTCTAACTACTGGA TGACCTGGGTCAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGCGCTAGCACT AAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGG TTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCG GCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGT GCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAG AACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAG GACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTG GTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCAC CTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGC AAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCA CGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGA CCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGA GAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTG ACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGC ACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 36 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 37 LCDR2DDSNRPS (Kabat) SEQ ID NO: 38 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 39LCDR1 DNIGSRP (Chothia) SEQ ID NO: 40 LCDR2 DDS (Cho thia) SEQ ID NO: 41LCDR3 WSSSTDH (Chothia) SEQ ID NO: 42 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 43 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 44 LightQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPFE Cs SEQ ID NO: 45 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P8D11B SEQ ID NO: 46 HCDR1 NYWMT(Kabat) SEQ ID NO: 47 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 48HCDR3 VRSGRYFALDD (Kabat) SEQ ID NO: 49 HCDR1 GFTFKNY (Chothia)SEQ ID NO: 50 HCDR2 KKDGSE (Chothia) SEQ ID NO: 51 HCDR3 VRSGRYFALDD(Chothia) SEQ ID NO: 52 VH QVQLVESGGTLVQPGGSLRLSCAASGFTFKNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 53 DNA VHCAGGTGCAGCTGGTGGAATCAGGCGGCACACTG GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCGCTGCTAGTGGCTTCACCTTTAAGAACTACTGGA TGACCTGGGTCAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGC SEQ ID NO: 54 HeavyQVQLVESGGTLVQPGGSLRLSCAASGFTFKNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 55 DNACAGGTGCAGCTGGTGGAATCAGGCGGCACACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCTGCTAGTGGCTTCACCTTTAAGAACTACTGGA TGACCTGGGTCAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGCGCTAGCACT AAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGG TTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCG GCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGT GCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAG AACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAG GACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTG GTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCAC CTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGC AAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCA CGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGA CCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGA GAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTG ACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGC ACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 56 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 57 LCDR2DDSNRPS (Kabat) SEQ ID NO: 58 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 59LCDR1 DNIGSRP (Chothia) SEQ ID NO: 60 LCDR2 DDS (Chothia) SEQ ID NO: 61LCDR3 WSSSTDH (Chothia) SEQ ID NO: 62 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 63 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 64 LightQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTE CS SEQ ID NO: 65 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P8D11C SEQ ID NO: 66 HCDR1 NYWMT(Kabat) SEQ ID NO: 67 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 68HCDR3 VRSGRYFALDD (Kabat) SEQ ID NO: 69 HCDR1 GFTFQNY (Chothia)SEQ ID NO: 70 HCDR2 KKDGSE (Chothia) SEQ ID NO: 71 HCDR3 VRSGRYFALDD(Chothia) SEQ ID NO: 72 VH QVQLVESGGTLVQPGGSLRLSCAASGFTFQNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 73 DNA VHCAGGTGCAGCTGGTGGAATCAGGCGGCACACTG GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCGCCGCTAGTGGATTCACCTTTCAGAACTACTGGA TGACCTGGGTCAGACAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGC SEQ ID NO: 74 HeavyQVQLVESGGTLVQPGGSLRLSCAASGFTFQNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 75 DNACAGGTGCAGCTGGTGGAATCAGGCGGCACACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCCGCTAGTGGATTCACCTTTCAGAACTACTGGA TGACCTGGGTCAGACAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTA GCGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAG CCTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGAT CAGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGCGCTAGCACT AAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGG TTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCG GCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGT GCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAG AACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAG GACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTG GTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCAC CTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGC AAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCA CGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGA CCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGA GAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTG ACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGC ACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 76 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 77 LCDR2DDSNRPS (Kabat) SEQ ID NO: 78 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 79LCDR1 DNIGSRP (Chothia) SEQ ID NO: 80 LCDR2 DDS (Chothia) SEQ ID NO: 81LCDR3 WSSSTDH (Chothia) SEQ ID NO: 82 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 83 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 84 LightQSVLTQPPSVSVAPGKTARTTCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPIE CS SEQ ID NO: 85 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P8D11D SEQ ID NO: 86 HCDR1 NYWMT(Kabat) SEQ ID NO: 87 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 88HCDR3 VRSGRYFALDD (Kabat) SEQ ID NO: 89 HCDR1 GFTFNNY (Chothia)SEQ ID NO: 90 HCDR2 KKDGSE (Chothia) SEQ ID NO: 91 HCDR3 VRSGRYFALDD(Cho thia) SEQ ID NO: 92 VH QVQLQESGPGLVQPGGSLRLSCAASGFTFNNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 93 DNA VHCAGGTGCAGCTGCAGGAATCAGGCCCAGGACTG GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCGCTGCTAGTGGCTTCACCTTTAACAACTACTGGA TGACCTGGGTCCGCCAGGCCCCTGGCAAAGGCCTGGAGTGGGTGGCAAATATCAAGAAGGACGGTAG CGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAGC CTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGATC AGGCCGCTACTTCGCCCTGGACGACTGGGGCCAGGGCACCCTGGTCACCGTGTCTTCC SEQ ID NO: 94 HeavyQVQLQESGPGLVQPGGSLRLSCAASGFTFNNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 95 DNACAGGTGCAGCTGCAGGAATCAGGCCCAGGACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCTGCTAGTGGCTTCACCTTTAACAACTACTGGA TGACCTGGGTCCGCCAGGCCCCTGGCAAAGGCCTGGAGTGGGTGGCAAATATCAAGAAGGACGGTAG CGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAGC CTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGATC AGGCCGCTACTTCGCCCTGGACGACTGGGGCCAGGGCACCCTGGTCACCGTGTCTTCCGCTAGCACT AAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGG TTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCG GCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGT GCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAG GTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAG AACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAG GACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTG GTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCAC CTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGC AAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCA CGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGA CCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGA GAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTG ACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGC ACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 96 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 97 LCDR2DDSNRPS (Kabat) SEQ ID NO: 98 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 99LCDR1 DNIGSRP (Chothia) SEQ ID NO: 100 LCDR2 DDS (Chothia)SEQ ID NO: 101 LCDR3 WSSSTDH (Chothia) SEQ ID NO: 102 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 103 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 104 LightQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPIE CS SEQ ID NO: 105 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P8D11E SEQ ID NO: 106 HCDR1 NYWMT(Kabat) SEQ ID NO: 107 HCDR2 NIKKDGSEKYYVDSVRG (Kabat) SEQ ID NO: 108HCDR3 VRSGRYFALDD (Kabat) SEQ ID NO: 109 HCDR1 GFTFNNY (Chothia)SEQ ID NO: 110 HCDR2 KKDGSE (Chothia) SEQ ID NO: 111 HCDR3 VRSGRYFALDD(Chothia) SEQ ID NO: 112 VH QVQLVESGGGLVQPGGSLRLSCAASGFTFNNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTTSRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS SEQ ID NO: 113 DNA VHCAGGTGCAGCTGGTGGAATCAGGCGGCGGACTG GTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGCGCTGCTAGTGGCTTCACCTTTAACAACTACTGGA TGACCTGGGTTAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTAG CGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAGC CTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGATC AGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGC SEQ ID NO: 114 HeavyQVQLVESGGGLVQPGGSLRLSCAASGFTFNNYWM ChainTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGR FTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPTEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDGSFFLYSKLTVDKSRWQQGNNTSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 115 DNACAGGTGCAGCTGGTGGAATCAGGCGGCGGACTG HeavyGTGCAGCCTGGCGGTAGCCTGAGACTGAGCTGC ChainGCTGCTAGTGGCTTCACCTTTAACAACTACTGGA TGACCTGGGTTAGGCAGGCCCCTGGTAAAGGCCTCGAGTGGGTGGCAAATATCAAGAAGGACGGTAG CGAGAAGTACTACGTGGACTCAGTCAGAGGCCGGTTCACTATCTCTAGGGATAACGCTAAGAATAGC CTGTTCCTGCAGATGAACTCACTGAGGCCCGAGGATACCGCCGTCTACTTCTGTGCTACCGTCAGATC AGGCCGCTACTTCGCCCTGGACGACTGGGGTCAAGGCACACTGGTCACCGTGTCTAGCGCTAGCACTA AGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCCCTGGGT TGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGACTTCCGG CGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACAGTG CCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGG TGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGCTCCAGA ACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCAGG ACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCAACTGGT ACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACAGCACCT ACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAA AGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCAGCCACG GGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCCCTGAC CTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAG AACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAAGCTGA CCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGCCCTGCA CAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 116 LCDR1 GGDNIGSRPVH (Kabat) SEQ ID NO: 117 LCDR2DDSNRPS (Kabat) SEQ ID NO: 118 LCDR3 QVWSSSTDHP (Kabat) SEQ ID NO: 119LCDR1 DNIGSRP (Chothia) SEQ ID NO: 120 LCDR2 DDS (Chothia)SEQ ID NO: 121 LCDR3 WSSSTDH (Chothia) SEQ ID NO: 122 VLQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY QQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTV L SEQ ID NO: 123 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG TGGCCCCTGGTAAAACCGCTAGAATCACCTGTGGCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTG SEQ ID NO: 124 LightQSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWY ChainQQKPGQAPILVVYDDSNRPSGTPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYP GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTE CS SEQ ID NO: 125 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightTGGCCCCTGGTAAAACCGCTAGAATCACCTGTGG ChainCGGCGATAATATCGGCTCTAGGCCCGTGCACTGG TATCAGCAGAAGCCCGGTCAAGCCCCTATCCTGGTGGTCTACGACGACTCTAATAGACCTAGCGGAAT CCCCGAGCGGTTTAGCGGCTCTAATTCTGGTAATACCGCTACCCTGACTATCTCTAGGGTGGAAGCCG GCGACGAGGCCGACTACTACTGTCAAGTCTGGTCTAGCTCTACCGATCACCCCTTCGGCGGAGGCACT AAGGTTACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCCCCAGCAGCGAGGA GCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGGCGCCGTGACCGTG GCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCCCAGCAAGCAGAGC AACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAAGAGCCACAGGTCC TACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCCAACCGAGTGCAGC P165E2 SEQ ID NO: 126 HCDR1 RDYWT(Kabat) SEQ ID NO: 127 HCDR2 NIYYSGSTNYNPSLKS (Kabat) SEQ ID NO: 128HCDR3 VPGCSSTSCIDGWFDP (Kabat) SEQ ID NO: 129 HCDR1 GGSISRD (Chothia)SEQ ID NO: 130 HCDR2 YYSGS (Chothia) SEQ ID NO: 131 HCDR3VPGCSSTSCIDGWFDP (Chothia) SEQ ID NO: 132 VHQVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWT WVRQPPGEGLEWIGNIYYSGSTNYNPSLKSRVTISVAASKKQFSLKLTSVTAADTAVYYCARVPGCSSTSC IDGWFDPWGQGILVTVSS SEQ ID NO: 133DNA VH CAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGC ACCGTCAGCGGCGGCTCTATCTCTAGGGACTACTGGACCTGGGTCCGACAGCCTCCTGGCGAGGGCC TCGAGTGGATCGGTAATATCTACTATAGCGGCTCTACTAACTATAACCCTAGCCTGAAGTCTAGGGTC ACAATTAGCGTGGCCGCCTCTAAGAAGCAGTTTAGCCTGAAGCTGACTAGCGTGACCGCCGCTGACA CCGCCGTCTACTACTGCGCTAGAGTGCCCGGCTGCTCTAGCACTAGCTGTATCGACGGCTGGTTTGAC CCTTGGGGTCAAGGGATCCTGGTCACCGTGTCTA GCSEQ ID NO: 134 Heavy QVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWT ChainWVRQPPGEGLEWIGNIYYSGSTNYNPSLKSRVTISV AASKKQFSLKLTSVTAADTAVYYCARVPGCSSTSCIDGWFDPWGQGILVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPTEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 135 DNACAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTG HeavyGTCAAGCCTAGCGAGACACTGAGCCTGACCTGC ChainACCGTCAGCGGCGGCTCTATCTCTAGGGACTACT GGACCTGGGTCCGACAGCCTCCTGGCGAGGGCCTCGAGTGGATCGGTAATATCTACTATAGCGGCTC TACTAACTATAACCCTAGCCTGAAGTCTAGGGTCACAATTAGCGTGGCCGCCTCTAAGAAGCAGTTTA GCCTGAAGCTGACTAGCGTGACCGCCGCTGACACCGCCGTCTACTACTGCGCTAGAGTGCCCGGCTG CTCTAGCACTAGCTGTATCGACGGCTGGTTTGACCCTTGGGGTCAAGGGATCCTGGTCACCGTGTCTA GCGCTAGCACTAAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACT GCTGCCCTGGGTTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGC TCTGACTTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGC GTGGTGACAGTGCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCA GCAACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCT GCCCAGCTCCAGAACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTG ATGATCAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTG AAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAG TACAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAG AATACAAGTGCAAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCA AGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACC AGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAA CGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTG TACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATG CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 136 LCDR1 SGSSSNIGNTYVS (Kab at)SEQ ID NO: 137 LCDR2 DNNKRPS (Kabat) SEQ ID NO: 138 LCDR3 GTWDSSLSAWV(Kabat) SEQ ID NO: 139 LCDR1 SSSNIGNTY (Chothia) SEQ ID NO: 140 LCDR2DNN (Chothia) SEQ ID NO: 141 LCDR3 WDSSLSAW (Chothia) SEQ ID NO: 142 VLQSVLTQPPSLSAAPGQRVTISCSGSSSNIGNTYVSWYQQLPGTAPKLLIYDNNKRPSGIPGRFSGSKSGTSA TLGTTGLQTGDEAAYYCGTWDSSLSAWVFGGGTRLTVL SEQ ID NO: 143 DNA VL CAGTCAGTCCTGACTCAGCCCCCTAGCCTGAGCGCCGCTCCCGGTCAAAGAGTGACTATTAGCTGTAG CGGCTCTAGCTCTAATATCGGTAATACCTACGTCAGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTA AGCTGCTGATCTACGATAACAACAAGCGGCCTAGCGGAATCCCTGGTCGCTTTAGCGGATCTAAATC AGGCACTAGCGCTACCCTGGGAATCACCGGCCTGCAGACCGGCGACGAAGCCGCCTACTACTGCGG CACCTGGGACTCTAGTCTGAGCGCCTGGGTGTTCGGCGGAGGCACTAGACTGACCGTGCTG SEQ ID NO: 144 LightQSVLTQPPSLSAAPGQRVTISCSGSSSNIGNTYVSW ChainYQQLPGTAPKLLIYDNNKRPSGIPGRFSGSKSGTSA TLGITGLQTGDEAAYYCGTWDSSLSAWVFGGGTRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLTSD FYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA PTECS SEQ ID NO: 145 DNACAGTCAGTCCTGACTCAGCCCCCTAGCCTGAGCG LightCCGCTCCCGGTCAAAGAGTGACTATTAGCTGTAG ChainCGGCTCTAGCTCTAATATCGGTAATACCTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCTGGTCGCTTTAGCGGATCTAAATCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAAGCCGCCTACTACTGCGGCACCTGGGACTCTAGTCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAGACTGACCGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCC CCAGCAGCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGG CGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCC CAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAA GAGCCACAGGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCC AACCGAGTGCAGC NEG447 SEQ ID NO: 146HCDR1 RDYWS (Kabat) SEQ ID NO: 147 HCDR2 NIYYSGSTNYNPSLKS (Kabat)SEQ ID NO: 148 HCDR3 VPGCSSTSCEDGWFDP (Kabat) SEQ ID NO: 149 HCDR1GGSISRD (Chothia) SEQ ID NO: 150 HCDR2 YYSGS (Chothia) SEQ ID NO: 151HCDR3 VPGCSSTSCIDGWFDP (Cho thia) SEQ ID NO: 152 VHQVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWS WVRQPPGAGLEWIGNIYYSGSTNYNPSLKSRVTISVATNKKQFSLKLTSVTAADTAVYYCARVPGCSSTSC IDGWFDPWGQGILVTVSS SEQ ID NO: 153DNA VH CAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTGGTCAAGCCTAGCGAGACACTGAGCCTGACCTGC ACCGTCAGCGGCGGCTCTATCTCTAGGGACTACTGGTCCTGGGTCCGACAACCTCCTGGCGCTGGCCT CGAGTGGATCGGTAATATCTACTATAGCGGCTCTACTAACTATAACCCTAGCCTGAAGTCTAGGGTCA CAATTAGTGTGGCTACTAACAAGAAGCAGTTTAGCCTGAAGCTGACTAGCGTGACCGCCGCTGACACC GCCGTCTACTACTGCGCTAGAGTGCCCGGCTGCTCTAGCACTAGCTGTATCGACGGTTGGTTTGACCC TTGGGGTCAAGGGATCCTGGTCACCGTGTCTAGCSEQ ID NO: 154 Heavy QVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWS ChainWVRQPPGAGLEWIGNIYYSGSTNYNPSLKSRVTISV ATNKKQFSLKLTSVTAADTAVYYCARVPGCSSTSCIDGWFDPWGQGILVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 155 DNACAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTG HeavyGTCAAGCCTAGCGAGACACTGAGCCTGACCTGC ChainACCGTCAGCGGCGGCTCTATCTCTAGGGACTACT GGTCCTGGGTCCGACAACCTCCTGGCGCTGGCCTCGAGTGGATCGGTAATATCTACTATAGCGGCTCT ACTAACTATAACCCTAGCCTGAAGTCTAGGGTCACAATTAGTGTGGCTACTAACAAGAAGCAGTTTAG CCTGAAGCTGACTAGCGTGACCGCCGCTGACACCGCCGTCTACTACTGCGCTAGAGTGCCCGGCTGCT CTAGCACTAGCTGTATCGACGGTTGGTTTGACCCTTGGGGTCAAGGGATCCTGGTCACCGTGTCTAGC GCTAGCACTAAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGC TGCCCTGGGTTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTC TGACTTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGT GGTGACAGTGCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGC AACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCC CAGCTCCAGAACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATG ATCAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAG TTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTAC AACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAA TACAAGTGCAAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAG GGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAG GTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACG GCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTA CAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCA CGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 156 LCDR1 SGSSSNIGNTYVS (Kabat)SEQ ID NO: 157 LCDR2 DNNKRPS (Kabat) SEQ ID NO: 158 LCDR3 GTWDSSLSAWV(Kabat) SEQ ID NO: 159 LCDR1 SSSNIGNTY (Chothia) SEQ ID NO: 160 LCDR2DNN (Chothia) SEQ ID NO: 161 LCDR3 WDSSLSAW (Chothia) SEQ ID NO: 162 VLQSVLTQPPSLSAAPGQKVTISCSGSSSNIGNTYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSA TLGITGLQTGDEAVYYCGTWDSSLSAWVFGGGTRLTVL SEQ ID NO: 163 DNA VL CAGTCAGTCCTGACTCAGCCCCCTAGCCTGAGCGCCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAG CGGCTCTAGCTCTAATATCGGTAATACCTACGTCAGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTA AGCTGCTGATCTACGATAACAACAAGCGGCCTAGCGGAATCCCCGATAGGTTTAGCGGATCTAAGTC AGGCACTAGCGCTACCCTGGGAATCACCGGCCTGCAGACCGGCGACGAGGCCGTCTACTACTGCGG CACCTGGGACTCTAGTCTGAGCGCCTGGGTGTTCGGCGGAGGCACTAGACTGACCGTGCTG SEQ ID NO: 164 LightQSVLTQPPSLSAAPGQKVTISCSGSSSNIGNTYVSW ChainYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSA TLGTTGLQTGDEAVYYCGTWDSSLSAWVFGGGTRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISD FYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA PTECS SEQ ID NO: 165 DNACAGTCAGTCCTGACTCAGCCCCCTAGCCTGAGCG LightCCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAG ChainCGGCTCTAGCTCTAATATCGGTAATACCTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCCGATAGGTTTAGCGGATCTAAGTCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAGGCCGTCTACTACTGCGGCACCTGGGACTCTAGTCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAGACTGACCGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCC CCAGCAGCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGG CGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCC CAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAA GAGCCACAGGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCC AACCGAGTGCAGC NEG447A SEQ ID NO: 166HCDR1 RDYWS (Kabat) SEQ ID NO: 167 HCDR2 NIYYSGSTNYNPSLKS (Kabat)SEQ ID NO: 168 HCDR3 VPGCSSTSCIDGWFDP (Kabat) SEQ ID NO: 169 HCDR1GGSISRD (Chothia) SEQ ID NO: 170 HCDR2 YYSGS (Chothia) SEQ ID NO: 171HCDR3 VPGCSSTSCIDGWFDP (Chothia) SEQ ID NO: 172 VHQVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWS WVRQPPGAGLEWIGNIYYSGSTNYNPSLKSRVTISVATNKKQFSLKLTSVTAADTAVYYCARVPGCSSTSC IDGWFDPWGQGILVTVSS SEQ ID NO: 173DNA VH CAGGTGCAATTGCAGGAAAGCGGCCCTGGCCTCGTGAAGCCCAGCGAGACACTGAGCCTGACCTGT ACCGTGTCCGGCGGCAGCATCAGCAGAGACTACTGGAGCTGGGTTCGCCAGCCTCCAGGCGCAGGA CTGGAATGGATCGGCAACATCTACTACAGCGGCAGCACCAACTACAACCCCAGCCTGAAGTCCAGA GTGACCATCAGCGTGGCCACAAACAAGAAACAGTTCTCCCTGAAGCTGACCAGCGTGACAGCCGCCG ATACCGCCGTGTACTACTGCGCCAGAGTGCCTGGCTGTAGCAGCACCAGCTGCATCGACGGATGGTTC GACCCTTGGGGCCAGGGCATTCTCGTGACCGTCAGCTCA SEQ ID NO: 174 Heavy QVQLQESGPGLVKPSETLSLTCTVSGGSISRDYWS ChainWVRQPPGAGLEWIGNIYYSGSTNYNPSLKSRVTISV ATNKKQFSLKLTSVTAADTAVYYCARVPGCSSTSCIDGWFDPWGQGILVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 175 DNACAGGTGCAATTGCAGGAAAGCGGCCCTGGCCTC HeavyGTGAAGCCCAGCGAGACACTGAGCCTGACCTGT ChainACCGTGTCCGGCGGCAGCATCAGCAGAGACTAC TGGAGCTGGGTTCGCCAGCCTCCAGGCGCAGGACTGGAATGGATCGGCAACATCTACTACAGCGGC AGCACCAACTACAACCCCAGCCTGAAGTCCAGAGTGACCATCAGCGTGGCCACAAACAAGAAACAG TTCTCCCTGAAGCTGACCAGCGTGACAGCCGCCGATACCGCCGTGTACTACTGCGCCAGAGTGCCTGG CTGTAGCAGCACCAGCTGCATCGACGGATGGTTCGACCCTTGGGGCCAGGGCATTCTCGTGACCGTCA GCTCAGCTAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGG CACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACCGTGTCCTGGAACAGC GGAGCCCTGACCTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGTC CAGCGTGGTGACAGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAA GCCCAGCAACACCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCC CCCCTGCCCAGCCCCAGAGCTGCTGGGCGGACCCTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACA CCCTGATGATCAGCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCACGAGGACCCAG AGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGG AGCAGTACAACAGCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACG GCAAGGAATACAAGTGCAAGGTCTCCAACAAGGCCCTGCCAGCCCCCATCGAAAAGACCATCAGCA AGGCCAAGGGCCAGCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCTCCCGGGAGGAGATGACCA AGAACCAGGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGA GAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTC TTCCTGTACAGCAAGCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCG TGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCCCGGCAAG SEQ ID NO: 176 LCDR1 SGSSSNIGNTYVS (Kabat)SEQ ID NO: 177 LCDR2 DNNKRPS (Kabat) SEQ ID NO: 178 LCDR3 GTWDSSLSAWV(Kabat) SEQ ID NO: 179 LCDR1 SSSNIGNTY (Chothia) SEQ ID NO: 180 LCDR2DNN (Chothia) SEQ ID NO: 181 LCDR3 WDSSLSAW (Chothia) SEQ ID NO: 182 VLQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNTYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSA TLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTRLTVL SEQ ID NO: 183 DNA VL CAAAGCGTGCTGACCCAGCCTCCTAGCGTGTCTGCTGCCCCTGGCCAGAAGGTGACCATCAGCTGTAG CGGCAGCAGCTCCAACATCGGCAACACCTACGTGTCCTGGTATCAGCAGCTGCCCGGCACCGCCCCC AAACTGCTGATCTACGACAACAACAAGCGGCCCAGCGGCATCCCCGATAGATTTTCTGGCAGCAAGA GCGGCACCAGCGCCACCCTGGGAATCACAGGACTGCAGACAGGGGACGAGGCCGATTACTACTGTG GCACCTGGGATTCTAGCCTGAGCGCCTGGGTGTTCGGCGGAGGCACAAGACTGACAGTGCTG SEQ ID NO: 184 LightQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNTYVSW ChainYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSA TLGITGLQTGDEADYYCGTWDSSLSAWVFGGGTRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISD FYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA PTECS SEQ ID NO: 185 DNACAAAGCGTGCTGACCCAGCCTCCTAGCGTGTCTG LightCTGCCCCTGGCCAGAAGGTGACCATCAGCTGTAG ChainCGGCAGCAGCTCCAACATCGGCAACACCTACGT GTCCTGGTATCAGCAGCTGCCCGGCACCGCCCCCAAACTGCTGATCTACGACAACAACAAGCGGCCC AGCGGCATCCCCGATAGATTTTCTGGCAGCAAGAGCGGCACCAGCGCCACCCTGGGAATCACAGGAC TGCAGACAGGGGACGAGGCCGATTACTACTGTGGCACCTGGGATTCTAGCCTGAGCGCCTGGGTGTT CGGCGGAGGCACAAGACTGACAGTGCTGGGTCAGCCTAAGGCCGCTCCCTCCGTGACCCTGTTCCCC CCCAGCTCCGAGGAACTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCTG GCGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACAACCACCC CCAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGA AGAGCCACAGAAGCTACAGCTGCCAGGTCACCCACGAGGGCAGCACCGTGGAGAAAACCGTGGCCC CCACCGAGTGCAGC P7G11 SEQ ID NO: 186HCDR1 SGGYSWS (Kabat) SEQ ID NO: 187 HCDR2 YIYYRGTTYYNPSLKS (Kabat)SEQ ID NO: 188 HCDR3 ALTHLVGVGWFDP (Kabat) SEQ ID NO: 189 HCDR1GGSISSGGY (Chothia) SEQ ID NO: 190 HCDR2 YYRGT (Chothia) SEQ ID NO: 191HCDR3 ALTHLVGVGWFDP (Chothia) SEQ ID NO: 192 VHQVQLQESGPGLAKPSQTLSLTCSVSGGSISSGGYSWSWIRQPPGKGLEYIGYIYYRGTTYYNPSLKSRITMS VDTSNNQISLKLTSVTAADTAVYYCARALTHLVGVGWFDPWGQGTMVTVSS SEQ ID NO: 193 DNA VH CAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTGGCTAAGCCTAGTCAGACCCTGAGCCTGACCTGTA GCGTCAGCGGAGGCTCTATCTCTAGCGGCGGCTATAGCTGGTCCTGGATTAGACAGCCCCCAGGTAAA GGCCTCGAGTATATCGGCTATATCTACTATAGGGGCACTACCTACTATAACCCTAGCCTGAAGTCTAG GATCACTATGAGCGTGGACACCTCTAACAATCAGATTAGCCTGAAGCTGACTAGCGTGACCGCCGCTG ACACCGCCGTCTACTACTGCGCTAGAGCCCTGACTCACCTCGTTGGAGTGGGCTGGTTTGACCCTTGG GGTCAAGGCACTATGGTCACCGTGTCTAGCSEQ ID NO: 194 Heavy QVQLQESGPGLAKPSQTLSLTCSVSGGSISSGGYSW ChainSWIRQPPGKGLEYIGYIYYRGTTYYNPSLKSRITMS VDTSNNQISLKLTSVTAADTAVYYCARALTHLVGVGWFDPWGQGTMVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 195 DNACAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTG HeavyGCTAAGCCTAGTCAGACCCTGAGCCTGACCTGTA ChainGCGTCAGCGGAGGCTCTATCTCTAGCGGCGGCTA TAGCTGGTCCTGGATTAGACAGCCCCCAGGTAAAGGCCTCGAGTATATCGGCTATATCTACTATAGGG GCACTACCTACTATAACCCTAGCCTGAAGTCTAGGATCACTATGAGCGTGGACACCTCTAACAATCAG ATTAGCCTGAAGCTGACTAGCGTGACCGCCGCTGACACCGCCGTCTACTACTGCGCTAGAGCCCTGAC TCACCTCGTTGGAGTGGGCTGGTTTGACCCTTGGGGTCAAGGCACTATGGTCACCGTGTCTAGCGCTA GCACTAAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCC CTGGGTTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGAC TTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTG ACAGTGCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACA CCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGC TCCAGAACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCA GCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCA ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACA GCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAA GTGCAAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCA GCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCC CTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGC CCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAA GCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGC CCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 196 LCDR1 SGGSSNLGSNYVS (Kabat)SEQ ID NO: 197 LCDR2 DNNKRPS (Kabat) SEQ ID NO: 198 LCDR3 GTWDGSLSAWV(Kabat) SEQ ID NO: 199 LCDR1 GSSNLGSNY (Chothia) SEQ ID NO: 200 LCDR2DNN (Chothia) SEQ ID NO: 201 LCDR3 WDGSLSAW (Chothia) SEQ ID NO: 202 VLQSVLTQPPSVSAAPGQKVTISCSGGSSNLGSNYVS WYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDGSLSAWVFGGGT KVTVL SEQ ID NO: 203 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG CCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAGCGGCGGCTCCTCTAACCTGGGCTCTAACTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCCGATAGGTTTAGCGGCTCTAAGTCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAGGCCGACTACTACTGTGGCACCTGGGACGGTAGCCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAAAGTCACAGTGCTGSEQ ID NO: 204 Light QSVLTQPPSVSAAPGQKVTISCSGGSSNLGSNYVS ChainWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTS ATLGITGLQTGDEADYYCGTWDGSLSAWVFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS SEQ ID NO: 205 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightCCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAG ChainCGGCGGCTCCTCTAACCTGGGCTCTAACTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCCGATAGGTTTAGCGGCTCTAAGTCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAGGCCGACTACTACTGTGGCACCTGGGACGGTAGCCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAAAGTCACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCC CCAGCAGCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGG CGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCC CAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAA GAGCCACAGGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCC AACCGAGTGCAGC P7G11A SEQ ID NO: 206HCDR1 SGGYSWS (Kabat) SEQ ID NO: 207 HCDR2 YIYYRGTTYYNPSLKS (Kabat)SEQ ID NO: 208 HCDR3 ALTHLVGVGWFDP (Kabat) SEQ ID NO: 209 HCDR1GGSISSGGY (Chothia) SEQ ID NO: 210 HCDR2 YYRGT (Cho thia) SEQ ID NO: 211HCDR3 ALTHLVGVGWFDP (Chothia) SEQ ID NO: 212 VHQVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYSWSWIRQPPGKGLEYIGYIYYRGTTYYNPSLKSRVTIS VDTSNNQISLKLSSVTAADTAVYYCARALTHLVGVGWFDPWGQGTMVTVSS SEQ ID NO: 213 DNA VH CAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTGGTCAAGCCTAGTCAGACCCTGAGCCTGACCTGCA CCGTCAGCGGAGGCTCTATCTCTAGCGGCGGCTATAGCTGGTCCTGGATTAGACAGCCCCCAGGTAAA GGCCTCGAGTATATCGGCTATATCTACTATAGGGGCACTACCTACTATAACCCTAGCCTGAAGTCTAG GGTCACAATTAGCGTGGACACCTCTAACAATCAGATTAGCCTGAAGCTGTCTAGCGTGACCGCCGCTG ACACCGCCGTCTACTACTGCGCTAGAGCCCTGACTCACCTCGTCGGAGTGGGCTGGTTTGACCCTTGG GGTCAAGGCACTATGGTCACCGTGTCTAGCSEQ ID NO: 214 Heavy QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYSW ChainSWIRQPPGKGLEYIGYIYYRGTTYYNPSLKSRVTIS VDTSNNQISLKLSSVTAADTAVYYCARALTHLVGVGWFDPWGQGTMVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 215 DNACAGGTGCAGCTGCAAGAATCAGGCCCTGGCCTG HeavyGTCAAGCCTAGTCAGACCCTGAGCCTGACCTGCA ChainCCGTCAGCGGAGGCTCTATCTCTAGCGGCGGCTA TAGCTGGTCCTGGATTAGACAGCCCCCAGGTAAAGGCCTCGAGTATATCGGCTATATCTACTATAGGG GCACTACCTACTATAACCCTAGCCTGAAGTCTAGGGTCACAATTAGCGTGGACACCTCTAACAATCAG ATTAGCCTGAAGCTGTCTAGCGTGACCGCCGCTGACACCGCCGTCTACTACTGCGCTAGAGCCCTGAC TCACCTCGTCGGAGTGGGCTGGTTTGACCCTTGGGGTCAAGGCACTATGGTCACCGTGTCTAGCGCTA GCACTAAGGGCCCAAGTGTGTTTCCCCTGGCCCCCAGCAGCAAGTCTACTTCCGGCGGAACTGCTGCC CTGGGTTGCCTGGTGAAGGACTACTTCCCCGAGCCCGTGACAGTGTCCTGGAACTCTGGGGCTCTGAC TTCCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTG ACAGTGCCCTCCAGCTCTCTGGGAACCCAGACCTATATCTGCAACGTGAACCACAAGCCCAGCAACA CCAAGGTGGACAAGAGAGTGGAGCCCAAGAGCTGCGACAAGACCCACACCTGCCCCCCCTGCCCAGC TCCAGAACTGCTGGGAGGGCCTTCCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGATGATCA GCAGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGTCCCACGAGGACCCAGAGGTGAAGTTCA ACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCAGAGAGGAGCAGTACAACA GCACCTACAGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAA GTGCAAAGTCTCCAACAAGGCCCTGCCAGCCCCAATCGAAAAGACAATCAGCAAGGCCAAGGGCCA GCCACGGGAGCCCCAGGTGTACACCCTGCCCCCCAGCCGGGAGGAGATGACCAAGAACCAGGTGTCC CTGACCTGTCTGGTGAAGGGCTTCTACCCCAGCGATATCGCCGTGGAGTGGGAGAGCAACGGCCAGC CCGAGAACAACTACAAGACCACCCCCCCAGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCAA GCTGACCGTGGACAAGTCCAGGTGGCAGCAGGGCAACGTGTTCAGCTGCAGCGTGATGCACGAGGC CCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGCAAG SEQ ID NO: 216 LCDR1 SGGSSNLGSNYVS (Kab at)SEQ ID NO: 217 LCDR2 DNNKRPS (Kab at) SEQ ID NO: 218 LCDR3 GTWDGSLSAWV(Kabat) SEQ ID NO: 219 LCDR1 GSSNLGSNY (Chothia) SEQ ID NO: 220 LCDR2DNN (Chothia) SEQ ID NO: 221 LCDR3 WDGSLSAW (Chothia) SEQ ID NO: 222 VLQSVLTQPPSVSAAPGQKVTISCSGGSSNLGSNYVS WYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDGSLSAWVFGGGT KVTVL SEQ ID NO: 223 DNA VLCAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG CCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAGCGGCGGCTCCTCTAACCTGGGCTCTAACTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCCGATAGGTTTAGCGGCTCTAAGTCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAGGCCGACTACTACTGTGGCACCTGGGACGGTAGCCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAAAGTCACAGTGCTGSEQ ID NO: 224 Light QSVLTQPPSVSAAPGQKVTISCSGGSSNLGSNYVS ChainWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTS ATLGITGLQTGDEADYYCGTWDGSLSAWVFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS SEQ ID NO: 225 DNACAGTCAGTCCTGACTCAGCCCCCTAGCGTCAGCG LightCCGCTCCCGGTCAAAAAGTGACTATTAGCTGTAG ChainCGGCGGCTCCTCTAACCTGGGCTCTAACTACGTC AGCTGGTATCAGCAGCTGCCCGGCACCGCCCCTAAGCTGCTGATCTACGATAACAACAAGCGGCCTA GCGGAATCCCCGATAGGTTTAGCGGCTCTAAGTCAGGCACTAGCGCTACCCTGGGAATCACCGGCCT GCAGACCGGCGACGAGGCCGACTACTACTGTGGCACCTGGGACGGTAGCCTGAGCGCCTGGGTGTTC GGCGGAGGCACTAAAGTCACAGTGCTGGGTCAACCTAAGGCTGCCCCCAGCGTGACCCTGTTCCCCC CCAGCAGCGAGGAGCTGCAGGCCAACAAGGCCACCCTGGTGTGCCTGATCAGCGACTTCTACCCAGG CGCCGTGACCGTGGCCTGGAAGGCCGACAGCAGCCCCGTGAAGGCCGGCGTGGAGACCACCACCCC CAGCAAGCAGAGCAACAACAAGTACGCCGCCAGCAGCTACCTGAGCCTGACCCCCGAGCAGTGGAA GAGCCACAGGTCCTACAGCTGCCAGGTGACCCACGAGGGCAGCACCGTGGAAAAGACCGTGGCCCC AACCGAGTGCAGC EBB-C1975-B5-SEQ ID NO: 226 HCDR1 AYYWT (Kabat) SEQ ID NO: 227 HCDR2 YISHSGSTNYNPSLKS(Kabat) SEQ ID NO: 228 HCDR3 LGDTASLSRFYYYIDV (Kabat) SEQ ID NO: 229HCDR1 GGSTSAY (Chothia) SEQ ID NO: 230 HCDR2 SHSGS (Chothia)SEQ ID NO: 231 HCDR3 LGDTASLSRFYYYIDV (Chothia) SEQ ID NO: 232 VHQVQLVQSGPGLVKPSETLSLTCTVSGGSTSAYYWT WIRQPPGKGLEWIGYISHSGSTNYNPSLKSRVTISADTSKNQLSLKVNSVTAADTAVYYCARLGDTASLS RFYYYIDVWGKGTTVTVSS SEQ ID NO: 233DNA VH CAGGTGCAGCTGGTGCAGTCTGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCA CTGTCTCTGGTGGCTCCACCAGTGCTTACTACTGGACCTGGATTCGGCAGCCCCCAGGGAAGGGACT GGAGTGGATTGGGTATATCTCTCACAGTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAGTCA CCATATCAGCAGACACGTCCAAGAACCAGCTCTCCCTGAAGGTGAACTCTGTGACCGCCGCAGACAC GGCCGTGTATTACTGTGCGAGACTTGGGGATACAGCTTCACTTAGCCGCTTCTACTACTACATTGACG TCTGGGGCAAAGGGACCACGGTCACCGTCTCCTC ASEQ ID NO: 234 Heavy QVQLVQSGPGLVKPSETLSLTCTVSGGSTSAYYWT ChainWIRQPPGKGLEWIGYISHSGSTNYNPSLKSRVTISA DTSKNQLSLKVNSVTAADTAVYYCARLGDTASLSRFYYYIDVWGKGTTVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 235 DNACAGGTGCAGCTGGTGCAGTCTGGCCCAGGACTG HeavyGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCA ChainCTGTCTCTGGTGGCTCCACCAGTGCTTACTACTG GACCTGGATTCGGCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGTATATCTCTCACAGTGGGAGC ACCAACTACAACCCCTCCCTCAAGAGTCGAGTCACCATATCAGCAGACACGTCCAAGAACCAGCTCTC CCTGAAGGTGAACTCTGTGACCGCCGCAGACACGGCCGTGTATTACTGTGCGAGACTTGGGGATACA GCTTCACTTAGCCGCTTCTACTACTACATTGACGTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTC AGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACA GCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCG CCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCA GCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTG CCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAA GTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAA GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAG GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATG GGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA CAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA SEQ ID NO: 236 LCDR1 RASQSVSSNYLA (Kabat)SEQ ID NO: 237 LCDR2 GASSRAT (Kabat) SEQ ID NO: 238 LCDR3 QQYGSSPPYT(Kabat) SEQ ID NO: 239 LCDR1 SQSVSSNY (Chothia) SEQ ID NO: 240 LCDR2 GAS(Chothia) SEQ ID NO: 241 LCDR3 YGSSPPY (Chothia) SEQ ID NO: 242  VLEIVMTQSPDTLSLSPGERATLSCRASQSVSSNYLAWYQQKPGEAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTRLEI K SEQ ID NO: 243 DNA VLGAAATTGTAATGACGCAGTCTCCAGACACCCTGT CTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTACTT AGCCTGGTACCAGCAGAAACCTGGCGAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCC ACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAC TGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCCGTACACTTTTGGC CAGGGGACACGACTGGAGATTAAACSEQ ID NO: 244 Light EIVMTQSPDTLSLSPGERATLSCRASQSVSSNYLAW ChainYQQKPGEAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC SEQ ID NO: 245 DNAGAAATTGTAATGACGCAGTCTCCAGACACCCTGT LightCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTG ChainCAGGGCCAGTCAGAGTGTTAGCAGCAACTACTT AGCCTGGTACCAGCAGAAACCTGGCGAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCC ACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGAC TGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCCGTACACTTTTGGC CAGGGGACACGACTGGAGATTAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGA TGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGCGAGGCCA AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGG ACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAAC ACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACCG CGGAGAGTGT EBB-C1975-A3SEQ ID NO: 246 HCDR1 RNYMS (Kabat) SEQ ID NO: 247 HCDR2 GIYSGGSTYYADSVKG(Kabat) SEQ ID NO: 248 HCDR3 EDEFWSGYSAGVD (Kabat) SEQ ID NO: 249 HCDR1GFTVRRN (Chothia) SEQ ID NO: 250 HCDR2 YSGGS (Chothia) SEQ ID NO: 251HCDR3 EDEFWSGYSAGVD (Chothia) SEQ ID NO: 252 VHEVQLVETGGGLVQPGGSLRLSCAASGFTVRRNYM SWVRQAPGKGLEWVSGIYSGGSTYYADSVKGRFTISRDYSKNTLSLQMNTLRVEDTAVYFCAREDEFWS GYSAGVDWGQGTLVTVSS SEQ ID NO: 253DNA VH GAGGTGCAGCTGGTGGAGACTGGAGGAGGCTTGGTCCAGCCGGGGGGGTCCCTGAGACTCTCATGTG CAGCCTCTGGATTCACCGTCAGACGCAATTACATGAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACT GGAGTGGGTCTCAGGGATCTACAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTC ACCATCTCCAGAGACTATTCCAAGAACACACTGTCTCTTCAAATGAACACCCTGAGAGTCGAGGACA CGGCCGTGTATTTCTGTGCGAGAGAAGACGAATTTTGGAGCGGGTATTCCGCTGGGGTCGACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCAGSEQ ID NO: 254 Heavy EVQLVETGGGLVQPGGSLRLSCAASGFTVRRNYM ChainSWVRQAPGKGLEWVSGIYSGGSTYYADSVKGRFTI SRDYSKNTLSLQMNTLRVEDTAVYFCAREDEFWSGYSAGVDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 255 DNAGAGGTGCAGCTGGTGGAGACTGGAGGAGGCTTG HeavyGTCCAGCCGGGGGGGTCCCTGAGACTCTCATGTG ChainCAGCCTCTGGATTCACCGTCAGACGCAATTACAT GAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACTGGAGTGGGTCTCAGGGATCTACAGTGGTGGTAG CACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACTATTCCAAGAACACACTGT CTCTTCAAATGAACACCCTGAGAGTCGAGGACACGGCCGTGTATTTCTGTGCGAGAGAAGACGAATT TTGGAGCGGGTATTCCGCTGGGGTCGACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCA CCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACC AGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGAC CGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACC AAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCA CCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTC CCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAG CACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC CCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA SEQ ID NO: 256 LCDR1 RASQSISSYLN (Kabat) SEQ ID NO: 257LCDR2 AASSLQS (Kabat) SEQ ID NO: 258 LCDR3 QQSYNTPRT (Kabat)SEQ ID NO: 259 LCDR1 SQSTSSY (Chothia) SEQ ID NO: 260 LCDR2 AAS(Chothia) SEQ ID NO: 261 LCDR3 SYNTPR (Chothia) SEQ ID NO: 262 VLDIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYNTPRTFGQGTKVEIKSEQ ID NO: 263 DNA VL GACATCCGGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG CCGGGCAAGTCAGAGCATTAGCAGCTATTTGAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAG CTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGG GACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGA GTTACAATACCCCTCGAACGTTCGGCCAAGGGACCAAGGTGGAGATCAAACG SEQ ID NO: 264 LightDIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQ ChainQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 265 DNAGACATCCGGTTGACCCAGTCTCCATCCTCCCTGT LightCTGCATCTGTAGGAGACAGAGTCACCATCACTTG ChainCCGGGCAAGTCAGAGCATTAGCAGCTATTTGAAT TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTG GGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAA CCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAATACCCCTCGAACGTTCGGCCAAGGGAC CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGCGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACCGCGGAGAG TGT EBB-C1975-A7 SEQ ID NO: 266 HCDR1RNYMS (Kabat) SEQ ID NO: 267 HCDR2 GIYSGGSTYYADSVKG (Kabat)SEQ ID NO: 268 HCDR3 EDEFWSGYSAGVD (Kabat) SEQ ID NO: 269 HCDR1 GFTVSRN(Chothia) SEQ ID NO: 270 HCDR2 YSGGS (Chothia) SEQ ID NO: 271 HCDR3EDEFWSGYSAGVD (Chothia) SEQ ID NO: 272 VHQVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMS WVRQAPGKGLEWVSGIYSGGSTYYADSVKGRFTISRDYSKNTLSLQMNTLRVEDTAVYFCAREDEFWSG YSAGVDWGQGTLVTVSS SEQ ID NO: 273DNA VH CAGGTGCAGCTGGTGGAATCTGGAGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCATGTG CAGCCTCTGGATTCACCGTCAGTCGCAATTACATGAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACT GGAGTGGGTCTCAGGGATTTACAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTC ACCATCTCCAGAGACTATTCCAAGAACACACTGTCTCTTCAAATGAACACCCTGAGAGTCGAGGACA CGGCCGTGTATTTCTGTGCGAGAGAAGACGAATTTTGGAGTGGGTATTCCGCTGGGGTCGACTGGGGC CAGGGAACCCTGGTCACCGTCTCCTCAGCSEQ ID NO: 274 Heavy QVQLVESGGGLVQPGGSLRLSCAASGFTVSRNYMS ChainWVRQAPGKGLEWVSGIYSGGSTYYADSVKGRFTIS RDYSKNTLSLQMNTLRVEDTAVYFCAREDEFWSGYSAGVDWGQGTLVTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 275 DNACAGGTGCAGCTGGTGGAATCTGGAGGAGGCTTG HeavyGTCCAGCCTGGGGGGTCCCTGAGACTCTCATGTG ChainCAGCCTCTGGATTCACCGTCAGTCGCAATTACAT GAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACTGGAGTGGGTCTCAGGGATTTACAGTGGTGGTAG CACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACTATTCCAAGAACACACTGT CTCTTCAAATGAACACCCTGAGAGTCGAGGACACGGCCGTGTATTTCTGTGCGAGAGAAGACGAATT TTGGAGTGGGTATTCCGCTGGGGTCGACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCA CCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCT GGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACC AGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGAC CGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACC AAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCA CCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTC CCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAG CACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC CCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGC TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA SEQ ID NO: 276 LCDR1 RASQSISSYLN (Kabat) SEQ ID NO: 277LCDR2 AASSLQS (Kabat) SEQ ID NO: 278 LCDR3 QQSYSTPRT (Kabat)SEQ ID NO: 279 LCDR1 SQSISSY (Chothia) SEQ ID NO: 280 LCDR2 AAS(Chothia) SEQ ID NO: 281 LCDR3 SYSTPR (Chothia) SEQ ID NO: 282 VLDIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPTLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSYSTPRTFGQGTKVEIKSEQ ID NO: 283 DNA VL GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG CCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTACG CTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGG GACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGA GTTACAGTACCCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAAC SEQ ID NO: 284 LightDIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWY ChainQQKPGKAPTLLIYAASSLQSGVPSRFSGSGSGTDFTLTTSSLQPEDFATYYCQQSYSTPRTFGQGTKVETKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNEYPREA KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 285 DNAGACATCCGGATGACCCAGTCTCCATCCTCCCTGT LightCTGCATCTGTAGGAGACAGAGTCACCATCACTTG ChainCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAAT TGGTATCAGCAGAAACCAGGGAAAGCCCCTACGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTG GGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAA CCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCGGACGTTCGGCCAAGGGAC CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGCGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACCGCGGAGAG TGT EBB-C1975-E7 SEQ ID NO: 286 HCDR1RNYMS (Kabat) SEQ ID NO: 287 HCDR2 GIYGGGRTYYAESVKG (Kabat)SEQ ID NO: 288 HCDR3 EDEFWSGYSAGVD (Kabat) SEQ ID NO: 289 HCDR1 GFTVSRN(Chothia) SEQ ID NO: 290 HCDR2 YGGGR (Chothia) SEQ ID NO: 291 HCDR3EDEFWSGYSAGVD (Chothia) SEQ ID NO: 292 VHEVQLLESGGGLVRPGGSLRVSCAASGFTVSRNYMS WVRQAPGKGLEWVSGIYGGGRTYYAESVKGRFTISRDYSKNTLFLQMNTLRVEDTALYFCAREDEFWS GYSAGVDWGQGTLVTVSS SEQ ID NO: 293DNA VH GAGGTGCAGCTGTTGGAGTCCGGGGGAGGCTTGGTCCGGCCTGGGGGGTCCCTGAGAGTCTCATGTG CAGCCTCTGGATTCACCGTCAGTCGCAATTACATGAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACT GGAGTGGGTCTCAGGGATTTACGGTGGTGGTAGGACTTACTACGCAGAGTCCGTGAAGGGCCGATTC ACCATCTCCAGAGACTATTCCAAGAACACACTGTTTCTTCAAATGAACACCCTGAGAGTCGAGGACAC GGCCCTGTATTTCTGTGCGAGAGAAGACGAATTTTGGAGTGGGTATTCTGCTGGGGTCGACTGGGGCC AGGGAACCCTGGTCACTGTCTCCTCASEQ ID NO: 294 Heavy EVQLLESGGGLVRPGGSLRVSCAASGFTVSRNYMS ChainWVRQAPGKGLEWVSGIYGGGRTYYAESVKGRFTI SRDYSKNTLFLQMNTLRVEDTALYFCAREDEFWSGYSAGVDWGQGTLVTVSSASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 295 DNAGAGGTGCAGCTGTTGGAGTCCGGGGGAGGCTTG HeavyGTCCGGCCTGGGGGGTCCCTGAGAGTCTCATGTG ChainCAGCCTCTGGATTCACCGTCAGTCGCAATTACAT GAGTTGGGTCCGCCAGGCTCCGGGGAAGGGACTGGAGTGGGTCTCAGGGATTTACGGTGGTGGTAG GACTTACTACGCAGAGTCCGTGAAGGGCCGATTCACCATCTCCAGAGACTATTCCAAGAACACACTGT TTCTTCAAATGAACACCCTGAGAGTCGAGGACACGGCCCTGTATTTCTGTGCGAGAGAAGACGAATTT TGGAGTGGGTATTCTGCTGGGGTCGACTGGGGCCAGGGAACCCTGGTCACTGTCTCCTCAGCTAGCAC CAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTG GGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCA GCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACC GTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCA AGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCAC CTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCC CGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC TGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGC ACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGT GCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCC CCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCT CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG CACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA SEQ ID NO: 296 LCDR1 RASQSISSYLN (Kabat) SEQ ID NO: 297LCDR2 AASTLQT (Kabat) SEQ ID NO: 298 LCDR3 QQSYNTPRT (Kabat)SEQ ID NO: 299 LCDR1 SQSISSY (Chothia) SEQ ID NO: 300 LCDR2 AAS(Chothia) SEQ ID NO: 301 LCDR3 SYNTPR (Chothia) SEQ ID NO: 302 VLDIQVTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQEPGKAPKLLIYAASTLQTGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSYNTPRTFGQGTKVEIKSEQ ID NO: 303 DNA VL GACATCCAGGTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG CCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGGAACCAGGGAAAGCCCCTAAA CTCCTGATCTACGCTGCATCCACTTTGCAAACTGGGGTCCCATCACGGTTCAGTGGTAGTGGATCTGG GACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTATTACTGTCAACAGA GTTACAATACCCCTCGAACCTTCGGCCAAGGGACCAAGGTGGAAATCAAACG SEQ ID NO: 304 LightDIQVTQSPSSLSASVGDRVTITCRASQSISSYLNWY ChainQQEPGKAPKLLIYAASTLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 305 DNAGACATCCAGGTGACCCAGTCTCCATCCTCCCTGT LightCTGCATCTGTAGGAGACAGAGTCACCATCACTTG ChainCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAAT TGGTATCAGCAGGAACCAGGGAAAGCCCCTAAACTCCTGATCTACGCTGCATCCACTTTGCAAACTG GGGTCCCATCACGGTTCAGTGGTAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAA CCTGAAGATTTTGCAACTTATTACTGTCAACAGAGTTACAATACCCCTCGAACCTTCGGCCAAGGGAC CAAGGTGGAAATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGCGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGT CTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACCGCGGAGAG TGT P46F4 SEQ ID NO: 306 HCDR1 NGGYYWS(Kabat) SEQ ID NO: 307 HCDR2 CIHYSGGTYYNPSLKS (Kabat) SEQ ID NO: 308HCDR3 ALIAAPGISDWFDP (Kabat) SEQ ID NO: 309 HCDR1 GGSISNGGY (Chothia)SEQ ID NO: 310 HCDR2 HYSGG (Chothia) SEQ ID NO: 311 HCDR3 ALIAAPGISDWFDP(Chothia) SEQ ID NO: 312 VH QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYYWSWIRLHPGKGLEWIGCIHYSGGTYYNPSLKSRVTVSLDTSKNQFSLNLISVTAADTAIYFCARALIAAPGI SDWFDPWGQGTLVTVSS SEQ ID NO: 313Heavy QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYY ChainWSWIRLHPGKGLEWIGCIHYSGGTYYNPSLKSRVTVSLDTSKNQFSLNLTSVTAADTAIYFCARALIAAPGISDWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 314 LCDR1 SGSNSNVGHNYVS(Kabat) SEQ ID NO: 315 LCDR2 DNNKRPS (Kabat) SEQ ID NO: 316 LCDR3GTWDSSLSAGV (Kabat) SEQ ID NO: 317 LCDR1 SNSNVGHNY (Chothia)SEQ ID NO: 318 LCDR2 DNN (Chothia) SEQ ID NO: 319 LCDR3 WDSSLSAG(Chothia) SEQ ID NO: 320 VL QSVLTQPPSVSAAPGQKVTISCSGSNSNVGHNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTS ATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKVTVL SEQ ID NO: 321 Light QSVLTQPPSVSAAPGQKVTISCSGSNSNVGHNYVS ChainWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTS ATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECS 2081-20-8 hz53 SEQ ID NO: 322HCDR1 SSWMN (Kabat) SEQ ID NO: 323 HCDR2 RIYPGDADTYYSGKFKG (Kabat)SEQ ID NO: 324 HCDR3 HSSGFTY (Kabat) SEQ ID NO: 325 HCDR1 GYTFSSS(Chothia) SEQ ID NO: 326 HCDR2 YPGDAD (Chothia) SEQ ID NO: 327 HCDR3HSSGFTY (Chothia) SEQ ID NO: 328 VH QVQLVQSGAEVKKPGASVKVSCKASGYTFSSSWMNWVRQAPGQRLEWMGRIYPGDADTYYSGKFKGR VTITADSSARTAYMELSSLRSEDTAVYYCAIHSSGFTYWGQGTLVTVSS SEQ ID NO: 329 DNA VH CAGGTCCAGCTTGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCA AGGCTTCTGGCTATACATTCAGCAGCTCTTGGATGAACTGGGTGCGCCAGGCCCCCGGACAAAGGCT TGAGTGGATGGGACGGATCTATCCAGGAGACGCCGATACTTACTACAGTGGGAAATTCAAGGGCAG AGTCACCATTACCGCCGACAGCTCCGCGAGAACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGA AGACACGGCTGTGTATTACTGTGCGATCCACAGCTCGGGCTTTACTTACTGGGGCCAGGGCACCCTGG TCACCGTCTCCTCAGC SEQ ID NO: 330 HeavyQVQLVQSGAEVKKPGASVKVSCKASGYTFSSSWM ChainNWVRQAPGQRLEWMGRIYPGDADTYYSGKFKGR VTITADSSARTAYMELSSLRSEDTAVYYCAIHSSGFTYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 331 DNACAGGTCCAGCTTGTGCAGTCTGGGGCTGAGGTGA HeavyAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCA ChainAGGCTTCTGGCTATACATTCAGCAGCTCTTGGAT GAACTGGGTGCGCCAGGCCCCCGGACAAAGGCTTGAGTGGATGGGACGGATCTATCCAGGAGACGC CGATACTTACTACAGTGGGAAATTCAAGGGCAGAGTCACCATTACCGCCGACAGCTCCGCGAGAAC AGCCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGATCCACAGC TCGGGCTTTACTTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATC GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA AGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACAC CTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCA GCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAG AGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGG GACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGC GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA AAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGT GTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAA AGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAG ACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAG CAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGC AGAAGAGCCTCTCCCTGTCTCCGGGTAAASEQ ID NO: 332 LCDR1 RASQDISDYLN (Kabat) SEQ ID NO: 333 LCDR2 YTSRLHS(Kabat) SEQ ID NO: 334 LCDR3 QQTHTLPFT (Kabat) SEQ ID NO: 335 LCDR1SQDISDY (Chothia) SEQ ID NO: 336 LCDR2 YTS (Chothia) SEQ ID NO: 337LCDR3 THTLPF (Chothia) SEQ ID NO: 338 VLDIQMTQSPSSLSASVGDRVTITCRASQDISDYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYT LTISSLQPEDFATYFCQQTHTLPFTFGGGTKVEIKSEQ ID NO: 339 DNA VL GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTG CAGGGCAAGTCAGGACATTAGCGATTATTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAA GCTCCTGATCTATTATACATCAAGATTACACTCAGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTG GGACAGATTACACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTTCTGTCAACAG ACTCATACGCTTCCTTTCACGTTCGGCGGAGGGACCAAGGTGGAGATCAAACG SEQ ID NO: 340 LightDIQMTQSPSSLSASVGDRVTITCRASQDISDYLNWY ChainQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQTHTLPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 341 DNAGACATCCAGATGACCCAGTCTCCATCCTCCCTGT LightCTGCATCTGTAGGAGACAGAGTCACCATCACTTG ChainCAGGGCAAGTCAGGACATTAGCGATTATTTAAA CTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTATACATCAAGATTACACTCA GGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTACACTCTCACCATCAGCAGTCTGCA ACCTGAAGATTTTGCAACTTACTTCTGTCAACAGACTCATACGCTTCCTTTCACGTTCGGCGGAGGGA CCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCA GTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCGCGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCA AGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAG TCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACCGCGGAGA GTGT 2075-16-1 SEQ ID NO: 342 HCDR1NYWMH (Kabat) SEQ ID NO: 343 HCDR2 NIYPGSGNTNYGENFKS (Kabat)SEQ ID NO: 344 HCDR3 SAIYYGYDGHYFAMDY (Kabat) SEQ ID NO: 345 HCDR1GYTFTNY (Chothia) SEQ ID NO: 346 HCDR2 YPGSGN (Chothia) SEQ ID NO: 347HCDR3 SAIYYGYDGHYFAMDY (Chothia) SEQ ID NO: 348 VHQVQLQQPGSELVRPGASVKLSCKASGYTFTNYWM HWVKQGHGQGLEWIGNIYPGSGNTNYGENFKSKGTLTVDTSSSTAYMHLSRLTSEDSAVYYCSRSAIYYG YDGHYFAMDYWGQGTSVTVSSSEQ ID NO: 349 LCDR1 KASQDIRKYIA (Kabat) SEQ ID NO: 350 LCDR2 YTSTLQS(Kabat) SEQ ID NO 351 LCDR3 LQYDNTLFT (Kabat) SEQ ID NO: 352 LCDR1SQDIRKY (Chothia) SEQ ID NO: 353 LCDR2 YTS (Chothia) SEQ ID NO: 354LCDR3 YDNILF (Chothia) SEQ ID NO: 355 VLDIQMTQSPSSLSASLGGKVTITCKASQDIRKYIAWYQHKPGKGPRLLINYTSTLQSGIPSRFRGSGSGRDYS FSISNLEPEDIATYYCLQYDNILFTFGTGTKLEIK2075-456-4 SEQ ID NO: 356 HCDR1 SCWMN (Kabat) SEQ ID NO: 357 HCDR2RIYPGDGDTKYTEKFKD (Kabat) SEQ ID NO: 358 HCDR3 SGSGLPY (Kabat)SEQ ID NO: 359 HCDR1 GYSFSSC (Chothia) SEQ ID NO: 360 HCDR2 YPGDGD(Chothia) SEQ ID NO: 361 HCDR3 SGSGLPY (Chothia) SEQ ID NO: 362 VHQVHLQQSGPELVKPGASVTISCKTSGYSFSSCWMN WVKQRPGQGLEWIGRIYPGDGDTKYTEKFKDKATLTADKSSSTAYMQLSSLTSVDSALYFCAISGSGLPY WGQGTLVTVSE SEQ ID NO: 363 LCDR1RASQDIHNYLN (Kabat) SEQ ID NO: 364 LCDR2 STSRLHS (Kabat) SEQ ID NO: 365LCDR3 QQTHTLPLT (Kabat) SEQ ID NO: 366 LCDR1 SQDIHNY (Chothia)SEQ ID NO: 367 LCDR2 STS (Chothia) SEQ ID NO: 368 LCDR3 THTLPL (Chothia)SEQ ID NO: 369 VL DIQMTQTTSSLSASLGDRVTISCRASQDIHNYLNWYQQKPDGTIKLLIYSTSRLHSGVPSRFSGSGSGTHYSL TINNLEQEDIATYFCQQTHTLPLTFGAGTKLELK2081-36-8 SEQ ID NO: 370 HCDR1 SYWMN (Kabat) SEQ ID NO: 371 HCDR2QIYPGNGDTNYNGKFKG (Kabat) SEQ ID NO: 372 HCDR3 EARQGYHYAMDY (Kabat)SEQ ID NO: 373 HCDR1 GYAFSSY (Chothia) SEQ ID NO: 374 HCDR2 YPGNGD(Chothia) SEQ ID NO: 375 HCDR3 EARQGYHYAMDY (Chothia) SEQ ID NO: 376 VHQVQLQQSGAGLVRPGSSVKISCKTSGYAFSSYWM NWVKQRPGQGLEWIGQIYPGNGDTNYNGKFKGKATLTADKSSNTAYIQLNSLTSEDSAVYFCAREARQ GYHYAMDYWGQGTSVTVSL SEQ ID NO: 377LCDR1 SASSMINSNYLH (Kabat) SEQ ID NO: 378 LCDR2 RTSNLAS (Kabat)SEQ ID NO: 379 LCDR3 QQGSNIFT (Kabat) SEQ ID NO: 380 LCDR1 SSMINSNY(Chothia) SEQ ID NO: 381 LCDR2 RTS (Chothia) SEQ ID NO: 382 LCDR3 GSNIF(Chothia) SEQ ID NO: 383 VL EIVFTQSPTTMAAFPGEKITITCSASSMINSNYLHWYQQKPGFSPKVLIYRTSNLASGVPARFSGTGSGTSFS LTIGTMEAEDVATYYCQQGSNIFTFGSGTKLEIK2081-66-5 SEQ ID NO: 384 HCDR1 NSWMN (Kabat) SEQ ID NO: 385 HCDR2RIYPGDGDTQYNEKFKG (Kabat) SEQ ID NO: 386 HCDR3 SRSGLDY (Kabat)SEQ ID NO: 387 HCDR1 GFTFSNS (Chothia) SEQ ID NO: 388 HCDR2 YPGDGD(Chothia) SEQ ID NO: 389 HCDR3 SRSGLDY (Chothia) SEQ ID NO: 390 VHQVQLQQSGPELVKPGASVRISCKVSGFTFSNSWMN WVKQRPGQGLEWIGRIYPGDGDTQYNEKFKGKATLTADTSSNTAYIQLNSLTSVDSAVFFCARSRSGLDY WGQGTTLTVSS SEQ ID NO: 391 LCDR1RASQDIYNYLN (Kabat) SEQ ID NO: 392 LCDR2 STSRLHS (Kabat) SEQ ID NO: 393LCDR3 HQSHTVPFT (Kabat) SEQ ID NO: 394 LCDR1 SQDIYNY (Chothia)SEQ ID NO: 395 LCDR2 STS (Chothia) SEQ ID NO: 396 LCDR3 SHTVPF (Chothia)SEQ ID NO: 397 VL DIQMTQSTSSLSASLGDRVTISCRASQDIYNYLNWFQQKPDGTVKPLIYSTSRLHSGVSSRFSGSGSGTDYS LTISNLEREDIATYFCHQSHTVPFTFGSGTKLEIK2081-38-5 SEQ ID NO: 398 HCDR1 SSWIN (Kabat) SEQ ID NO: 399 HCDR2RIYPGDGDTNYNGKFKG (Kabat) SEQ ID NO: 400 HCDR3 HSSGFPH (Kabat)SEQ ID NO: 401 HCDR1 GYTFSSS (Chothia) SEQ ID NO: 402 HCDR2 YPGDGD(Chothia) SEQ ID NO: 403 HCDR3 HSSGFPH (Chothia) SEQ ID NO: 404 VHQVQLQQSGPELVKPGASVKISCKASGYTFSSSWIN WVKQRPGQGLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTVDMHLSSLTYVDSAVYFCAIHSSGFPH WGQGTLVTVSA SEQ ID NO: 405 LCDR1RTSQDISDYLN (Kabat) SEQ ID NO: 406 LCDR2 YTSRLHS (Kabat) SEQ ID NO: 407LCDR3 QQTNTLPFT (Kabat) SEQ ID NO: 408 LCDR1 SQDISDY (Chothia)SEQ ID NO: 409 LCDR2 YTS (Chothia) SEQ ID NO: 410 LCDR3 TNTLPF (Chothia)SEQ ID NO: 411 VL DIQMTQTTSSLSASLGGRVTISCRTSQDISDYLNWYQQKPDGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYS LTISNLEQEDIATYFCQQTNTLPFTFGGGTKLEIK2081-25-6 SEQ ID NO: 412 HCDR1 RYWMN (Kabat) SEQ ID NO: 413 HCDR2QIYPGDGDTKYNGKFKD (Kabat) SEQ ID NO: 414 HCDR3 YGNYGMDY (Kabat)SEQ ID NO: 415 HCDR1 GYAFSRY (Chothia) SEQ ID NO: 416 HCDR2 YPGDGD(Chothia) SEQ ID NO: 417 HCDR3 YGNYGMDY (Chothia) SEQ ID NO: 418 VHQVQLQQSGAELVRPGSSVKISCKASGYAFSRYWM NWVKQRPGQGLEWIGQIYPGDGDTKYNGKFKDTATLTADKSSSTAYLQLSSLTSEDSAVYFCAKYGNYG MDYWGQGTSVTVSS SEQ ID NO: 419 LCDR1RSSQSLEYGNGNTYLN (Kabat) SEQ ID NO: 420 LCDR2 RVSNRFS (Kabat)SEQ ID NO: 421 LCDR3 LQFTHVPYT (Kabat) SEQ ID NO: 422 LCDR1 SQSLEYGNGNTY(Chothia) SEQ ID NO: 423 LCDR2 RVS (Chothia) SEQ ID NO: 424 LCDR3 FTHVPY(Chothia) SEQ ID NO: 425 VL DAVMTQTPLSLPVSLGDQASISCRSSQSLEYGNGNTYLNWYLQKPGQSPQLLIYRVSNRFSGVLDRFSGSG SGTDFTLKISRVEAEDLGVYFCLQFTHVPYTFGGGTKLEIK 2077-4-1 SEQ ID NO: 426 HCDR1 GYTMN (Kabat) SEQ ID NO: 427 HCDR2LFNPYNGGTRYNQKFKG (Kabat) SEQ ID NO: 428 HCDR3 LRNYGIGDDFFDY (Kabat)SEQ ID NO: 429 HCDR1 GYSFTGY (Chothia) SEQ ID NO: 430 HCDR2 NPYNGG(Chothia) SEQ ID NO: 431 HCDR3 LRNYGIGDDFFDY (Chothia) SEQ ID NO: 432 VHEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMN WVKQSHGENLEWIGLFNPYNGGTRYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARLRNYGI GDDFFDYWGQGTTLTVSS SEQ ID NO: 433LCDR1 KASQDVGTAVA (Kabat) SEQ ID NO: 434 LCDR2 WASTRHT (Kabat)SEQ ID NO: 435 LCDR3 QQYSNYPYT (Kabat) SEQ ID NO: 436 LCDR1 SQDVGTA(Chothia) SEQ ID NO: 437 LCDR2 WAS (Chothia) SEQ ID NO: 438 LCDR3 YSNYPY(Chothia) SEQ ID NO: 439 VL DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGT DFTLTISNVQSEDLTDYFCQQYSNYPYTFGGGTKLEIK 2077-7-5 SEQ ID NO: 440 HCDR1 GYTMN (Kabat) SEQ ID NO: 441 HCDR2LFNPYNGGINYNQKFKG (Kabat) SEQ ID NO: 442 HCDR3 LRYYGIGDDFFDY (Kabat)SEQ ID NO: 443 HCDR1 GYSFTGY (Chothia) SEQ ID NO: 444 HCDR2 NPYNGG(Chothia) SEQ ID NO: 445 HCDR3 LRYYGIGDDFFDY (Chothia) SEQ ID NO: 446 VHEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMN WVKQSHGKNLEWIGLFNPYNGGINYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARLRYYGI GDDFFDYWGQGTSLTVSS SEQ ID NO: 447LCDR1 KASRDVGTAVA (Kabat) SEQ ID NO: 448 LCDR2 WASTRHT (Kabat)SEQ ID NO: 449 LCDR3 QQYSNYPYT (Kabat) SEQ ID NO: 450 LCDR1 SRDVGTA(Chothia) SEQ ID NO: 451 LCDR2 WAS (Chothia) SEQ ID NO: 452 LCDR3 YSNYPY(Chothia) SEQ ID NO: 453 VL DIVMTQSHKFMSTSVGDRVSITCKASRDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGT DFTLTISNVQSEDLADYFCQQYSNYPYTFGGGTKLEMK 2077-10-1 SEQ ID NO: 454 HCDR1 GYTMN (Kabat) SEQ ID NO: 455 HCDR2LFNPYNGGPNYNQKFKG (Kabat) SEQ ID NO: 456 HCDR3 LRYYGIGDDFFDY (Kabat)SEQ ID NO: 457 HCDR1 GYSFTGY (Chothia) SEQ ID NO: 458 HCDR2 NPYNGG(Chothia) SEQ ID NO: 459 HCDR3 LRYYGIGDDFFDY (Chothia) SEQ ID NO: 460 VHEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMN WMKQGHGKNLEWIGLFNPYNGGPNYNQKFKGKATLTVDKSSSTAYMELLSLTSEDSAVYYCARLRYYG IGDDFFDYWGQGTTLTVSS SEQ ID NO: 461LCDR1 KASQDVGTAVA (Kabat) SEQ ID NO: 462 LCDR2 WASTRHT (Kabat)SEQ ID NO: 463 LCDR3 QQYSSYPYT (Kabat) SEQ ID NO: 464 LCDR1 SQDVGTA(Chothia) SEQ ID NO: 465 LCDR2 WAS (Chothia) SEQ ID NO: 466 LCDR3 YSSYPY(Chothia) SEQ ID NO: 467 VL DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGT DFTLTITNVQSEDLTDYFCQQYSSYPYTFGGGTKLEIK 2077-26-1 SEQ ID NO: 468 HCDR1 GYTMN (Kabat) SEQ ID NO: 469 HCDR2LFNPYNGGPSYNQKFKG (Kabat) SEQ ID NO: 470 HCDR3 LRYYGIGDDFFDY (Kabat)SEQ ID NO: 471 HCDR1 GYSFTGY (Chothia) SEQ ID NO: 472 HCDR2 NPYNGG(Chothia) SEQ ID NO: 473 HCDR3 LRYYGIGDDFFDY (Chothia) SEQ ID NO: 474 VHEVQLQQSGPDLVKPGASMKLSCKASGYSFTGYTM NWVKQSHGKNLEWIGLFNPYNGGPSYNQKFKGKATLTVDKSSSTAYMELLSLTPEDSAVYYCARLRYYG IGDDFFDYWGQGTTLTVSS SEQ ID NO: 475LCDR1 KASQDVGTAVA (Kabat) SEQ ID NO: 476 LCDR2 WASTRHT (Kabat)SEQ ID NO: 477 LCDR3 QQYSNYPYT (Kabat) SEQ ID NO: 478 LCDR1 SQDVGTA(Chothia) SEQ ID NO: 479 LCDR2 WAS (Chothia) SEQ ID NO: 480 LCDR3 YSNYPY(Chothia) SEQ ID NO: 481 VL DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQEKPGQSPKLLIYWASTRHTGVPDRFTGSGSGT DFTLTISNVQSEDLAYYFCQQYSNYPYTFGGGTKLEIK 2077-28-2 SEQ ID NO: 482 HCDR1 GYTMN (Kabat) SEQ ID NO: 483 HCDR2LFNPYNGGATYNQRFKG (Kabat) SEQ ID NO: 484 HCDR3 LRKYGIGDDFFDY (Kabat)SEQ ID NO: 485 HCDR1 GYSFTGY (Chothia) SEQ ID NO: 486 HCDR2 NPYNGG(Chothia) SEQ ID NO: 487 HCDR3 LRKYGIGDDFFDY (Chothia) SEQ ID NO: 488 VHEVQLQQSGPELVKPGASMKISCKASGYSFTGYTMN WVKQSHGKNLEWIGLFNPYNGGATYNQRFKGKATLTVDKSSSTAYMDLLSLTSEDSAVYYCTRLRKYG IGDDFFDYWGQGTTLTVSS SEQ ID NO: 489LCDR1 KASQDVGTAVA (Kabat) SEQ ID NO: 490 LCDR2 WASTRHT (Kabat)SEQ ID NO: 491 LCDR3 QQYSTYTYT (Kabat) SEQ ID NO: 492 LCDR1 SQDVGTA(Chothia) SEQ ID NO: 493 LCDR2 WAS (Chothia) SEQ ID NO: 494 LCDR3 YSTYTY(Chothia) SEQ ID NO: 495 VL DIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGT DFTLTISNVQSEDLADYFCQQYSTYTYTFGGGTKLEIK P8D11 SEQ ID NO: 508 HCDR1 GFTFNNYWMT (Combined) SEQ ID NO: 509HCDR2 NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 510 HCDR3 VRSGRYFALDD(Combined) SEQ ID NO: 511 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 512LCDR2 DDSNRPS (Combined) SEQ ID NO: 513 LCDR3 QVWSSSTDHP (Combined)P8D11A SEQ ID NO: 514 HCDR1 GFTFSNYWMT (Combined) SEQ ID NO: 515 HCDR2NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 516 HCDR3 VRSGRYFALDD (Combined)SEQ ID NO: 517 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 518 LCDR2 DDSNRPS(Combined) SEQ ID NO: 519 LCDR3 QVWSSSTDHP (Combined) P8D11BSEQ ID NO: 520 HCDR1 GFTFKNYWMT (Combined) SEQ ID NO: 521 HCDR2NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 522 HCDR3 VRSGRYFALDD (Combined)SEQ ID NO: 523 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 524 LCDR2 DDSNRPS(Combined) SEQ ID NO: 525 LCDR3 QVWSSSTDHP (Combined) P8D11CSEQ ID NO: 526 HCDR1 GFTFQNYWMT (Combined) SEQ ID NO: 527 HCDR2NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 528 HCDR3 VRSGRYFALDD (Combined)SEQ ID NO: 529 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 530 LCDR2 DDSNRPS(Combined) SEQ ID NO: 531 LCDR3 QVWSSSTDHP (Combined) P8D11DSEQ ID NO: 532 HCDR1 GFTFNNYWMT (Combined) SEQ ID NO: 533 HCDR2NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 534 HCDR3 VRSGRYFALDD (Combined)SEQ ID NO: 535 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 536 LCDR2 DDSNRPS(Combined) SEQ ID NO: 537 LCDR3 QVWSSSTDHP (Combined) P8D11ESEQ ID NO: 538 HCDR1 GFTFNNYWMT (Combined) SEQ ID NO: 539 HCDR2NIKKDGSEKYYVDSVRG (Combined) SEQ ID NO: 540 HCDR3 VRSGRYFALDD (Combined)SEQ ID NO: 541 LCDR1 GGDNIGSRPVH (Combined) SEQ ID NO: 542 LCDR2 DDSNRPS(Combined) SEQ ID NO: 543 LCDR3 QVWSSSTDHP (Combined)

Other antibodies of the present disclosure include those where the aminoacids or nucleic acids encoding the amino acids have been mutated; yethave at least 60, 70, 80, 90 or 95 percent identity to the sequencesdescribed in Table 2. In some aspects, it includes mutant amino acidsequences wherein no more than 1, 2, 3, 4 or 5 amino acids have beenmutated in the variable regions when compared with the variable regionsdepicted in the sequence described in Table 2, while retainingsubstantially the same therapeutic activity.

Since each of these antibodies can bind to VP1, the VH, VL, full lengthlight chain, and full length heavy chain sequences (amino acid sequencesand the nucleotide sequences encoding the amino acid sequences) can be“mixed and matched” to create other VP1-binding antibodies. Such “mixedand matched” VP1-binding antibodies can be tested using the bindingassays known in the art (e.g., ELISAs, and other assays described in theExample section). When these chains are mixed and matched, a VH sequencefrom a particular VH/VL pairing should be replaced with a structurallysimilar VH sequence. Likewise a full length heavy chain sequence from aparticular full length heavy chain/full length light chain pairingshould be replaced with a structurally similar full length heavy chainsequence. Likewise, a VL sequence from a particular VH/VL pairing shouldbe replaced with a structurally similar VL sequence. Likewise, a fulllength light chain sequence from a particular full length heavychain/full length light chain pairing should be replaced with astructurally similar full length light chain sequence. Accordingly, inone aspect, the disclosure provides for an isolated monoclonal antibodyor antigen binding region thereof having: a heavy chain variable regioncomprising an amino acid sequence selected from the group consisting ofSEQ ID NO:12, 32, 52, 72, 92, 112, 132, 152, 172, 192, 212, 232, 252,272, 292, 312, 328, 348, 362, 376, 390, 404, 418, 432, 446, 460, 474,and 488 (Table 2); and a light chain variable region comprising an aminoacid sequence selected from the group consisting of SEQ ID NO: 22, 42,62, 82, 102, 122, 142, 162, 182, 202, 222, 242, 262, 282, 302, 320, 338,355, 369, 383, 397, 411, 425, 439, 453, 467, 481 and 495 (Table 2);wherein the antibody specifically binds to VP1.

In another aspect, the disclosure provides (i) an isolated monoclonalantibody having: a full length heavy chain comprising an amino acidsequence that has been optimized for expression in the cell of amammalian selected from the group consisting of SEQ ID NOs: 14, 34, 54,74, 94, 114, 134, 154, 174, 194, 214, 234, 254, 274, 294, 313 and 330;and a full length light chain comprising an amino acid sequence that hasbeen optimized for expression in the cell of a mammalian selected fromthe group consisting of SEQ ID NOs: 24, 44, 64, 84, 104, 124, 144, 164,184, 204, 224, 244, 264, 284, 304, 321, 340, or (ii) a functionalprotein comprising an antigen binding portion thereof.

In another aspect, the present disclosure provides VP1-bindingantibodies that comprise the heavy chain and light chain CDR1s, CDR2sand CDR3s as described in Table 2, or combinations thereof. The aminoacid sequences of the VH CDR1 s of the antibodies are shown in SEQ IDNOs: 6, 26, 46, 66, 86, 106, 126, 146, 166, 186, 206, 226, 246, 266,286, 306, 322, 342, 356, 370, 384, 398, 412, 426, 440, 454, 468, and482. The amino acid sequences of the VH CDR2s of the antibodies and areshown in SEQ ID NOs: 7, 27, 47, 67, 87, 107, 127, 147, 167, 187, 207,227, 247, 267, 287, 307, 323, 343, 357, 371, 385, 399, 413, 427, 441,455, 469, and 483. The amino acid sequences of the VH CDR3s of theantibodies are shown in SEQ ID NOs: 8, 28, 48, 68, 88, 108, 128, 148,168, 188, 208, 228, 248, 268, 288, 308, 324, 344, 358, 372, 386, 400,414, 428, 442, 456, 470, and 484. The amino acid sequences of the VLCDR1s of the antibodies are shown in SEQ ID NOs: 16, 36, 56, 76, 96,116, 136, 156, 176, 196, 216, 236, 256, 276, 296, 314, 332, 349, 363,377, 391, 405, 419, 433, 447, 461, 475 and 489. The amino acid sequencesof the VL CDR2s of the antibodies are shown in SEQ ID NOs 17, 37, 57,77, 97, 117, 137, 157, 177, 197, 217, 237, 257, 277, 297, 315, 333, 350,364, 378, 392, 406, 420, 434, 448, 462, 476 and 490. The amino acidsequences of the VL CDR3s of the antibodies are shown in SEQ ID NOs: 18,38, 58, 78, 98, 118, 138, 158, 178, 198, 218, 238, 258, 278, 298, 316,334, 351, 365, 379, 393, 407, 421, 435, 449, 463, 477 and 491.

Given that each of these antibodies can bind to VP1 and thatantigen-binding specificity is provided primarily by the CDR1, 2 and 3regions, the VH CDR1, 2 and 3 sequences and VL CDR1, 2 and 3 sequencescan be “mixed and matched” (i.e., CDRs from different antibodies can bemixed and matched, although each antibody must contain a VH CDR1, 2 and3 and a VL CDR1, 2 and 3 to create other VP1-binding molecules. Such“mixed and matched” VP1-binding antibodies can be tested using thebinding assays known in the art and those described in the Examples(e.g., ELISAs). When VH CDR sequences are mixed and matched, the CDR1,CDR2 and/or CDR3 sequence from a particular VH sequence should bereplaced with a structurally similar CDR sequence(s). Likewise, when VLCDR sequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequencefrom a particular VL sequence should be replaced with a structurallysimilar CDR sequence(s). It will be readily apparent to the ordinarilyskilled artisan that novel VH and VL sequences can be created bysubstituting one or more VH and/or VL CDR region sequences withstructurally similar sequences from the CDR sequences shown herein formonoclonal antibodies of the present disclosure.

Accordingly, the present disclosure provides an isolated monoclonalantibody or antigen binding region thereof comprising a heavy chain CDR1comprising an amino acid sequence selected from the group consisting ofSEQ ID NOs: 6, 26, 46, 66, 86, 106, 126, 146, 166, 186, 206, 226, 246,266, 286, 306, 322, 342, 356, 370, 384, 398, 412, 426, 440, 454, 468,and 482; a heavy chain CDR2 comprising an amino acid sequence selectedfrom the group consisting of SEQ TD NOs: 7, 27, 47, 67, 87, 107, 127,147, 167, 187, 207, 227, 247, 267, 287, 307, 323, 343, 357, 371, 385,399, 413, 427, 441, 455, 469, and 483; a heavy chain CDR3 comprising anamino acid sequence selected from the group consisting of SEQ ID NOs: 8,28, 48, 68, 88, 108, 128, 148, 168, 188, 208, 228, 248, 268, 288, 308,324, 344, 358, 372, 386, 400, 414, 428, 442, 456, 470, and 484; a lightchain CDR1 comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 16, 36, 56, 76, 96, 116, 136, 156, 176, 196,216, 236, 256, 276, 296, 314, 332, 349, 363, 377, 391, 405, 419, 433,447, 461, 475 and 489; a light chain CDR2 comprising an amino acidsequence selected from the group consisting of SEQ ID NOs: 17, 37, 57,77, 97, 117, 137, 157, 177, 197, 217, 237, 257, 277, 297, 315, 333, 350,364, 378, 392, 406, 420, 434, 448, 462, 476 and 490; and a light chainCDR3 comprising an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 18, 38, 58, 78, 98, 118, 138, 158, 178, 198,218, 238, 258, 278, 298, 316, 334, 351, 365, 379, 393, 407, 421, 435,449, 463, 477 and 491; wherein the antibody specifically binds to VP1.

In certain aspects, an antibody that specifically binds to VP1 is anantibody or antibody fragment (e.g., antigen binding fragment) that isdescribed in Table 2.

1. Identification of Epitopes and Antibodies that Bind to the SameEpitope

The present disclosure provides antibodies and antibody fragments (e.g.,antigen binding fragments) that bind to an epitope of VP1. In certainaspects the antibodies and antibody fragments can bind to the sameepitope within all four BKV serotypes and/or JCV.

The present disclosure also provides antibodies and antibody fragments(e.g., antigen binding fragments) that bind to the same epitope as dothe anti-VP1 antibodies described in Table 2. Additional antibodies andantibody fragments (e.g., antigen binding fragments) can therefore beidentified based on their ability to cross-compete (e.g., tocompetitively inhibit the binding of, in a statistically significantmanner) with other antibodies in binding assays. The ability of a testantibody to inhibit the binding of antibodies and antibody fragments(e.g., antigen binding fragments) of the present disclosure to VP1(e.g., human BKV or JCV VP1) demonstrates that the test antibody cancompete with that antibody or antibody fragment (e.g., antigen bindingfragments) for binding to VP1; such an antibody may, according tonon-limiting theory, bind to the same or a related (e.g., a structurallysimilar or spatially proximal) epitope on VP1 as the antibody orantibody fragment (e.g., antigen binding fragments) with which itcompetes. In a certain aspect, the antibody that binds to the sameepitope on VP1 as the antibodies or antibody fragments (e.g., antigenbinding fragments) of the present disclosure is a human or humanizedmonoclonal antibody. Such human or humanized monoclonal antibodies canbe prepared and isolated as described herein.

2. Further Alteration of the Framework of Fc Region

The present disclosure disclosed specific anti-VP1 antibodies. Theseantibodies comprise modified antibodies or antigen binding fragmentsthereof that further comprise modifications to framework residues withinVH and/or VL, e.g. to improve the properties of the antibody. Typicallysuch framework modifications are made to decrease the immunogenicity ofthe antibody. For example, one approach is to “back-mutate” one or moreframework residues to the corresponding germline sequence. Morespecifically, an antibody that has undergone somatic mutation maycontain framework residues that differ from the germline sequence fromwhich the antibody is derived. Such residues can be identified bycomparing the antibody framework sequences to the germline sequencesfrom which the antibody is derived. To return the framework regionsequences to their germline configuration, the somatic mutations can be“back-mutated” to the germline sequence by, for example, site-directedmutagenesis. Such “back-mutated” antibodies are also intended to beencompassed.

Another type of framework modification involves mutating one or moreresidues within the framework region, or even within one or more CDRregions, to remove T-cell epitopes to thereby reduce the potentialimmunogenicity of the antibody. This approach is also referred to as“dcimmunization” and is described in further detail in U.S. PatentPublication No. 2003/0153043 by Carr et al.

In addition or alternative to modifications made within the framework orCDR regions, antibodies can be engineered to include modificationswithin the Fc region, typically to alter one or more functionalproperties of the antibody, such as serum half-life, complementfixation, Fc receptor binding, and/or antigen-dependent cellularcytotoxicity. Furthermore, an antibody can be chemically modified (e.g.,one or more chemical moieties can be attached to the antibody) or bemodified to alter its glycosylation, again to alter one or morefunctional properties of the antibody. Each of these aspects isdescribed in further detail below.

In one aspect, the hinge region of CH1 is modified such that the numberof cysteine residues in the hinge region is altered, e.g., increased ordecreased. This approach is described further in U.S. Pat. No. 5,677,425by Bodmer et al. The number of cysteine residues in the hinge region ofCH1 is altered to, for example, facilitate assembly of the light andheavy chains or to increase or decrease the stability of the antibody.

In another aspect, the Fc hinge region of an antibody is mutated todecrease the biological half-life of the antibody. More specifically,one or more amino acid mutations are introduced into the CH2-CH3 domaininterface region of the Fc-hinge fragment such that the antibody hasimpaired Staphylococcyl protein A (SpA) binding relative to nativeFc-hinge domain SpA binding. This approach is described in furtherdetail in U.S. Pat. No. 6,165,745 by Ward et al.

In yet other aspects, the Fc region is altered by replacing at least oneamino acid residue with a different amino acid residue to alter theeffector functions of the antibody. For example, one or more amino acidscan be replaced with a different amino acid residue such that theantibody has an altered affinity for an effector ligand but retains theantigen-binding ability of the parent antibody. The effector ligand towhich affinity is altered can be, for example, an Fc receptor or the C1component of complement. This approach is described in, e.g., U.S. Pat.Nos. 5,624,821 and 5,648,260, both by Winter et al.

In another aspect, one or more amino acids selected from amino acidresidues can be replaced with a different amino acid residue such thatthe antibody has altered C1q binding and/or reduced or abolishedcomplement dependent cytotoxicity (CDC). This approach is described in,e.g., U.S. Pat. No. 6,194,551 by Idusogie el al.

In another aspect, one or more amino acid residues are altered tothereby alter the ability of the antibody to fix complement. Thisapproach is described in, e.g., the PCT Publication WO 94/29351 byBodmer et al. In a specific aspect, one or more amino acids of anantibody or antigen binding fragment thereof of the present disclosureare replaced by one or more allotypic amino acid residues, for the IgG1subclass and the kappa isotype. Allotypic amino acid residues alsoinclude, but are not limited to, the constant region of the heavy chainof the IgG1, IgG2, and IgG3 subclasses as well as the constant region ofthe light chain of the kappa isotype as described by Jefferis et al.,MAbs. 1:332-338 (2009).

In yet another aspect, the Fc region is modified to increase the abilityof the antibody to mediate antibody dependent cellular cytotoxicity(ADCC) and/or to increase the affinity of the antibody for an Fcγreceptor by modifying one or more amino acids. This approach isdescribed in, e.g., the PCT Publication WO 00/42072 by Presta. Moreover,the binding sites on human IgG1 for FcγR1, FcγRII, FcγRIII and FcRn havebeen mapped and variants with improved binding have been described (seeShields et al., J. Biol. Chem. 276:6591-6604, 2001).

In still another aspect, the glycosylation of an antibody is modified.For example, an aglycosylated antibody can be made (i.e., the antibodylacks glycosylation). Glycosylation can be altered to, for example,increase the affinity of the antibody for “antigen.” Such carbohydratemodifications can be accomplished by, for example, altering one or moresites of glycosylation within the antibody sequence. For example, one ormore amino acid substitutions can be made that result in elimination ofone or more variable region framework glycosylation sites to therebyeliminate glycosylation at that site. Such aglycosylation may increasethe affinity of the antibody for antigen. Such an approach is describedin, e.g., U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.

Additionally or alternatively, an antibody can be made that has analtered type of glycosylation, such as a hypofucosylated antibody havingreduced amounts of fucosyl residues or an antibody having increasedbisecting GlcNac structures. Such altered glycosylation patterns havebeen demonstrated to increase the ADCC ability of antibodies. Suchcarbohydrate modifications can be accomplished by, for example,expressing the antibody in a host cell with altered glycosylationmachinery. Cells with altered glycosylation machinery have beendescribed in the art and can be used as host cells in which to expressrecombinant antibodies to thereby produce an antibody with alteredglycosylation. For example, EP 1,176,195 by Hang et al. describes a cellline with a functionally disrupted FUT8 gene, which encodes a fucosyltransferase, such that antibodies expressed in such a cell line exhibithypofucosylation. PCT Publication WO 03/035835 by Presta describes avariant CHO cell line, Lecl3 cells, with reduced ability to attachfucose to Asn(297)-linked carbohydrates, also resulting inhypofucosylation of antibodies expressed in that host cell (see alsoShields et al., (2002) J. Biol. Chem. 277:26733-26740). PCT PublicationWO 99/54342 by Umana et al. describes cell lines engineered to expressglycoprotein-modifying glycosyl transferases (e.g., beta(1,4)-Nacetylglucosaminyltransferase III (GnTIII)) such that antibodiesexpressed in the engineered cell lines exhibit increased bisectingGlcNac structures which results in increased ADCC activity of theantibodies (see also Umana et al., Nat. Biotech. 17:176-180, 1999).

In another aspect, the antibody is modified to increase its biologicalhalf-life. Various approaches are possible. For example, one or more ofthe following mutations can be introduced: T252L, T254S, T256F, asdescribed in U.S. Pat. No. 6,277,375 to Ward. Alternatively, to increasethe biological half-life, the antibody can be altered within the CH1 orCL region to contain a salvage receptor binding epitope taken from twoloops of a CH2 domain of an Fc region of an IgG, as described in U.S.Pat. Nos. 5,869,046 and 6,121,022 by Presta et al.

In order to minimize the ADCC activity of an antibody, specificmutations in the Fc region result in “Fc silent” antibodies that haveminimal interaction with effector cells. In general, the “IgG Fc region”is used to define the C-terminal region of an immunoglobulin heavychain, including native sequence Fc region and variant Fc regions. Thehuman IgG heavy chain Fc region is generally defined as comprising theamino acid residue from position C226 or from P230 to thecarboxyl-terminus of the IgG antibody. The numbering of residues in theFc region is that of the EU index of Kabat. The C-terminal lysine(residue K447) of the Fc region may be removed, for example, duringproduction or purification of the antibody.

Silenced effector functions can be obtained by mutation in the Fc regionof the antibodies and have been described in the art: LALA and N297A(Strohl, W., 2009, Curr. Opin. Biotechnol. vol. 20(6):685-691); andD265A (Baudino et al., 2008, J. Immunol. 181:6664-69) see also Heusseret al., WO2012065950. Examples of silent Fc IgG1 antibodies are the LALAmutant comprising L234A and L235A mutation in the IgG1 Fc amino acidsequence. Another example of a silent IgG1 antibody is the DAPA (D265A,P329A) mutation (U.S. Pat. No. 6,737,056). Another silent IgG1 antibodycomprises the N297A mutation, which results inaglycosylated/non-glycosylated antibodies.

Fc silent antibodies result in no or low ADCC activity, meaning that anFc silent antibody exhibits an ADCC activity that is below 50% specificcell lysis (low ADCC activity), or that is below 1% specific cell lysis(no ADCC activity).

3. Production of the Anti-VP1 Antibodies

Anti-VP1 antibodies and antibody fragments (e.g., antigen bindingfragments) thereof can be produced by any means known in the art,including but not limited to, recombinant expression, chemicalsynthesis, and enzymatic digestion of antibody tetramers, whereasfull-length monoclonal antibodies can be obtained by, e.g., hybridoma orrecombinant production. Recombinant expression can be from anyappropriate host cells known in the art, for example, mammalian hostcells, bacterial host cells, yeast host cells, insect host cells, etc.

The disclosure further provides polynucleotides encoding the antibodiesdescribed herein, e.g., polynucleotides encoding heavy or light chainvariable regions or segments comprising the complementarity determiningregions as described herein. In some aspects, the polynucleotideencoding the heavy chain variable regions has at least 85%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% nucleic acidsequence identity with a polynucleotide selected from the groupconsisting of SEQ ID NOs: 13, 33, 53, 73, 93, 113, 133, 153, 173, 193,213, 233, 253, 273 and 293. In some aspects, the polynucleotide encodingthe light chain variable regions has at least 85%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% nucleic acid sequenceidentity with a polynucleotide selected from the group consisting of SEQID NOs:23, 43, 63, 83, 103, 123, 143, 163, 183, 203, 223, 243, 263, 283and 303.

In some aspects, the polynucleotide encoding the heavy chain has atleast 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or100% nucleic acid sequence identity with a polynucleotide of SEQ ID NO:15, 35, 55, 75, 95, 115, 135, 155, 175, 195, 215, 235, 255, 275 and 295.In some aspects, the polynucleotide encoding the light chain has atleast 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or100% nucleic acid sequence identity with a polynucleotide of SEQ ID NO:25, 45, 65, 85, 105, 125, 145, 165, 185, 205, 225, 245, 265, 285 and305.

The polynucleotides of the present disclosure can encode only thevariable region sequence of an anti-VP1 antibody. They can also encodeboth a variable region and a constant region of the antibody. Some ofthe polynucleotide sequences encode a polypeptide that comprisesvariable regions of both the heavy chain and the light chain of one ofan exemplified anti-VP1 antibody. Some other polynucleotides encode twopolypeptide segments that respectively are substantially identical tothe variable regions of the heavy chain and the light chain of one ofthe mouse antibodies.

The polynucleotide sequences can be produced by de novo solid-phase DNAsynthesis or by PCR mutagenesis of an existing sequence (e.g., sequencesas described in the Examples below) encoding an anti-VP1 antibody or itsbinding fragment. Direct chemical synthesis of nucleic acids can beaccomplished by methods known in the art, such as the phosphotriestermethod of Narang et al., Meth Enzymol. 68:90, 1979; the phosphodiestermethod of Brown et al., Meth. Enzymol. 68:109, 1979; thediethylphosphoramidite method of Beaucage et al., Tetra. Lett., 22:1859,1981; and the solid support method of U.S. Pat. No. 4,458,066.Introducing mutations to a polynucleotide sequence by PCR can beperformed as described in, e.g., PCR Technology: Principles andApplications for DNA Amplification, H. A. Erlich (Ed.), Freeman Press,NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications, Inniset al. (Ed.), Academic Press, San Diego, Calif., 1990; Mattila et al.,Nucleic Acids Res. 19:967, 1991; and Eckert et al., PCR Methods andApplications 1:17, 1991.

Also provided in the present disclosure are expression vectors and hostcells for producing the anti-VP1 antibodies described above. Variousexpression vectors can be employed to express the polynucleotidesencoding the anti-VP1 antibody chains or binding fragments. Bothviral-based and nonviral expression vectors can be used to produce theantibodies in a mammalian host cell. Nonviral vectors and systemsinclude plasmids, episomal vectors, typically with an expressioncassette for expressing a protein or RNA, and human artificialchromosomes (see, e.g., Harrington et al., Nat Genet 15:345, 1997). Forexample, nonviral vectors useful for expression of the anti-VP1polynucleotides and polypeptides in mammalian (e.g., human) cellsinclude pThioHis A, B & C, pcDNA3.1/His, pEBVHis A, B & C (Invitrogen,San Diego, Calif.), MPSV vectors, and numerous other vectors known inthe art for expressing other proteins. Useful viral vectors includevectors based on retroviruses, adenoviruses, adeno-associated viruses,herpes viruses, vectors based on SV40, papilloma virus, HBP Epstein Barrvirus, vaccinia virus vectors and Semliki Forest virus (SFV). See, Brentet al., supra; Smith, Annu Rev. Microbiol. 49:807, 1995; and Rosenfeldet al., Cell 68:143, 1992.

The choice of expression vector depends on the intended host cells inwhich the vector is to be expressed. Typically, the expression vectorscontain a promoter and other regulatory sequences (e.g., enhancers) thatare operably linked to the polynucleotides encoding an anti-VP1 antibodychain or fragment. In some aspects, an inducible promoter is employed toprevent expression of inserted sequences except under inducingconditions. Inducible promoters include, e.g., arabinose, lacZ,metallothionein promoter or a heat shock promoter. Cultures oftransformed organisms can be expanded under non-inducing conditionswithout biasing the population for coding sequences whose expressionproducts are better tolerated by the host cells. In addition topromoters, other regulatory elements may also be required or desired forefficient expression of an anti-VP1 antibody chain or fragment. Theseelements typically include an ATG initiation codon and adjacent ribosomebinding site or other sequences. In addition, the efficiency ofexpression may be enhanced by the inclusion of enhancers appropriate tothe cell system in use (see, e.g., Scharf et al., Results Probl. CellDiffer. 20:125, 1994; and Bittner et al., Meth. Enzymol., 153:516,1987). For example, the SV40 enhancer or CMV enhancer may be used toincrease expression in mammalian host cells.

The expression vectors may also provide a secretion signal sequenceposition to form a fusion protein with polypeptides encoded by insertedanti-VP1 antibody sequences. More often, the inserted anti-VP1 antibodysequences are linked to a signal sequences before inclusion in thevector. Vectors to be used to receive sequences encoding anti-VP1antibody light and heavy chain variable domains sometimes also encodeconstant regions or parts thereof. Such vectors allow expression of thevariable regions as fusion proteins with the constant regions therebyleading to production of intact antibodies or fragments thereof.Typically, such constant regions are human.

The host cells for harboring and expressing the anti-VP1 antibody chainscan be either prokaryotic or eukaryotic. E. coli is one prokaryotic hostuseful for cloning and expressing the polynucleotides of the presentdisclosure. Other microbial hosts suitable for use include bacilli, suchas Bacillus subtilis, and other enterobacteriaceae, such as Salmonella,Serratia, and various Pseudomonas species. In these prokaryotic hosts,one can also make expression vectors, which typically contain expressioncontrol sequences compatible with the host cell (e.g., an origin ofreplication). In addition, any number of a variety of well-knownpromoters will be present, such as the lactose promoter system, atryptophan (tip) promoter system, a beta-lactamase promoter system, or apromoter system from phage lambda. The promoters typically controlexpression, optionally with an operator sequence, and have ribosomebinding site sequences and the like, for initiating and completingtranscription and translation. Other microbes, such as yeast, can alsobe employed to express anti-VP1 polypeptides. Insect cells incombination with baculovirus vectors can also be used.

In other aspects, mammalian host cells are used to express and producethe anti-VP1 polypeptides of the present disclosure. For example, theycan be either a hybridoma cell line expressing endogenous immunoglobulingenes (e.g., the myeloma hybridoma clones as described in the Examples)or a mammalian cell line harboring an exogenous expression vector. Theseinclude any normal mortal or normal or abnormal immortal animal or humancell. For example, a number of suitable host cell lines capable ofsecreting intact immunoglobulins have been developed, including the CHOcell lines, various COS cell lines, HeLa cells, myeloma cell lines,transformed B-cells and hybridomas. The use of mammalian tissue cellculture to express polypeptides is discussed generally in, e.g.,Winnacker, From Genes to Clones, VCH Publishers, N.Y., N.Y., 1987.Expression vectors for mammalian host cells can include expressioncontrol sequences, such as an origin of replication, a promoter, and anenhancer (see, e.g., Queen et al., Immunol Rev. 89:49-68, 1986), andnecessary processing information sites, such as ribosome binding sites,RNA splice sites, polyadenylation sites, and transcriptional terminatorsequences. These expression vectors usually contain promoters derivedfrom mammalian genes or from mammalian viruses. Suitable promoters maybe constitutive, cell type-specific, stage-specific, and/or modulatableor regulatable. Useful promoters include, but are not limited to, themetallothionein promoter, the constitutive adenovirus major latepromoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter,the MRP polIII promoter, the constitutive MPSV promoter, thetetracycline-inducible CMV promoter (such as the human immediate-earlyCMV promoter), the constitutive CMV promoter, and promoter-enhancercombinations known in the art.

Methods for introducing expression vectors containing the polynucleotidesequences of interest vary depending on the type of cellular host. Forexample, calcium chloride transfection is commonly utilized forprokaryotic cells, whereas calcium phosphate treatment orelectroporation may be used for other cellular hosts (see generallySambrook et al., supra). Other methods include, e.g., electroporation,calcium phosphate treatment, liposome-mediated transformation, injectionand microinjection, ballistic methods, virosomes, immunoliposomes,polycation:nucleic acid conjugates, naked DNA, artificial virions,fusion to the herpes virus structural protein VP22 (Elliot and O'Hare,Cell 88:223, 1997), agent-enhanced uptake of DNA, and ex vivotransduction. For long-term, high-yield production of recombinantproteins, stable expression will often be desired. For example, celllines which stably express anti-VP1 antibody chains or binding fragmentscan be prepared using expression vectors which contain viral origins ofreplication or endogenous expression elements and a selectable markergene. Following introduction of the vector, cells may be allowed to growfor 1-2 days in an enriched media before they are switched to selectivemedia. The purpose of the selectable marker is to confer resistance toselection, and its presence allows growth of cells which successfullyexpress the introduced sequences in selective media. Resistant, stablytransfected cells can be proliferated using tissue culture techniquesappropriate to the cell type.

Therapeutic and Diagnostic Uses

The antibodies, antibody fragments (e.g., antigen binding fragments) ofthe present disclosure are useful in a variety of applicationsincluding, but not limited to, polyoma viral infection and disease. Incertain aspects, the antibodies, antibody fragments (e.g., antigenbinding fragments), and are useful for neutralizing BKV or JCV infectionand the prevention or treatment of BK virus nephropathy, for example,BKVAN). The methods of use can be in vitro, ex vivo, or in vivo methods.

In one aspect, the antibodies, antibody fragments (e.g., antigen bindingfragments), are useful for detecting the presence of BKV in a biologicalsample. The term “detecting” as used herein encompasses quantitative orqualitative detection. In certain aspects, a biological sample comprisesa cell or tissue. In certain aspects, such tissues include normal and/orcancerous tissues that express BKV at higher levels relative to othertissues.

In one aspect, the present disclosure provides a method of detecting thepresence of BKV in a biological sample. In certain aspects, the methodcomprises contacting the biological sample with an anti-VP1 antibodyunder conditions permissive for binding of the antibody to the antigen,and detecting whether a complex is formed between the antibody and theantigen. The biological sample can include, without limitation, urine orblood samples.

Also included is a method of diagnosing a disorder associated withexpression of BKV or JCV virus. In certain aspects, the method comprisescontacting a test cell with an anti-VP1 antibody; determining the levelof expression (either quantitatively or qualitatively) of BK virus inthe test cell by detecting binding of the anti-VP1 antibody to the BKvirus; and comparing the level of infection in the test cell with thelevel of infection of BK virus in a control cell (e.g., a normal cell ofthe same tissue origin as the test cell or a non-BK virus infectedcell), wherein a higher level of presence of BK vines in the test cellas compared to the control cell indicates the presence of a disorderassociated with infection with BK virus. In certain aspects, the testcell is obtained from an individual suspected of having a BK virusinfection.

In certain aspects, a method of diagnosis or detection, such as thosedescribed above, comprises detecting binding of an anti-VP1 antibody toa BKV infected cell. An exemplary assay for detecting binding of ananti-VP1 antibody to a BKV infected cell is a “FACS” assay.

Certain other methods can be used to detect binding of anti-VP1antibodies. Such methods include, but are not limited to,antigen-binding assays that are well known in the art, such as Westernblots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay),“sandwich” immunoassays, immunoprecipitation assays, fluorescentimmunoassays, protein A immunoassays, and immunohistochemistry (IHC).

In certain aspects, anti-VP1 antibodies are labeled. Labels include, butare not limited to, labels or moieties that are detected directly (suchas fluorescent, chromophoric, electron-dense, chemiluminescent, andradioactive labels), as well as moieties, such as enzymes or ligands,that are detected indirectly, e.g., through an enzymatic reaction ormolecular interaction.

In certain aspects, anti-VP1 antibodies are immobilized on an insolublematrix. Immobilization entails separating the anti-VP1 antibody from anyBKV or JCV proteins that remains free in solution. This conventionallyis accomplished by either insolubilizing the anti-VP1 antibody beforethe assay procedure, as by adsorption to a water-insoluble matrix orsurface (Bennich et al, U.S. Pat. No. 3,720,760), or by covalentcoupling (for example, using glutaraldehyde cross-linking), or byinsolubilizing the anti-VP1 antibody after formation of a complexbetween the anti-VP1 antibody and BKV or JCV protein, e.g., byimmunoprecipitation.

Any of the above aspects of diagnosis or detection can be carried outusing an anti-VP1 antibody of the present disclosure in place of or inaddition to another anti-VP1 antibody.

In one aspect, the disclosure provides for a method of treating,reducing the likelihood of or ameliorating a disease comprisingadministering the antibodies, antibody fragments (e.g., antigen bindingfragments), to a patient, thereby treating the disease. In certainaspects, the disease treated with the antibodies, antibody fragments(e.g., antigen binding fragments), is BK viral or JC viral infection.Examples of BKV and JCV diseases which can be treated and/or preventedinclude, but are not limited to, nephropathy, hemorrhagic cystitis,Progressive Multifocal Leukoencephalopathy (PML), interstitial kidneydisease, ureteral stenosis, granule cell neuronopathy (GCN), vasculitis,colitis, retinitis, meningitis, and immune reconstitution inflammatorysyndrome (IRIS). In certain aspects, the infection is characterized byBKV or JCV expressing cells to which the anti-VP1 antibodies, antibodyfragments (e.g., antigen binding fragments) can specifically bind.

The present disclosure provides for methods of treating BK viralinfection and BKVAN comprising administering a therapeutically effectiveamount of the antibodies, antibody fragments (e.g., antigen bindingfragments). In certain aspects, the subject is a human.

In certain aspects, the method of reducing BK viral infection comprisesadministering to a subject a therapeutically effective amount ofantibodies or antibody fragments (e.g., antigen binding fragments). Incertain aspects, the subject is a human. In certain aspects, the subjectis immunosuppressed. For immunosuppresed subjects, the amount ofimmunosuppression can be increased or decreased due to the therapeuticeffects of the anti-VP1 antibodies.

In certain aspects, the transplanted tissue is infected with BK virus towhich the anti-VP 1 antibody binds. As the incidence of BK infection inthe general population is high, there is a high probability that in thecase of kidney transplantation, the patient accepting the kidney is BKvirus positive or the donor providing the kidney is BK virus positive orboth are BK virus positive. In order to prevent BKVAN, anti-VP1antibodies can be administered to the kidney transplant recipient,before and/or after the kidney transplant procedure, depending on theseropositivity of the kidney donor or transplant recipient. In anotheraspect, the anti-VP1 antibodies can be administered to the patient whenvirus is detected in the urine (viruria), or when virus is detected inthe blood (viremia).

For the treatment of BK or JCV viral infection, the appropriate dosageof the antibodies, or antibody fragments (e.g., antigen bindingfragments), depend on various factors, such as the type of infection tobe treated, the severity and course of the infection, the responsivenessof the infection, the generation of viral resistance to therapy,previous therapy, patient's clinical history, and so on. The antibodycan be administered one time or over a series of treatments lasting fromseveral days to several months, or until a cure is effected or adiminution of the infection is achieved (e.g., reduction in viruria orviral damage to the kidney). Optimal dosing schedules can be calculatedfrom measurements of drug accumulation in the body of the patient andwill vary depending on the relative potency of an individual antibody orantibody fragment (e.g., antigen binding fragment). In certain aspects,dosage is from 0.0 mg to 10 mg (e.g., 0.01 mg, 0.05 mg, 0.1 mg, 0.5 mg,1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 7 mg, 8 mg, 9 mg, or 10 mg) per kg of bodyweight, and can be given once or more daily, weekly, monthly or yearly.In certain aspects, the antibody or antibody fragment (e.g., antigenbinding fragment), of the present disclosure is given once every twoweeks or once every three weeks. The treating physician can estimaterepetition rates for dosing based on measured half-life andconcentrations of the antibody in bodily fluids or tissues.

Combination Therapy

In certain instances, the antibody or antibody fragment (e.g., antigenbinding fragment), of the present disclosure is combined with othertherapeutic agents, such as other anti-viral agents, anti-allergicagents, anti-nausea agents (or anti-emetics), pain relievers,cytoprotective agents, immunosuppressants and combinations thereof.

The term “pharmaceutical combination” as used herein refers to either afixed combination in one dosage unit form, or non-fixed combination or akit of parts for the combined administration where two or moretherapeutic agents may be administered independently at the same time orseparately within time intervals, especially where these time intervalsallow that the combination partners show a cooperative, e.g. synergisticeffect.

The term “combination therapy” refers to the administration of two ormore therapeutic agents to treat a therapeutic condition or infectiondescribed in the present disclosure. Such administration encompassesco-administration of these therapeutic agents in a substantiallysimultaneous manner, such as in a single capsule having a fixed ratio ofactive ingredients. Alternatively, such administration encompassesco-administration in multiple, or in separate containers (e.g.,capsules, powders, and liquids) for each active ingredient. Powdersand/or liquids may be reconstituted or diluted to a desired dose priorto administration. In addition, such administration also encompasses useof each type of therapeutic agent in a sequential manner, either atapproximately the same time or at different times. In either case, thetreatment regimen will provide beneficial effects of the drugcombination in treating the conditions or disorders described herein.

The combination therapy can provide “synergy” and prove “synergistic”,i.e., the effect achieved when the active ingredients used together isgreater than the sum of the effects that results from using thecompounds separately. A synergistic effect can be attained when theactive ingredients are: (1) co-formulated and administered or deliveredsimultaneously in a combined, unit dosage formulation; (2) delivered byalternation or in parallel as separate formulations; or (3) by someother regimen. When delivered in alternation therapy, a synergisticeffect can be attained when the compounds are administered or deliveredsequentially, e.g., by different injections in separate syringes. Ingeneral, during alternation therapy, an effective dosage of each activeingredient is administered sequentially, i.e., serially, whereas incombination therapy, effective dosages of two or more active ingredientsare administered together.

In one aspect, the present disclosure provides a method of treating BKVor JCV infection by administering to a subject in need thereof anantibody in together with immunosuppressant therapies. The anti-VP1antibodies will act prophylactically to neutralize BKV or JCV primaryinfection or viral reactivation resulting from the immunosuppressanttherapy prior to or post-transplantation Examples of immunosuppressanttherapy include, but are not limited to; a monophosphate dehydrogenaseinhibitor, a purine synthesis inhibitor, a calcineurin inhibitor or anmTOR inhibitor. Specific examples of immunosuppressive therapeuticsinclude but are not limited to; mycophenolate mofetil (MMF),mycophenolate sodium, azathioprine, tacrolimus, sirolimus andcyclosporine.

Pharmaceutical Compositions

To prepare pharmaceutical or sterile compositions including anti-VP1antibodies, the antibodies of the present disclosure are mixed with apharmaceutically acceptable carrier or excipient. The compositions canadditionally contain one or more other therapeutic agents that aresuitable for neutralizing BKV or JCV infection.

Formulations of therapeutic and diagnostic agents can be prepared bymixing with physiologically acceptable carriers, excipients, orstabilizers in the form of, e.g., lyophilized powders, slurries, aqueoussolutions, lotions, or suspensions (see, e.g., Hardman et al., Goodmanand Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, NewYork, N.Y., 2001; Gennaro, Remington: The Science and Practice ofPharmacy, Lippincott, Williams, and Wilkins, New York, N.Y., 2000; Avis,et al. (eds.), Pharmaceutical Dosage Forms: Parenteral Medications,Marcel Dekker, NY, 1993; Lieberman, et al. (eds.), Pharmaceutical DosageForms: Tablets, Marcel Dekker, NY, 1990; Lieberman, et al. (eds.)Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY, 1990;Weiner and Kotkoskie, Excipient Toxicity and Safety, Marcel Dekker,Inc., New York, N.Y., 2000).

In a specific aspect, the anti-VP1 antibody is a lyophilisate in a vialcontaining the antibody. The lyophilisate can be reconstituted withwater or a pharmaceutical carrier suitable for injection. For subsequentintravenous administration, the obtained solution will usually befurther diluted into a carrier solution.

The antibodies disclosed herein are useful in the neutralization of BKVor JCV in tissue transplant patients who can be immunosuppressed, so apharmaceutical carrier of sucrose and human albumin as used previouslyin bone marrow transplant patients receiving CytoGam® can be used(DeRienzo et al. Pharmacotherapy 2000; 20:1175-8). Alternatively, theanti-VP1 antibodies can be introduced into transplant patients via apharmaceutical carrier as described for another anti-viral antibody,Synagis®, as described in WO2003/105894. In this publication, thepharmaceutical carrier was comprised of histidine and/or glycine, asaccharide (e.g. sucrose) and a polyol (e.g. polysorbate).

Selecting an administration regimen for a therapeutic depends on severalfactors, including the severity of the infection, the level of symptoms,and the accessibility of the target cells in the biological matrix. Incertain aspects, an administration regimen maximizes the amount oftherapeutic delivered to the patient consistent with an acceptable levelof side effects. Accordingly, the amount of biologic delivered dependsin part on the particular entity and the severity of the condition beingtreated. Guidance in selecting appropriate doses of antibodies,cytokines, and small molecules are available (see, e.g., Wawrzynczak,Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK, 1996;Kresina (ed.), Monoclonal Antibodies, Cytokines and Arthritis, MarcelDekker, New York, N.Y., 1991; Bach (ed.), Monoclonal Antibodies andPeptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, N.Y.,1993; Baert et al., New Engl. J. Med. 348:601-608, 2003; Milgrom et al.,New Engl. J. Med. 341:1966-1973, 1999; Slamon et al., New Engl. J. Med.344:783-792, 2001; Beniaminovitz et al., New Engl. J. Med. 342:613-619,2000; Ghosh et al., New Engl. J. Med. 348:24-32, 2003; Lipsky et al.,New Engl. J. Med. 343:1594-1602, 2000).

Determination of the appropriate dose is made by the clinician, e.g.,using parameters or factors known or suspected in the art to affecttreatment or predicted to affect treatment. Generally, the dose beginswith an amount somewhat less than the optimum dose and it is increasedby small increments thereafter until the desired or optimum effect isachieved relative to any negative side effects. Important diagnosticmeasures include those of symptoms of, e.g., infusion reactions.

Actual dosage levels of the active ingredients in the pharmaceuticalcompositions with the anti-VP1 antibodies can be varied so as to obtainan amount of the active ingredient which is effective to achieve thedesired therapeutic response for a particular patient, composition, andmode of administration, without being toxic to the patient. The selecteddosage level will depend upon a variety of pharmacokinetic factorsincluding the neutralizing activity of the antibodies, the route ofadministration, the time of administration, the half-life of theantibody in the patient, the duration of the treatment, other drugs,compounds and/or materials used in combination with the particularcompositions employed, the age, sex, weight, condition, general healthand prior medical history of the patient being treated, and like factorsknown in the medical arts.

Compositions comprising antibodies or fragments thereof can be providedby continuous infusion, or by doses at intervals of, e.g., one day, oneweek, or 1-7 times per week. Doses can be provided intravenously,subcutaneously, topically, orally, nasally, rectally, intramuscular,intracerebrally, or by inhalation A specific dose protocol is oneinvolving the maximal dose or dose frequency that avoids significantundesirable side effects.

For the antibodies described herein, the dosage administered to apatient may be 0.0001 mg/kg to 100 mg/kg of the patient's body weight.The dosage may be between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg,0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's bodyweight. The dosage of the antibodies or fragments thereof can becalculated using the patient's weight in kilograms (kg) multiplied bythe dose to be administered in mg/kg.

Doses of the antibodies then can be repeated and the administrations maybe separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6months.

An effective amount for a particular patient may vary depending onfactors such as the condition being treated, the overall health of thepatient, the method, route and dose of administration and the severityof side effects (see, e.g., Maynard et al., A Handbook of SOPs for GoodClinical Practice, Interpharm Press, Boca Raton, Fla., 1996; Dent, GoodLaboratory and Good Clinical Practice, Urch Publ., London, UK, 2001).

The route of administration may be by, e.g., topical or cutaneousapplication, injection or infusion by intravenous, intraperitoneal,intracerebral, intramuscular, intraocular, intraarterial,intracerebrospinal, intralesional, or by sustained release systems or animplant (see, e.g., Sidman et al., Biopolymers 22:547-556, 1983; Langeret al., J. Biomed. Mater. Res. 15:167-277, 1981; Langer, Chem. Tech.12:98-105, 1982; Epstein et al., Proc. Natl. Acad. Sci. USA82:3688-3692, 1985; Hwang et al., Proc. Natl. Acad. Sci. USA77:4030-4034, 1980; U.S. Pat. Nos. 6,350,466 and 6,316,024). Wherenecessary, the composition may also include a solubilizing agent or alocal anesthetic such as lidocaine to ease pain at the site of theinjection, or both. In addition, pulmonary administration can also beemployed, e.g., by use of an inhaler or nebulizer, and formulation withan aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320,5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078;and PCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO98/31346, and WO 99/66903, each of which is incorporated herein byreference their entirety.

A composition of the present disclosure can also be administered via oneor more routes of administration using one or more of a variety ofmethods known in the art. As will be appreciated by the skilled artisan,the route and/or mode of administration will vary depending upon thedesired results. Selected routes of administration for the antibodiesinclude intravenous, intramuscular, intradermal, intraperitoneal,subcutaneous, spinal or other parenteral routes of administration, forexample by injection or infusion. Parenteral administration mayrepresent modes of administration other than enteral and topicaladministration, usually by injection, and includes, without limitation,intravenous, intramuscular, intraarterial, intrathecal, intracapsular,intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid,intraspinal, epidural and intrasternal injection and infusion.Alternatively, a composition of the present disclosure can beadministered via a non-parenteral route, such as a topical, epidermal ormucosal route of administration, for example, intranasally, orally,vaginally, rectally, sublingually or topically. In one aspect, theantibodies of the present disclosure are administered by infusion. Inanother aspect, the antibodies are administered subcutaneously.

If the antibodies of the present disclosure are administered in acontrolled release or sustained release system, a pump may be used toachieve controlled or sustained release (see Langer, supra; Sefton, CRCCrit. Ref Biomed. Eng. 14:20, 1987; Buchwald et al., Surgery 88:507,1980; Saudek et al., N. Engl. J. Med. 321:574, 1989). Polymericmaterials call be used to achieve controlled or sustained release of thetherapies of the antibodies (see e.g., Medical Applications ofControlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla.,1974; Controlled Drug Bioavailability, Drug Product Design andPerformance, Smolen and Ball (eds.), Wiley, New York, 1984; Ranger andPeppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983; see alsoLevy et al., Science 228:190, 1985; During et al., Ann. Neurol. 25:351,1989; Howard et al., J. Neurosurg. 7 1:105, 1989; U.S. Pat. Nos.5,679,377; 5,916,597; 5,912,015; 5,989,463; 5,128,326; PCT PublicationNo. WO 99/15154; and PCT Publication No. WO 99/20253. Examples ofpolymers used in sustained release formulations include, but are notlimited to, poly(2-hydroxy ethyl methacrylate), poly (methylmethacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate),poly(methacrylic acid), polyglycolides (PLG), polyanhydrides,poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide,poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides)(PLGA), and polyorthoesters. In one aspect, the polymer used in asustained release formulation is inert, free of leachable impurities,stable on storage, sterile, and biodegradable. A controlled or sustainedrelease system can be placed in proximity of the prophylactic ortherapeutic target, thus requiring only a fraction of the systemic dose(see, e.g., Goodson, in Medical Applications of Controlled Release,supra, vol. 2, pp. 115-138, 1984).

Controlled release systems are discussed in the review by Langer,Science 249:1527-1533, 1990). Any technique known to one of skill in theart can be used to produce sustained release formulations comprising oneor more antibodies of the present disclosure. See, e.g., U.S. Pat. No.4,526,938, PCT publication WO 91/05548, PCT publication WO 96/20698,Ning et al., Radiotherapy & Oncology 39:179-189, 1996; Song et al., PDAJournal of Pharmaceutical Science & Technology 50:372-397, 1995; Cleeket al., Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854, 1997;and Lam et al., Proc. Int'l. Symp. Control Rel. Bioact. Mater.24:759-760, 1997, each of which is incorporated herein by reference intheir entirety.

If the antibodies of the disclosure are administered topically, they canbe formulated in the form of an ointment, cream, transdermal patch,lotion, gel, spray, aerosol, solution, emulsion, or other formwell-known to one of skill in the art. See, e.g., Remington'sPharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms,19th ed., Mack Pub. Co., Easton, Pa. (1995). For non-sprayable topicaldosage forms, viscous to semi-solid or solid forms comprising a carrieror one or more excipients compatible with topical application and havinga dynamic viscosity, in some instances, greater than water are typicallyemployed. Suitable formulations include, without limitation, solutions,suspensions, emulsions, creams, ointments, powders, liniments, salves,and the like, which are, if desired, sterilized or mixed with auxiliaryagents (e.g., preservatives, stabilizers, wetting agents, buffers, orsalts) for influencing various properties, such as, for example, osmoticpressure. Other suitable topical dosage forms include sprayable aerosolpreparations wherein the active ingredient, in some instances, incombination with a solid or liquid inert carrier, is packaged in amixture with a pressurized volatile (e.g., a gaseous propellant, such asfreon) or in a squeeze bottle. Moisturizers or humectants can also beadded to pharmaceutical compositions and dosage forms if desired.Examples of such additional ingredients are well-known in the art.

If the compositions comprising the antibodies are administeredintranasally, it can be formulated in an aerosol form, spray, mist or inthe form of drops. In particular, prophylactic or therapeutic agents foruse according to the present disclosure can be conveniently delivered inthe form of an aerosol spray presentation from pressurized packs or anebuliser, with the use of a suitable propellant (e.g.,dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In thecase of a pressurized aerosol the dosage unit may be determined byproviding a valve to deliver a metered amount. Capsules and cartridges(composed of, e.g., gelatin) for use in an inhaler or insufflator may beformulated containing a powder mix of the compound and a suitable powderbase such as lactose or starch.

Methods for co-administration or treatment with a second therapeuticagent, e.g., an immunosuppressant, a cytokine, steroid, chemotherapeuticagent, antibiotic, or radiation, are known in the art (see, e.g.,Hardman et al., (eds.) (2001) Goodman and Gilman's The PharmacologicalBasis of Therapeutics, 10th ed., McGraw-Hill, New York, N.Y.; Poole andPeterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice: APractical Approach, Lippincott, Williams & Wilkins, Phila., Pa.; Chabnerand Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott,Williams & Wilkins, Phila., Pa.). An effective amount of therapeutic maydecrease the symptoms by at least 10%; by at least 20%; at least about30%; at least 40%, or at least 50%.

Additional therapies (e.g., prophylactic or therapeutic agents), whichcan be administered in combination with the anti-VP1 antibodies may beadministered less than 5 minutes apart, less than 30 minutes apart, 1hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, atabout 2 hours to about 3 hours apart, at about 3 hours to about 4 hoursapart, at about 4 hours to about 5 hours apart, at about 5 hours toabout 6 hours apart, at about 6 hours to about 7 hours apart, at about 7hours to about 8 hours apart, at about 8 hours to about 9 hours apart,at about 9 hours to about 10 hours apart, at about 10 hours to about 11hours apart, at about 11 hours to about 12 hours apart, at about 12hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours apartfrom the anti-VP1 antibodies of the present disclosure. The two or moretherapies may be administered within one same patient visit.

In certain aspects, anti-VP1 antibodies can be formulated to ensureproper distribution in vivo. For example, the blood-brain barrier (BBB)excludes many highly hydrophilic compounds. To ensure that the anti-VP1antibodies cross the BBB (if desired), they can be formulated, forexample, in liposomes. For methods of manufacturing liposomes, see,e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; and 5,399,331. The liposomesmay comprise one or more moieties which are selectively transported intospecific cells or organs, thus enhance targeted drug delivery (see,e.g., Ranade, (1989) J. Clin. Pharmacol. 29:685). Exemplary targetingmoieties include folate or biotin (see, e.g., U.S. Pat. No. 5,416,016 toLow et al.); mannosides (Umezawa et al., (1988) Biochem. Biophys. Res.Commun. 153:1038); antibodies (Bloeman et al., (1995) FEBS Lett.357:140; Owais et al., (1995) Antimicrob. Agents Chemother. 39:180);surfactant protein A receptor (Briscoe et al., (1995) Am. J. Physiol.1233:134); p 120 (Schreier et al, (1994) J. Biol. Chem. 269:9090); seealso K. Keinanen; M. L. Laukkanen (1994) FEBS Lett. 346:123; J. J.Killion; I. J. Fidler (1994) Immunomethods 4:273.

The present disclosure provides protocols for the administration ofpharmaceutical composition comprising antibodies alone or in combinationwith other therapies to a subject in need thereof. The combinationtherapies (e.g., prophylactic or therapeutic agents) can be administeredconcomitantly or sequentially to a subject. The therapy (e.g.,prophylactic or therapeutic agents) of the combination therapies canalso be cyclically administered. Cycling therapy involves theadministration of a first therapy (e.g., a first prophylactic ortherapeutic agent) for a period of time, followed by the administrationof a second therapy (e.g., a second prophylactic or therapeutic agent)for a period of time and repeating this sequential administration, i.e.,the cycle, in order to reduce the development of resistance to one ofthe therapies (e.g., agents) to avoid or reduce the side effects of oneof the therapies (e.g., agents), and/or to improve, the efficacy of thetherapies.

The therapies (e.g., prophylactic or therapeutic agents) of thecombination therapies of the disclosure can be administered to a subjectconcurrently. The term “concurrently” is not limited to theadministration of therapies (e.g., prophylactic or therapeutic agents)at exactly the same time, but rather it is meant that a pharmaceuticalcomposition comprising antibodies or fragments thereof are administeredto a subject in a sequence and within a time interval such that theantibodies can act together with the other therapy(ies) to provide anincreased benefit than if they were administered otherwise. For example,each therapy may be administered to a subject at the same time orsequentially in any order at different points in time; however, if notadministered at the same time, they should be administered sufficientlyclose in time so as to provide the desired therapeutic or prophylacticeffect. Each therapy can be administered to a subject separately, in anyappropriate form and by any suitable route. In various aspects, thetherapies (e.g., prophylactic or therapeutic agents) are administered toa subject less than 15 minutes, less than 30 minutes, less than 1 hourapart, at about 1 hour apart, at about 1 hour to about 2 hours apart, atabout 2 hours to about 3 hours apart, at about 3 hours to about 4 hoursapart, at about 4 hours to about 5 hours apart, at about 5 hours toabout 6 hours apart, at about 6 hours to about 7 hours apart, at about 7hours to about 8 hours apart, at about 8 hours to about 9 hours apart,at about 9 hours to about 10 hours apart, at about 10 hours to about 11hours apart, at about 11 hours to about 12 hours apart, 24 hours apart,48 hours apart, 72 hours apart, or 1 week apart. In other aspects, twoor more therapies (e.g., prophylactic or therapeutic agents) areadministered to a within the same patient visit.

The prophylactic or therapeutic agents of the combination therapies canbe administered to a subject in the same pharmaceutical composition.Alternatively, the prophylactic or therapeutic agents of the combinationtherapies can be administered concurrently to a subject in separatepharmaceutical compositions. The prophylactic or therapeutic agents maybe administered to a subject by the same or different routes ofadministration.

EXAMPLES Example 1 Generation of Anti-VP1 Antibodies

B cells expressing anti-VP1 antibodies were lysed and the VH (heavy) andVL (light) chains were sequenced by RT-PCR and analyzed to identifycritical post translational modification (PTM) sites. Plasmids of the VHand VL chains were then transfected in a CHO mammalian cell line in anIgG1 back bone vector for expression of the full IgG1 antibodies.

Methods for generation of monoclonal antibodies using hybridomatechnology are known in the art (Antibody Methods and Protocols, Methodsin Molecular Biology vol. 901, 2012, Chapter 7: 117). Briefly, femaleBalb/c mice were immunized with VLPs from BKV serotype I, serotype IV,and JCV (either individually or in combination) using variousprime-boost strategies, doses of immunogen, and adjuvants (including butnot limited to Freund's adjuvant and MF59 adjuvant). Supernatant ofsuccessfully fused (growing) hybridomas were screened for the presenceof anti-VP1 antibodies by ELISA, then for functional activity inneutralization assays. CDRs from select murine IgGs were humanized bygrafting onto human framework acceptor templates, cloned into mammalianIgG1 backbone expression vectors and transfected in a CHO mammalian cellline for expression of the full IgG1 antibodies.

Methods for generation of monoclonal antibodies using phage displaytechnology are known in the art (Antibody Methods and Protocols, Methodsin Molecular Biology vol. 901, 2012, Chapter 3: 33). Briefly, a humanB-cell antibody library in scFv format with Vκ was screened for anti-VP1antibodies by solution panning with streptavidin-coupled magnetic beadscomplexed with biotinylated BKV serotype IV VLPs over 3 rounds ofselection with increasing stringency. Isolates were first expressed asscFv and screened for binding to both BKV serotype IV VLPs and pentamersby ELISA. Select isolates were then cloned and expressed as IgG1,reanalyzed for binding to VP1 (serotype I and IV) by ELISA and forfunctional activity in neutralization assays, and transfected in a CHOmammalian cell line for expression of the full IgG1 antibodies.

A summary of the anti-VP1 antibodies is provided in Table 3.

TABLE 3 anti-VP 1 antibodies Antibody P165E2 NEG447 P165E2 changes:germlined/affinity matured for serotype IV; VH (T35S, E43A. A73T, S74N),VL (R17K, G61D, A86V) resulted in no significant change in affinity oractivity. NEG447A P165E2 changes: germlined NEG447; VL (L10V, V86D)resulted in ~3-fold greater affinity and ~8- fold more potent activity(EC90) on serotype II, ~10-fold greater affinity for serotype IV P7G11P7G11A P7G11 variant: germlined P7G11; VH (A12V, S23T, I69V, M71I, T85S)resulted in ~150-fold greater affinity for serotype II, ~14-fold greateraffinity for serotype IV P8D11 P8D11A P8D11 change to removepost-translational modifi- cation: N30S in HCDR1 resulted in nosignificant change in affinity or activity P8D11B P8D11 change to removepost-translational modifi- cation: N30K in HCDR1 resulted in nosignificant change in affinity or activity P8D11C P8D11 change to removepost-translational modifi- cation: N30Q in HCDR1 resulted in nosignificant change in affinity or activity P8D11D P8D11 change in HeavyChain framework 1 region to fix proteolysis/clipping liability (V5Q,G9P, T10G) resulted in no significant change in affinity or activityP8D11E P8D11 change in Heavy Chain framework 1 region to fixproteolysis/clipping liability (T10G) resulted in no significant changein affinity or activity P46F4 EBB-C1975-B5 phage display EBB-C1975-A3phage display EBB-C1975-A7 phage display EBB-C1975-E7 phage display2081-20-8 mouse hybridoma 2075-16-1 mouse hybridoma 2075-456-4 mousehybridoma 2081-36-8 mouse hybridoma 2081-66-5 mouse hybridoma 2081-38-5mouse hybridoma 2081-25-6 mouse hybridoma 2077-4-1 mouse hybridoma2077-7-5 mouse hybridoma 2077-10 1 mouse hybridoma 2077-26-1 mousehybridoma 2077-28-2 mouse hybridoma

Example 2 Affinity Maturation of Anti-VP1 Antibodies

The anti-VP1 antibodies were affinity matured in yeast by error-pronePCR or CDR-directed mutagenesis. VP1 proteins from each of the fourserotypes of BKV (as shown in Table 4) were used as the antigen in up tothree rounds of selection by FACS analysis. VH (heavy) and/or VL (light)chains with enhanced binding affinity to VP1 by FACS analysis were thencloned into mammalian IgG1 backbone expression vectors and transfectedin a CHO mammalian cell line for expression of the full IgG1 antibodies.

TABLE 4 Name VP1 protein SEQ ID NO Serotype 1,FSLKLSAENDFSSDSPERKMLPCYSTARIPLP (SEQ ID amino acidsNLNEDLTCGNLLMWEAVTVQTEVIGITSML NO: 496) 66-145 NLHAGSQKVHEHGGGKPISerotype II, YSLKLTAENAFDSDSPDKKMPCYSTARIPL (SEQ ID amino acidsPNLNEDLTCGNLLMWEAVTVKTEVIGITSM NO: 497) 66-145 LNLHAGSQKVHENGGGKPVSerotype III, YSQHLSAENAFDSDSPDKKMLPCYSTARIPL (SEQ ID amino acidsPNLNEDLTCGNLLMWEAVTVKTEVIGITSM NO: 498) 66-145 LNLHAGSQKVHENGGGKPVSerotype IV, YSLRLTAETAFDSDSPDRKMLPCYSTARIPLP (SEQ ID amino acidsNLNEDLTCGNLLMWEAVTVKTEVIGITSML NO: 499) 66-145 NLHAGSQKVHENGGGKPI

Example 3 BK Virus and Virus-Like Particle (VLP) Generation

Genomic clones of BKV serotype I were obtained from ATCC (pBR322-BKV cat#45026; pBR322-BKV Dunlop, cat #45025). Infectious genomic clones ofchimeric viruses for serotype II, III and IV were generated using thecloning strategy described previously (Broekema et al, Virology 2010407:368-373). Briefly, unique restriction sites (SacII, PmlI) wereintroduced into BKV serotype I genomes flanking the VP1-VP2-VP3 codingregion using site-directed mutagenesis. The coding region for VP1 fromserotype II isolate SB (GenBank Accession CAA79596.1), serotype IIIisolate AS (GenBank Accession AAA46882.1) and serotype IV strain ITA-4(GenBank Accession BAF75132) were synthesized in the context of VP2/VP3coding region from the serotype I isolates (Genewiz, La Jolla, Calif.),such that the synthesized fragments encompassed the SacII-PmlI region tobe used for swap combinations as described in Broekema et al., supra.The resulting chimeric genomic clones were then used to generate hightiter infectious viral stocks in primary renal proximal tubuleepithelial (RPTE) cells (ATCC, cat #PCS-400-010) as previously described(Abend et al, J. Virology 2007 81:272-279).

VLPs representing each of the four BKV serotypes were generated byexpression of VP1 in Sf9 insect cells and extracted from frozen cellpellets from 1 L cultures by microtip sonication (3×45 second pulses,rest 5 min between pulses on ice), isolation by pelleting VLPs through a20% sucrose cushion (116,000 g for 2.5 hours), and purification by anionexchange with a 5 ml GE HiTrap Q HP column (GE Healthcare, Pittsburgh,Pa.) followed by purification using a 10 ml Capto™ Core700 (GEHealthcare, Pittsburgh, Pa.) resin-based size exclusion column, andfinally purification on a GE Sephacryl S500 26/60 (GE Healthcare,Pittsburgh, Pa.) size exclusion column. The prepared VLPs were used inELISA and SPR based binding assays in Examples 6 and 7.

Example 4 Purification of BKV VP1 Pentamers

VP1 proteins from each of the four serotypes of BKV (sequences shown inTable 5 below) were cloned with N terminal GST-6×His-TEV sequences andsubcloned into pGEX destination vector (GE Healthcare, Pittsburgh, Pa.).GST fusion proteins were expressed in E. coli, extracted from cellpellets using a microfluidizer (15,000 PSI), and purified by immobilizedmetal ion affinity chromatography (IMAC) using a 20 ml nickel sepharose6 Fast Flow column (GE Healthcare, Pittsburg, Pa.). The GST-6×His-TEVtag was cleaved by overnight incubation with TEV protease and finalpurification was performed using a 5 ml His-Trap Fast Flow column (GEHealthcare, Pittsburg, Pa.), followed by Superdex 200 26/60 sizeexclusion column (GE Healthcare, Pittsburg, Pa.).

TABLE 5 BKV SEQ ID Serotype VP1 Sequence NO. SerotypeKGGVEVLEVKTGVDAITEVECFLNPEMGDPDENLRGFSLKLSAENDF SEQ ID I, aminoSSDSPERKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVQTEVIGIT NO: 502 acids 30-SMLNLHAGSQKVHEHGGGKPIQGSNFHFFAVGGDPLEMQGVLMNYR 297TKYPEGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTFTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVK SerotypeKGGVEVLEVKTGVDAITEVECFLNPEMGDPDDNLRGYSLKLTAENAF SEQ ID II, aminoDSDSPDKKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGIT NO: 503 acids 30-SMLNLHAGSQKVHENGGGKPVQGSNFHFFAVGGDPLEMQGVLMNY 297RTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVK SerotypeKGGVEVLEVKTGVDAITEVECFLNPEMGDPDDHLRGYSQHLSAENAF SEQ ID III, aminoDSDSPDKKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGIT NO: 504 acids 30-SMLNLHAGSQKVHENGGGKPVQGSNFHFFAVGGDPLEMQGVLMNY 297RTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSKNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVK SerotypeKGGVEVLEVKTGVDAITEVECFLNPEMGDPDNDLRGYSLRLTAETAF SEQ ID IV, aminoDSDSPDRKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGIT NO: 505 acids 30-SMLNLHAGSQKVHENGGGKPIQGSNFHFFAVGGDPLEMQGVLMNYR 297TKYPEGTVTPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLPRYFKIRLRKRSVK

Example 5 Affinity Measurements of Anti-VP1 Antibodies (SET Assay)

Solution equilibration titration (SET) assay was used to determine theinteraction affinities (K_(D)) of antibodies with BKV VP1 pentamers fromall four serotypes. Antibodies were assayed at 1 pM concentration(constant), VP1 pentamers were serially diluted from a startingconcentration of 10 nM. Antibody:VP1 pentamer solution was incubatedovernight, then assayed for unbound antibody using an MSD array plate(Meso Scale Discovery Cat #L21XA, Rockville Md.) coated with VP1pentamer. The K_(D) was determined by fitting the plot with a 1:1 fitmodel (according to Piehler et al. J. Immunol. Methods. 1997;201(2):189-206).

In SET assays, K_(D) values were similar for anti-VP1 antibodies bindingto BKV serotype I pentamers, ranging from 0.9 to 5.0 pM. P8D11 andderivatives of P8D11 had comparable K_(D) values for binding to BKVserotype II, III, and IV pentamers, and when compared to the otherantibodies, had at least 3.5-fold greater affinity on serotype IIpentamers and 47-fold greater affinity on serotype IV pentamers. This isshown in FIG. 1A-1D. In addition, P8D11 and derivatives of P8D11demonstrated binding affinity ranging from 2.5 to 6.0 pM on serotype IIIpentamers, whereas the other antibodies had no detectable binding toserotype III pentamers within the tested conditions. A summary of SETaffinity data for these anti-VP1 antibodies is found in FIG. 2.

Example 6 Binding of Anti-VP1 Antibodies to VP1 Pentamers and VLPs(ELISA)

The binding of anti-VP1 antibodies to VP1 pentamers and VLPs wereanalyzed by ELISA. Briefly, Immulon 2HB plates (VWR, 62402-972) werecoated with 100 ng/well BKV VLPs or VP1 pentamers overnight. Antibodieswere serially diluted in PBS with 0.5% BSA and allowed to bindantigen-coated plates for 2 h. Plates were washed with PBS and thenincubated with secondary antibody (HRP-conjugated rabbit anti-human IgG,Southern Biotech #6140-05) diluted 1:6000 in 0.5% BSA in PBS for 1 h.Plates were washed with PBS and tetramethylbenzidine (TMB) microwellperoxidase substrate (KPL, 52-00-03 1L) was used to develop thereactions.

The anti-VP1 antibodies EBB-C1975-A3, A7, E7, and B5 showed similarbinding to VLPs (IC50s ranging from 0.044 to 0.1 nM) or VP1 pentamers(IC50s ranging from 0.026 to 0.078 nM) from BKV serotype IV, but reducedand more variable binding activity to serotype I VLPs (IC50s rangingfrom 4.32 to 85.7 nM). This data is shown graphically in FIGS. 4-6 andsummarized in FIG. 7. In contrast, anti-VP1 antibodies from the 2081 and2075 series showed enhanced binding activity to serotype I VLPs, withIC50s ranging from 0.046 to 0.267 nM and this data is shown in FIGS. 8and 9. The JCV-specific anti-VP1 antibodies of the 2077 seriesdemonstrated binding activity to JCV VLPs ranging from 0.034 to 0.651 nMand this data is provided in FIGS. 10 and 11.

Example 7 Binding of Anti-VP1 Antibodies to VP1 Pentamers and VLPs bySPR

The binding of anti-VP1 antibodies to VP1 pentamers and VLPs wereanalyzed by surface plasmon resonance (SPR). Briefly, biotinylatedProtein A is immobilized on a streptavidin-coated SPR chip surface, andanti-VP1 antibodies are captured on the resulting surface by binding toProtein A. BKV VP1 pentamers or VLPs are then flowed over the surfaceand allowed to bind anti-VP1 antibodies during the association phase,followed by a buffer wash during the dissociation phase.

SPR was used to evaluate binding of anti-VP1 antibodies EBB-C1975-A3,A7, E7, and B5 to the four serotypes of BKV, relative to a positivecontrol (P165E2). All four antibodies had very similar binding profilesto VP1 pentamers: no binding to serotype I and III pentamers, atypicalbinding to serotype II pentamers (large bulk shift and no return tobaseline), and binding to serotype IV pentamers similar to P165E2 butwith lower affinity (FIGS. 3A, 3C and 3E). For VLPs, EBB-C1975-A3, A7,and E7 shared similar binding profiles: atypical binding to serotype TVLPs and no binding to serotype III VLPs. However, EBB-C1975-B5 bindingprofile was distinct with significant binding to serotype I and IIIVLPs, demonstrating binding to a different epitope on VP1 (FIGS. 3B and3D).

SPR was also used to characterize binding of anti-VP1 antibodies P165E2,NEG447, P7G11A, and P8D11 to VP1 pentamers by scanning alaninemutagenesis (FIGS. 13A-F and FIG. 14). All anti-VP1 antibodies showedreduced binding to F66A and I145A VP1 mutants, due to an overall impactof the mutation on VP1 pentamer structure (FIGS. 13B and 13F). Inaddition, K69A and E82A impacted binding of P165E2, NEG447, and P7G11A(FIGS. 13D and 13E).

Example 8 Anti-VP1 Antibodies Bind to a Conformational Epitope

To determine if the anti-VP1 antibodies bind a conformational epitope,Western blots of denatured protein by SDS-PAGE and dot blots of proteinin native conformation were used. Briefly, BKV serotype 1 or IVVP1-pentamer were run on SDS-PAGE and transferred to nitrocellulosemembrane (Western blot) or spotted directly onto nitrocellulose membrane(dot blot). Both membranes were incubated with anti-VP1 antibodiesfollowed by anti-human IgG secondary antibody conjugated to infraredfluorescing dyes for detection using the Licor Odyssey system.

Commercially available positive control antibody (Abcam 53977) known torecognize a linear epitope detected both the denatured and non-denaturedVP1. However, P165E2, P7G11 and P8D11 failed to detect denatured VP1 onthe Western blot and only recognized native VP1 on the dot blot,indicating that these antibodies bind to a conformational (non-linear)epitope of VP1 (FIGS. 12A and 12B).

To further characterize the epitope of anti-VP1 antibodies, scanningalanine mutagenesis was performed for residues, primarily in the VP1 BCloop, known to be exposed on the virion surface and within a majorinteraction site for cell surface receptors. These mutant VP1 pentamerswere assayed for binding to P8D11 and P7G11A in surface plasmonresonance (SPR) studies as described above in Example 7. Mutations atseveral positions impacted binding of P7G11A (F66A, K69A, E82A, I145A)(FIGS. 13A-F and FIG. 14). However, mutations at only two sites resultedin reduction of P8D11 binding (F66A, I145A) (FIG. 14). As the mutationsat F66 and 1145 resulted in a loss of binding of all antibodies tested,without being bound by any one theory, it is likely that these mutationsresult in a general disruption of the VP1 pentamer structure. All otherVP1 pentamers with BC loop mutations tested retained P8D11 binding. Incontrast, hydrogen-deuterium exchange studies have identified aprotected region within the EF loop of VP1 upon binding of P8D11 Fabfragment. Follow-up scanning alanine mutagenesis studies confirm thatkey contact residues for P8D11 binding within this region include Y169,R170 and K172, with D/E175, K181, N182, T184 and Q186 to M190 beingimportant residues as determined by deuterium exchange((YRXKXX(D/E)XXXXXKNXTXQ) (SEQ ID NO: 500)). This is further describedin Example 14 through Example 17.

Example 9 Neutralization of BK Virus by Anti-VP1 Antibodies

Infectious BKV serotype I and chimeric viruses representing serotype II,III, and IV were pre-incubated with purified antibodies for 1 hour toallow for binding and neutralization. Primary renal proximal tubuleepithelial (RPTE) cells (ATCC, cat #PCS-400-010) were then exposed tothe virus-antibody mixture for 4 hours, replaced with fresh medium, andincubated for 48 hours to allow for viral entry and gene expression.Cells were fixed with 4% paraformaldehyde and analyzed byimmunofluorescence to detect TAg expression (Calbiochem DP02, pAb416mouse anti-SV40 TAg antibody). The immunofluorescence was analyzed byhigh content image analysis using the Cellomics ArrayScan®VTI HCS Readerto quantify the percent of BKV-infected cells (TAg-positive,DAP1-positive), with data presented as percent inhibition of infectionrelative to untreated control wells.

As shown in FIGS. 15-23, anti-VP1 antibodies neutralized infection byBKV, including the subset of antibodies that neutralize infection by allfour serotypes of BKV (I-IV). These anti-VP1 antibodies specificallyinclude P8D11, the modifications of P8D11, and EBB-C1975-B5.

Example 10 Neutralization of JC Virus by Anti-VP1 Virus Antibodies

The infectious JCV isolates Mad-1 and Mad-4, have identical VP1sequences (GenBank Accession NP_043511). These JCV isolates werepre-incubated with purified antibodies for 1 hour to allow for bindingand neutralization. COST cells (African green monkey kidneyfibroblast-like cell line expressing SV40 TAg, ATCC cat #CRL-1651) werethen exposed to the vines-antibody mixture for 4 hours, replaced withfresh medium, and incubated for 72 hours to allow for viral entry andgene expression. Cells were fixed with 4% paraformaldehyde and analyzedby immunofluorescence to detect JCV VP1 expression (Abcam 53977, rabbitpolyclonal anti-SV40 VP1 antibody). The assay was analyzed by highcontent image analysis using the Cellomics ArrayScan®VTI HCS Reader(Thermo Fisher, Waltham Mass.) to quantify the percent of JCV-infectedcells (VP1-positive, DAP1-positive), with data presented as percentinhibition of infection relative to untreated control wells. As shown inFIGS. 24-26, a subset of anti-VP1 antibodies neutralize infection byJCV, including P8D11 and the 2077-series of antibodies.

Example 11 Viral Resistance

Resistance selection experiments with P8D11 antibodies were carried outin renal proximal tubular epithelial (RPTE) cell cultures infected withBKV serotype I or serotype IV. In serotype I studies, no viralbreakthrough was observed in cultures with P8D11 out to 6 passages (84days) and thus no resistance-associated variants (RAVs) were identified.No further passaging past this point was done, as no virus could bedetected. In contrast, viral breakthrough was detected at passage 3 (day42) with another antibody. Sequencing of BKV VP1 from these culturesidentified a resistance-associated variant (RAV) with 20 amino acidchanges throughout VP1, with no changes clustering around specific aminoacids in the VP1 sequence. Subsequent phenotypic characterization ofthis pooled RAV virus showed a complete loss of neutralization activity(>7,692-fold shift in EC50) when compared to wild-type virus, but littlechange (3.9 fold) in the EC50 of P8D11. In addition, the VP1 mutant E82Kwas identified as a RAV during selection with another anti-VP1 antibody(see Example 8), and characterization of a cloned E82K mutant virusshowed this variant conferred a 15,880-fold shift in EC50 when comparedto wild-type virus, but showed no cross-resistance to P8D11.

Similarly, in BKV serotype IV cultures, resistance was not detected withP8D11 after 6 passages (84 days) Again, No further passaging past thispoint was done, as no virus could be detected. However, resistance to adifferent anti-BK antibody was selected as early as passage 1 (day 14).Changes in amino acids L68R and E73K were identified aschange-from-reference mutations and conferred 600- and 227-fold shiftsin EC50 values respectively, but displayed no cross-resistance to P8D11.In summary, P8D11 has a high barrier-to-resistance and maintainsneutralizing activity against resistant variants for both serotypes Iand IV.

Example 12 Toxicity

Because VP1 is an exogenous, non-human target that is not expressed onthe cell surface, the anti-VP1 antibodies disclosed herein constitute alow risk for toxicity in human A TCR study demonstrated there was nostaining of 42 human tissues and blood smears by P8D11, supporting theabsence of anti-VP1 antibody cross-reactivity with human proteins. Theanti-VP1 antibodies have shown no antibody-dependent cell-mediatedcytotoxicity (ADCC) in vitro, consistent with the fact that VP1 proteinis not expressed on the host cell surface.

Example 13 SET Affinity Assay of P8D11 on JCV VLPs

Progressive Multifocal Leukoencephalopathy (PML) is a rare, butfrequently fatal infection of the brain of immunocomprimised patients byJC virus. The major capsid protein (VP1) of JC virus, is involved inbinding sialic acid receptors on the surface of host cells. Certainmutations in the VP1, such as at amino acids L55 and 5269, abolishsialic acid recognition and play a role in PML pathogenesis (Chen etal., mAbs 2015; 7(4), 681-692). These two mutations occur frequently inPML patients (Gorelik et al., J. Infect. Dis. 2011 204:103-114 and Reidet al., J. Infect. Dis. 2011; 204:237-244). The antibodies of thedisclosure were tested to see if they bound to the mutated JCV VLPs withmutations at those positions. Binding of the anti-VP1 antibodies tothese VLPs would indicate that JC vines carrying these common VP1mutations would not be resistant to therapy.

Two series of twenty-two serial dilution of VLP were prepared in samplebuffer. Two constant concentrations of the P8D11 antibody were added.The concentration of P8D11 antibody used was either 9 nM or 1 pM. Theconcentration range of JCV consensus ranged from 105 μg/ml-72 pg/ml. Theconcentration range of JCV L55F mutant was 300 μg/ml-143 pg/ml. Theconcentration range of JCV 5269F mutant was 300 μg/ml-143 pg/ml. Avolume of 60 μl of each VLP:antibody mix was distributed in duplicatesto a 384-well polypropylene microtiter plate (PP MTP). Sample bufferserved as negative control and a sample containing no antigen aspositive control (Bmax). The plate was sealed and incubated over night(o/n) at room temperature (RT). A 384-well standard MSD array plate wascoated o/n with 2 and 0.002 μg/ml of BKV-VP1 serotype 1 pentamericprotein. After three times washing with 50 μl/well washing buffer, theplate was blocked with 50 μl/well blocking buffer for 1 hour at RT.After washing, a volume of 30 μl/well of each VLP:antibody mix wastransferred from the PP MTP to the coated MSD plate and incubated for 20min at RT. After an additional wash step, 30 μl of detection antibody(diluted 1:2000) in sample buffer was added to each well and incubatedfor 30 min at RT. The MSD plate was washed and 35 μl/well of read bufferwas added and incubated for 5 min. ECL signals were measured with theMSD SECTOR Imager 6000.

The reagents used were: Bovine serum albumin (BSA), (VWR Cat #422351S),Phosphate-buffered saline (PBS) 10×, (Teknova Cat #P0195), MSD ReadBuffer T 4×, (Meso Scale Discovery Cat #R92TC-1), Tris-buffered saline(TBS) 20×, (Teknova Cat #T1680), Tween-20, (VWR Cat #437082Q). Thebuffers used were; Blocking buffer: 1×PBS+5% (w/v) BSA, Coating buffer:1× PBS, Sample buffer: 1×PBS+0.5% (w/v) BSA+0.02% (v/v) Tween-20, Washbuffer: 1×TBS+0.05% (v/v) Tween-20 and Read buffer: 1×MSD Read Buffer.

A solution equilibrium titration (SET) assay was used to determine theinteraction affinities (K_(D)) of P8D11 with JCV VLPs as described inExample 5. P8D11 antibody was assayed at either 9 nM or 1 pMconcentrations (constant) and JCV VLPs were serially diluted as follows:consensus VLPs ranged from 105 μg/ml-72 pg/ml, and L55F and S269F mutantVLPs both ranged from 300 μg/ml-143 pg/ml. Antibody:VP1 pentamersolution was incubated overnight, then assayed for unbound antibodyusing an MSD array plate (Meso Scale Discovery, Cat #L21XA, RockvilleMd.) coated with VP1 pentamer. The K_(D) was determined by fitting theplot with a 1:1 fit model (according to Piehler et al. J. Immunol.Methods. 1997; 201(2):189-206). The analysis was performed by usingKinExA® Pro and n-Curve Analysis softwares from Sapidyne (Boise Id.).

FIG. 27 depicts the results of the SET assay in tabular form. This dataprovides the affinity determination (K_(D)) of P8D11 antibody toconsensus JCV VLPs and VLPs containing VP1 mutations commonly associatedwith PML. P8D11 showed binding affinities to all JCV VLPs in the lownanomolar range. However, the binding affinity to the L55F mutant wasapproximately 2-fold lower than the affinity for wild type (consensus)and S269F mutant VLPs. Therefore, this indicates that the P8D11 antibodywould still be an effective therapy against either wild type JC virus orJC virus with mutations commonly associated with PML.

Example 14 Deuterium Exchange Study (P8D11 Fab in Complex with BKV VP1Pentamers) for Epitope Mapping

Deuterium exchange mass spectrometry (HDx-MS) measures the deuteriumuptake on the amide backbone of a protein. These measurements aresensitive to the amide's solvent accessibility and to changes in thehydrogen bonding network of the backbone amides. HDx-MS is often used tocompare proteins in two different states, such as apo and ligand-bound,and coupled with rapid digestion with pepsin. In such experiments onecan locate regions, typically of 10 to 15 amino acids, that showdifferential deuterium uptake between two different states. Regions thatare protected are either directly involved in ligand binding orallosterically affected by binding of the antibody to the ligand.

In these experiments, the deuterium uptake of BKV VP1 protein (SEQ IDNO:502), was measured in the absence and presence of P8D11 Fab fragment.Regions in VP1 that show a decrease in deuterium uptake upon binding ofthe Fab fragment are likely to be involved in the epitope; however, dueto the nature of the measurement it is also possible to detect changesremote from the direct binding site (allosteric effects). In general,the regions that have the greatest amount of protection are involved indirect binding.

The epitope mapping experiments are performed on a Waters Synapt® G2HDx-MS platform, which includes LEAP® robot system, nanoACQUITY® UPLCSystem, and Synapt G2 mass spectrometer. In this method, triplicatecontrol experiments are carried out as follows. BKV serotype I VP1pentamer is diluted into 110 μl of 95% deuterated PBS buffer (pH 7.4)and incubated at room temperature on a bench rotator for 25 minutes (%D=85.5%). Deuterium exchange is quenched by 1:1 dilution with coldquench buffer (6M Urea and 1M TCEP pH=2.5) on ice for 5 min. Afterquenching the tube is transferred onto a LEAP system (Thermo box is setat 2° C.) and the quenched sample is injected by the LEAP system ontothe UPLC system for analysis. The UPLC system incorporates animmobilized pepsin column 2.1 mm×30 mm (Life Technologies 2-3131-00)that is maintained at 12° C. An 8-minute 2 to 35% acetonitrile gradientand Waters UPLC CSH C18 1.0×100 mm column is used for separation. Next,triplicate experiments are carried out using the antibody. The P8D11 Fabfragment is immobilized on Protein G agarose beads (Thermo ScientificCat #22851) using standard techniques. Briefly, the antibody iscentrifuged to remove a storage buffer. Then 200 μl of PBS buffer (pH7.4) and a concentration of VP1 pentamers are added to the immobilizedP8D11 Fab fragment and incubated for 30 min at room temperature. Afterincubation, the complex is centrifuged and washed with 200 μl PBS bufferand centrifuged again. For deuterium exchange, 200 μl of deuterated PBSis added to the antigen-antibody complex for incubation at roomtemperature for 25 minutes (% D=85.5%). Deuterium buffer is thenremoved, and immediately, 125 μl ice cold quench buffer is added. Afterquenching for 5 minutes, the column is centrifuged and the flow-throughis transferred into a prechilled HPLC vial. The sample is analyzed usingthe same on-line pepsin digestion/LC-MS setup as the control experiment.

The results of these measurements are summarized in FIG. 28. FIG. 28shows the baseline corrected differences between the control and P8D11antibody bound sample divided by the standard error in the measurement.In this plot the more negative value indicates a greater amount ofprotection in a given region upon binding of P8D11 Fab fragment to BKVserotype I VP1 pentamer. We observe the most significant amounts ofprotection in amino acids 168-190 of the VP1 protein upon binding ofP8D11 Fab fragment. This region of the EF loop is highly conservedacross all four serotypes of BK virus and JC virus, as can be seen withthe sequences bolded and underlined in Table 1((NYRTKYPXGTXXPKNXTXQSQVM) (SEQ ID NO:501)).

In conclusion, the deuterium mapping data indicate that P8D11 antibodybinds to an epitope within the EF loop of BKV VP1. This region is highlyconserved across all four BKV serotypes and JC virus, and thus supportsthe result that P8D11 has neutralizing activity across all four BKVserotypes and JC virus.

Example 15 Targeted Alanine Scanning and SPR for Epitope Mapping ofP8D11

Biacore surface plasmon resonance (SPR) was used to characterize thebinding of anti-VP1 antibodies to VP1 pentamers generated for epitopemapping by scanning alanine mutagenesis. Experiments were performed at25° C. in phosphate buffered saline (PBS) supplemented with 0.005% Tween20 detergent (Calbiochem #655206) and run on a Biacore T-200 instrument(GE Healthcare Life Sciences). Biotinylated protein A (Sigma #P2165) wasimmobilized onto a Series S streptavidin sensor chip to approximately1200 response units (RUs) and remaining free streptavidin sites wereblocked with biotin-PEG (Pierce EZ-Link #PI21346). Antibodies werecaptured onto the prepared protein A sensor chip with a 4 secondinjection at a flow rate of 30 μl/minute. Antibodies were immobilized at20-40 RUs on flowcells 2, 3 and 4, leaving flowcell 1 as a referencecell without any antibody. VP1 pentamers were then injected over thechip for 200 seconds at 100 μl/min followed by injections of buffer tomonitor dissociation. Between each pentamer and pentamer concentration,the sensor chip surface was regenerated with an injection of 25 mM NaOHfor 60 seconds at 30 μl/minute to remove antibodies before re-capture ofantibodies onto the protein A surfaces for the next cycle. Data analysiswas done in the GE BiaEvaluation software where double referencesubtraction was applied. Assessment of the effect of alanine mutagenesison VP1 pentamer binding was achieved by comparison of the binding RUlevels and shapes of the binding curves compared to those of thewildtype pentamer.

As discussed previously, the epitopes for antibodies P8D11 and P7G11Aare conformational and non-contiguous (FIGS. 12A-B). Here, singlemutations to alanine at Y169, R170 and K172 in the EF loop of BKV VP1abolishes binding of P8D11 (FIGS. 29A and 29B). Mutations at Y169 andR170 also abolish binding of the P7G11A antibody, however binding ofthis antibody is not affected by changes at position K172 of the EF loopof BKV VP1 (FIGS. 29A and 29C).

Example 16 Epitope Mapping by X-Ray Crystallography

The crystal structure of the scFv chain of the antibody P8D11 bound tothe BKV major capsid protein VP1 in its pentameric form was determined.As detailed below, a 5.5:1 solution of scFv:BKV-VP1 pentamer was used toproduce a crystallographically suitable complex composed of five scFvchains bound to each pentamer. Protein crystallography was then employedto generate an atomic resolution structure and define the epitope.

Crystallization and Structure Determination

The P8D11 scFv/BKV-VP1 complex was concentrated to 5.2 mg/ml andscreened for crystallization. Crystals for data collection were grown byhanging drop vapor diffusion at 18° C. Crystals were grown by mixing 1.0μl of the complex with 1.0 μl of reservoir solution containing 25% (w/v)PEG3350, 0.2 M magnesium chloride and 0.1M Bis-Tris pH 7.0, andequilibrating the drop against 350 μl of the same reservoir solution.Crystals grew overnight and continued to grow for a few days. Beforedata collection, the crystals were transferred to 75% of reservoirsolutions plus 25% glycerol and flash cooled in liquid nitrogen.

Diffraction data were collected in-house on a Rigaku FRE+ copper sourceand an R-axis X-ray detector. Data was processed and scaled usingAutoproc (Global Phasing, LTD). The data of BKV-VP1 was processed to2.66 Å in space group P42212 with cell dimensions a=224.4 Å, b=224.4 Å,c=144.04 Å, alpha=90°, beta=90°, gamma=90°. The structure of the complexwas solved by molecular replacement using Phaser (McCoy et al., (2007)J. Appl. Cryst. 40:658-674) with a BKV-VP1 pentamer as the search model.The final model was built in COOT (Emsley & Cowtan (2004) Acta Cryst.D60:2126-2132) and refined with Buster (Global Phasing, LTD, Cambridge,UK). The Rwork and Rfree values are 17.1% and 21.4%, respectively; androot-mean-square (r.m.s) deviation values of bond lengths and bondangles are 0.010 Å and 1.18°, respectively.

Residues of BKV-VP1-Pentamer that are in contact with the P8D11 scFv,the types of interactions, and the buried surface areas are allidentified by PISA (Krissinel et al., (2007) J Mol Biol. 372:774-97) andlisted in Table 6 below. It was found the each monomer of theVP1-pentamer contains a single isolated epitope for the P8D11 antibody.Thus five scFv domains bind to each pentamer at five chemically andsterically equivalent positions. Details for the interactions at eachepitope are essentially identical so that only one scFv/VP1-epitopeinterface is analyzed here.

Epitopes of P8D11-scFv on BKV-VP1

Overall Structure

The overall folding of each polyomavirus VP1-pentmer structure is highlyhomologous at the level of tertiary structure. Primary sequences arewell conserved with identity as at 69-85%. Each pentamer is composed offive monomers, each of which is composed by a three-strand β sheetstacking against another five-strand β sheet and then a four-strand βsheet. The P8D11 scFv is a VH-VL fusion protein with a 20 amino acidlinker between VH and VL domains. As shown in FIG. 30, the VH-VL fusionprotein binds to an epitope located on the lateral, exterior surface ofthe BKV-VP1-pentamer.

Epitope of P8D11

The crystal structure of the BKV-VP1/P8D11 complex is used to identifythe P8D11 epitope on BKV-VP1. The interaction surface on VP1 byP8D11-scFv is formed by several continuous and discontinuous (i.e.noncontiguous) sequences: namely residues 77-80, 169-186, and 191-192,as detailed in Table 6. These residues form the three-dimensionalconformational epitope that is recognized by the P8D11-scFv (FIG.31A-B). This epitope defined by crystallography is in good agreementwith that defined by hydrogen deuterium exchange mass spectrometry(HDx-MS), in which residues 168-190 are substantially protected byP8D11-Fab (FIG. 28). There is also good agreement with the Alanine scanthat was done on the key amino acids of the epitope (FIG. 29A-C) whichshowed that TYR169, ARG170 and LYS172 are contact residues which arepart of the epitope of the P8D11 antibody.

P8D11-scFv epitope on BKV-VP1. All residues of BKV-VP1 that are incontact with P8D11-scFv in the crystal structure are identified by PISA,listed and sorted by their buried surface area by P8D11-scFv. Types ofinteraction are also listed where applicable.

TABLE 6 Anti-VP1 VP1 scFv Hydrogen Salt Pentamer Hydrogen Salt residuebond Bridge ASA* BSA* residue bond Bridge ASA* BSA* ASN31 0 0 72.36 1.11SER77 1 0 74.90 25.99 TYR32 0 0 60.89 6.59 SER78 0 0 73.45 46.46 TRP33 00 42.56 39.19 ASP79 1 0 36.90 2.33 LYS52 2 0 66.84 59.49 SER80 0 0 63.8220.03 LYS53 0 1 89.76 40.27 TYR169 2 0 66.99 44.33 ASP54 0 0 100.58 3.42ARG170 1 0 117.97 54.91 SER56 0 0 78.38 5.60 THR171 1 0 12.44 9.58 GLU572 0 63.29 46.19 LYS172 2 2 142.87 121.15 TRY59 0 0 55.86 13.29 TYR173 30 33.81 24.25 VAL99 0 0 19.54 17.42 PRO174 1 0 27.18 4.61 ARG100 1 097.42 14.49 GLU175 1 0 165.93 61.70 GLY102 1 0 45.24 23.46 GLY176 0 030.62 0.58 ARG103 5 0 190.68 157.62 THR177 1 0 21.14 13.74 TYR104 4 068.25 63.79 ILE178 0 0 63.25 0.67 PHE105 0 0 37.94 32.69 THR179 2 029.52 22.67 ASN526 0 0 84.174 16.28 PRO180 0 0 11.34 7.66 GLY528 1 027.52 11.48 LYS181 2 0 164.73 85.21 SER529 0 0 62.31 55.68 ASN182 1 0111.76 104.95 ARG530 4 0 83.56 70.86 PRO183 0 0 50.84 49.34 PRO531 0 014.77 13.77 THR184 1 0 67.62 67.45 ASP549 0 0 21.15 4.11 ALA185 0 061.12 6.85 ASP550 0 2 37.36 16.62 GLN186 1 0 103.62 42.67 SER551 0 068.46 11.52 ASN191 2 0 13.15 12.56 ASN552 1 0 65.13 28.37 THR192 0 089.19 1.87 TRP590 0 0 51.46 50.45 ASP193 0 1 123.11 71.49 SER591 0 040.49 16.66 SER592 0 0 51.90 25.61 SER593 2 0 45.01 33.37 *ASA:Accessible Surface Area *BSA: Buried Surface Area

Example 18 Formulation

The anti-VP1 antibodies described herein are monoclonal antibodies, IgG1isotype with lambda light chain, and can be lyophilized. Theseantibodies are soluble and stable in a histidine-sucrose formulationbuffer for 4 weeks. In addition, anti-VP1 antibodies were solubleat >200 mg/ml as minimally formulated drug substance (e.g., in histidinebuffer in the absence of stabilizers).

For subsequent intravenous administration, the obtained solution willusually be further diluted into a carrier solution to the ready-to-useantibody solution for infusion.

Important stability-indicating analytical methods to select the moststable formulation encompassed, amongst others, size-exclusionchromatography to determine aggregation levels, subvisible particulatematter testing, and potency testing.

It is understood that the examples and aspects described herein are forillustrative purposes only and that various modifications or changes inlight thereof will be suggested to persons skilled in the art and are tobe included within the spirit and purview of this application and scopeof the appended claims

What is claimed is:
 1. A pharmaceutical composition, comprising anantibody or antigen binding fragment thereof, wherein said antibody orantigen binding fragment thereof binds to BK virus VP1 and comprises: aheavy chain variable region that comprises (a) a HCDR1(CDR-Complementarity Determining Region) of SEQ ID NO: 186, (b) a HCDR2of SEQ ID NO: 187, (c) a HCDR3 of SEQ ID NO: 188, and a light chainvariable region that comprises: (d) a LCDR1 of SEQ ID NO: 196, (e) aLCDR2 of SEQ ID NO: 197, and (f) a LCDR3 of SEQ ID NO:
 198. 2. Thepharmaceutical composition of claim 1, wherein the composition isprepared as a lyophilisate.
 3. The pharmaceutical composition of claim1, wherein the antibody or antigen binding fragment thereof is amonoclonal antibody, a chimeric antibody, a humanized antibody, a humanengineered antibody, a human antibody, a single chain antibody (scFv),or an antibody fragment.
 4. The pharmaceutical composition of claim 1,wherein said antibody or antigen binding fragment thereof comprises: aheavy chain variable region (vH) that comprises a sequence having atleast 95% identity to SEQ ID NO: 192, and a light chain variable region(vL) that comprises a sequence having at least 95% identity to SEQ IDNO:
 202. 5. The pharmaceutical composition of claim 4, wherein the vHcomprises SEQ ID NO: 192 or a modification thereof selected from one ormore of A12V, S23T, I69V, M71I, and T85S, and wherein the vL comprisesSEQ ID NO:
 202. 6. The pharmaceutical composition of claim 4, whereinthe antibody or antigen binding fragment thereof is a monoclonalantibody, a chimeric antibody, a humanized antibody, a human engineeredantibody, a human antibody, a single chain antibody (scFv), or anantibody fragment.
 7. The pharmaceutical composition of claim 1 or claim4, wherein the antibody or antigen binding fragment thereof has reducedglycosylation or no glycosylation or is hypofucosylated.
 8. Thepharmaceutical composition of claim 1 or claim 4, further comprising apharmaceutically acceptable carrier.
 9. The pharmaceutical compositionof claim 8, wherein the pharmaceutically acceptable carrier containshistidine or a sugar.
 10. The pharmaceutical composition of claim 9,wherein the sugar is sucrose.
 11. The pharmaceutical composition ofclaim 1 or claim 4, comprising a plurality of the antibody or antigenbinding fragment thereof, wherein at least 0.05%, 0.1%, 0.5%, 1%, 2%,3%, 5% or more or more of the antibodies in the composition have anα2,3-linked sialic acid residue.
 12. The pharmaceutical composition ofclaim 1 or claim 4, comprising a plurality of the antibody or antigenbinding fragment thereof, wherein none of the antibodies comprise abisecting GlcNAc.
 13. A method of neutralizing a BK virus or JC virusinfection comprising administering via injection or infusion to apatient in need an effective amount of the pharmaceutical composition ofclaim 1 or claim
 4. 14. The method of claim 13, wherein the patient inneed is diagnosed with BK viruria or BK viremia.
 15. A method oftreating or reducing the likelihood of a BK virus or JC virus associateddisorder, comprising administering via injection or infusion to apatient in need an effective amount of the pharmaceutical composition ofclaim 1 or claim 4, and wherein the disorder is: nephropathy, BKVAN,hemorrhagic cystitis (HC), Progressive Multifocal Leukoencephalopathy(PML), granule cell neuronopathy (GCN), interstitial kidney disease,ureteral stenosis, vasculitis, colitis, retinitis, meningitis, or immunereconstitution inflammatory syndrome (IRIS).
 16. The method of claim 15,wherein the pharmaceutical composition is administered in combinationwith another therapeutic agent.
 17. The method of claim 16, wherein thetherapeutic agent is an immunosuppressive agent.
 18. The method of claim17, wherein the immune suppressive agent is: a monophosphatedehydrogenase inhibitor, a purine synthesis inhibitor, a calcineurininhibitor, or an mTOR inhibitor.
 19. The method of claim 18, wherein theimmunosuppressive agent is mycophenolate mofetil (MMF), mycophenolatesodium, azathioprine, tacrolimus, sirolimus, or cyclosporine.
 20. Themethod of claim 16, wherein the therapeutic agent is an additionalanti-VP1 antibody.
 21. A pharmaceutical composition, comprising anantibody and a pharmaceutically acceptable carrier, wherein the antibodycomprises a heavy chain variable region (vH) that comprises SEQ ID NO:192, and a light chain variable region (vL) that comprises SEQ ID NO:202, and wherein the pharmaceutically acceptable carrier containshistidine, sucrose, and a polysorbate.